Cancer Treatment

JP2024501121A5Pending Publication Date: 2024-11-29INNATE PHARMA SA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023531534
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-08-05
Filing Date
2021-11-24
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

Existing anti-Nectin-4 antibody-drug conjugates (ADCs) face limitations in efficacy and safety, particularly in treating urothelial carcinoma and other cancers, due to high toxicity and limited antitumor activity, despite targeting the Ig-like type V domain, and cancers often develop resistance to these treatments.

Method used

Conjugating cytotoxic agents to antibodies that bind to the VC1 bridging domain between the Ig-like V and Ig-like C2 type 1 domains of Nectin-4, utilizing intracellularly cleavable linkers to release exatecan, enhancing antitumor effects and overcoming drug resistance in Nectin-4 expressing tumors.

Benefits of technology

The approach achieves three times higher potency and improved therapeutic window compared to standard ADCs, reducing toxicity and enhancing tumor invasion, making it effective against resistant cancers.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000135_0000
    Figure 00000135_0000
  • Figure 00000142_0000
    Figure 00000142_0000
  • Figure 00000142_0001
    Figure 00000142_0001
Patent Text Reader

Abstract

The present invention relates to antigen-binding proteins capable of binding to Nectin-4 polypeptides, conjugated to chemotherapeutic agents, for use in increasing the sensitivity of tumors to chemotherapeutic agents and for use in the treatment of cancers characterized by Nectin-4-expressing tumor cells.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Application No. 63 / 118,198, filed November 25, 2020, and U.S. Provisional Application No. 63 / 229,58, filed August 5, 2021, which are incorporated by reference in their entirety, including any drawings.

[0002] Sequence Listing Reference This application has been filed with a Sequence Listing in electronic format. The Sequence Listing is provided as a file entitled "Nectin-4-2 PCT_ST25", created on November 24, 2021, with a size of 67 KB. The information in the electronic format of the Sequence Listing is incorporated herein by reference in its entirety.

[0003] The present invention provides antigen-binding proteins capable of binding to Nectin-4 polypeptides, conjugated to chemotherapeutic agents, for use in the treatment of cancers characterized by Nectin-4-expressing tumor cells, for use in increasing the sensitivity of tumors to chemotherapeutic agents. [Background technology]

[0004] In 2016, it was estimated that there were over 70,000 new diagnoses of bladder cancer in the United States along with approximately 16,000 deaths. Urothelial carcinoma encompasses carcinoma of the bladder, ureter, and renal pelvis, which occur in a ratio of 50:3:1, respectively. Cancer of the urothelium is a multifocal process. Patients with cancer of the upper urinary tract have a 30%-50% chance of developing cancer of the bladder at some point in their lives. Bladder cancer occurs when cells in the bladder begin to grow abnormally or uncontrollably. The most common type of bladder cancer is called urothelial carcinoma (UC). In UC, abnormal growth occurs in the lining of the bladder (urothelium). The disease may spread as it progresses. The disease may spread (metastasize) to areas around the bladder or to other parts of the body. This is called advanced urothelial carcinoma.

[0005] Urothelial carcinoma (UC) is characterized by increased expression of a variety of different cell surface antigens, thus offering the opportunity for specific targeting as a treatment with the use of antibody-drug conjugates (ADCs). Among the surface antigens, several antigens have been shown to be amenable to the development of ADCs, including TROP-2 (human trophoblast cell surface antigen), SLITRK family proteins (e.g., SLITRK6), EpCAM, HER2, TF-Ag (Thomsen-Friedrich antigen), FGF1V, Fn14 (FGF-inducible 14), PSMA (prostate-specific membrane antigen), and nectin-4 (poliovirus receptor-related protein 4, also known as PVRL4).

[0006] Nectin-4 was first isolated from human trachea by Lopez's group in 2001 (see Reymond et al. (2001) J. Biol. Chem. 276(46):43205-15). It has been reported that copy number gain of the nectin-4 gene is a frequent event in carcinogenesis and may further promote epithelial-mesenchymal transition, invasion and metastasis. Nectin-4 protein expression is limited in healthy tissues, but is expressed at significantly higher levels in some tumors, and is particularly overexpressed in breast cancer, including triple-negative breast cancer (TNBC) (see M-Rabet et al. Ann Oncol. 2017 Apr 1;28(4):769-776), pancreatic cancer and UC. However, nectin-4 is also expressed in non-small cell lung cancer, ovarian cancer, head and neck squamous cell carcinoma and esophageal cancer tumor specimens. Challita-Eid et al. (2016) Cancer Res. 76(10): 3003-3013 reported moderate to strong immunohistochemical staining (H-score ≥ 100) in bladder (60%) and breast (53%) tumor tissues. Zeindler et al. 2019 Front. Med. 6:200 reported that high expression of Nectin-4 was present in 86 (58%) of 148 TNBC cases.

[0007] Challita-Eid et al. (2016), supra, developed an anti-nectin-4 antibody conjugated to the highly potent microtubule disrupting agent MMAE, based on the antibody AGS-22. This work resulted in the ADC drug candidate enfortumab vedotin (see U.S. Patent No. 8,637,642 and PCT Publication No. WO2012 / 047724, Agensys Inc.), which has produced promising results in human clinical trials in the treatment of patients with locally advanced or metastatic urothelial carcinoma who have previously received platinum-containing chemotherapy and PD-1 / PD-L1 checkpoint inhibitors in the neoadjuvant / adjuvant, locally advanced, or metastatic setting. Several other groups have also proposed anti-nectin-4 agents conjugated to various toxic agents. PCT Patent Application No. WO2018 / 158398 (INSERM) reports several anti-nectin-4 antibodies and proposes potential coupling to a variety of cytotoxic agents. Similarly, US Patent No. 8,637,642 (Agensys Inc.) also provides anti-nectin-4 antibodies and suggests potential coupling to various cytotoxic agents. Furthermore, Bicycle Therapeutics has reported the development of an anti-nectin-4 targeting agent composed of a nectin-4 binding protein conjugated to a cytotoxic auristatin (MMAE) payload via a cleavable valine-citrulline (val-cit) linker. To date, all anti-nectin-4 antibodies reported to be active when conjugated to chemotherapeutic agents target the Ig-like V-type domain of nectin-4, and therefore, the Ig-like V-type domain is believed to achieve the most potent internalization of anti-nectin-4 ADCs.

[0008] Enfortumab vedotin (anti-nectin-4 ADC) binds to the Ig-like V-type domain of nectin-4, which is associated with a high degree of internalization of anti-nectin-4 antibodies. Enfortumab vedotin showed impressive therapeutic responses in UC with an ORR (objective response rate) of 44% and a CR (complete response rate) of 12% in the EV-201 Phase 2 study (2019), but approximately half of patients discontinued treatment. The majority of discontinuations were due to progressive disease as assessed by RECIST (48%) or clinical symptoms (5%). Also, 18% of patients who discontinued experienced adverse events, especially neuropathy. Thus, nectin-4-targeted ADCs have limitations and there is a need in the art for improved benefits for patients with UC and other cancers.

[0009] In UC, individuals are generally initially treated with cisplatin-based regimens (with or without radiation) either when the cancer has not spread to distant sites in the body or when it has spread. Camptothecin compounds are generally not used in the treatment of UC. de Jonge et al., 2004 Invest New Drugs 22: 329-333 studied the camptothecin analogue RFS2000 in patients with advanced or metastatic urothelial tumors. De Jonge et al. 2004 concluded that RFS2000 did not exert significant activity in patients with advanced / metastatic urothelial tumors who had previously failed chemotherapy, and the results of this study did not encourage further consideration of RFS2000. A number of camptothecin analogues have been created over the past several decades, including exatecan. Abou-Alfa et al., 2006 Journal of Clinical Oncology 24(27): 4441-4447, evaluated exatecan in the treatment of pancreatic cancer in a phase 3 trial of 349 patients and found that exatecan added to gemcitabine was not as effective as gemcitabine alone. Summary of the Invention

[0010] Although many highly potent cytotoxic agents, such as pyrrolobenzodiazepines and auristatins, have been developed for conjugation to antibodies, ADCs incorporating these agents at doses used for treatment still cause severe side effects due to the toxicity of the agents. Other cytotoxic agents, such as camptothecins, are less toxic but also have limited antitumor activity by themselves. Although the antitumor activity of cytotoxic agents can be enhanced by conjugation to anti-nectin-4 antibodies, as demonstrated herein, camptothecin analog-based ADCs still have limitations when tested in vivo when conjugated to gold-standard anti-nectin-4 antibodies, such as enfortumab (ASG-22). The present inventors herein provide methods for improving the delivery of cytotoxic agents to nectin-4 positive tumors. In particular, the present application shows that potent antitumor effects can be obtained by conjugating cytotoxic agents to antibodies that bind to a domain or region of Nectin-4 that bridges the Ig-like V and Ig-like C2 type 1 domains. The domain that bridges the Ig-like V and Ig-like C2 type 1 domains, also referred to herein as the VC1 cross-linking domain, VC1 determinant or VC1 epitope, is associated with cell-cell interactions. Targeting this domain with ADCs that show reduced binding to Nectin-4 mutants with VC1 cross-linking domain amino acid substitutions (at residues K197 and / or S199, as exemplified by mutants containing the K197T / S199A double substitution) compared to wild-type or non-mutated Nectin-4, resulted in 3-fold higher potency in antitumor activity compared to the gold standard anti-Ig-like V type domain ADCs with high intracellular internalization potential. The cell-cell interaction can be mediated by the interaction of nectin-4 from a first cell with nectin-1 and / or nectin-4 from a second cell (nectin-4:nectin-1 or nectin-4:nectin-4 interactions).

[0011] Furthermore, the present application shows that functionalizing an antibody conjugated to a VC cross-linking domain with an intracellularly cleavable linker that releases exatecan upon cleavage of the linker results in particularly potent antitumor efficacy in cancers characterized by tumors with high Pgp expression. Anti-nectin-4-exatecan ADCs provide effective antitumor efficacy in highly MDR tumor models resistant to the same antibody that instead releases the camptothecin analog Dxd.

[0012] In some embodiments, an antibody (e.g., a full-length antibody, an antibody fragment) (or a protein comprising such an antibody) that specifically binds to human Nectin-4 polypeptide and can sensitize tumors to cytotoxic agents is provided for use in a method for treating cancer and / or suppressing anticancer drug resistance.An antibody that binds to human Nectin-4 polypeptide may be used (administered) in combination with a cytotoxic agent (e.g., a chemotherapeutic agent).

[0013] One object of the present disclosure is to provide an anti-cancer composition comprising a cancer-sensitizing composition and an anti-cancer agent (e.g., a cytotoxic agent, a chemotherapeutic agent), wherein the cancer-sensitizing composition comprises an antibody (e.g., a full-length antibody, an antibody fragment) that binds to the VC1 cross-linking domain of Nectin-4 polypeptide.

[0014] In some embodiments, there is provided an antibody (e.g., full length antibody, antibody fragment) that binds to a human Nectin-4 polypeptide and can sensitize tumors to cytotoxic agents for use in preparing an antibody drug conjugate.

[0015] In some embodiments, improved methods of delivering cytotoxic agents (e.g., camptothecin, exatecan) to tumors (e.g., tumor cells in solid tumors) are provided by conjugating the cytotoxic agent to an antibody (e.g., full-length antibody, antibody fragment) that binds to the VC1 cross-linking domain of Nectin-4.

[0016] In any of the embodiments herein relating to immunoconjugates or ADCs, the cytotoxic agent may be conjugated or attached to the antibody via a linker that includes an intracellularly cleavable moiety (e.g., an oligopeptide, di-, tri-, or tetrapeptide) and, optionally, a self-eliminating spacer. In any of the embodiments, the cytotoxic agent is conjugated or attached to the antibody via a linker that includes an intracellularly cleavable moiety and, optionally, a self-eliminating spacer, such that, upon cleavage of the cleavable moiety, for example, in a tumor or tumor cell, the cytotoxic agent (e.g., a camptothecin analog, exatecan, a compound having the structure of compound 1, 2, or 13) is released.

[0017] Improved delivery of cytotoxic agents and / or sensitization to chemotherapeutic or cytotoxic agents may be the result of antibody-mediated inhibition of clustering and / or anchorage-independent growth of Nectin-4-expressing tumor cells, leading to improved tumor infiltration of ADCs.

[0018] In one embodiment of the invention, there is provided a sensitizer-cytotoxic drug conjugate that may be used for the treatment of cancer, comprising: (a) at least one antigen-binding domain that binds to the VC1 cross-linking domain of human Nectin-4, wherein (i) an amino acid sequence having at least 70%, 80%, 85%, 90%, 95% or 98% identity to an amino acid sequence having Kabat heavy chain CDRs 1, 2 and 3 of antibody 5E7, 10B12, 6C11B or 6A7 and a human framework region (e.g., from the human V gene (IGHV) family disclosed herein). and / or (ii) a light chain variable region comprising an amino acid sequence having at least 70%, 80%, 85%, 90%, 95% or 98% identity with an amino acid sequence having Kabat light chain CDR1, 2 and 3 of antibody 5E7, 10B12, 6C11B or 6A7 and a human framework region (e.g., from the human V gene (IGKV) family disclosed herein), and (b) at least one cytotoxic drug moiety. The polypeptides (i) and (ii) may be defined as associating with each other (e.g., by covalent and / or non-covalent bonds) to form an antigen-binding domain that binds to Nectin-4.

[0019] In one aspect, ADCs incorporating the antibodies of the present disclosure achieve enhanced efficacy and are therefore particularly advantageous for treating diseases with lower Nectin-4 expression (e.g., less than high expression) or heterologous Nectin-4 expression (e.g., urothelial carcinoma), especially for patients with resistant disease. In some embodiments, this allows for treatment that is not dependent on or involves assessment or detection of the level of Nectin-4 expression in tumors prior to treatment.

[0020] In one embodiment, ADCs incorporating the antibodies of the present disclosure achieve enhanced tumor penetration of the ADC, thereby improving antitumor activity, reducing the amount of ADC required, and / or reducing toxicity associated with cytotoxic agents. As a result of this improved therapeutic window compared to gold-standard internalizing anti-Nectin-4 antibodies (e.g., Ig V-domain antibodies), the ADCs of the present disclosure are advantageous for treating patients with diseases resistant to other treatments where conventional ADCs are not suitable (e.g., due to toxicity) and / or for use in combination with additional therapeutic agents (e.g., chemotherapeutic agents alone or incorporated into the ADC) as single agents that mediate their own toxicity.

[0021] In some embodiments, an antibody that specifically binds to Nectin-4 (e.g., a full-length antibody, an antibody fragment) is provided, the antibody binding to the VC1 cross-linking domain of human Nectin-4.

[0022] In some aspects, an antibody (e.g., a full-length antibody, an antibody fragment) that specifically binds to Nectin-4 is provided, which exhibits reduced binding to a mutant human Nectin-4 polypeptide comprising an amino acid substitution at residues K197 and / or S199 (according to SEQ ID NO:1) compared to binding to a wild-type human Nectin-4 polypeptide.

[0023] In some embodiments, antibodies (eg, full length antibodies, antibody fragments) are provided that include the heavy and light chain CDRs of antibodies 5E7, 10B12, 6C11B, or 6A7.

[0024] In any embodiment, the antibody of the present disclosure is for use in preparing an antibody-drug conjugate.In any embodiment, the antibody of the present disclosure is for use in (e.g., for use in a method of) reducing cell-cell adhesion between nectin-4-expressing tumor cells, inhibiting nectin-4:nectin-1 interaction, inhibiting nectin-4:nectin-4 interaction, suppressing the growth of nectin-4-expressing tumor cells, and / or suppressing the clustering of nectin-4-expressing tumor cells.

[0025] In some embodiments, there is provided an antibody (e.g., full length antibody, antibody fragment) capable of binding to human Nectin-4 polypeptide and reducing cell-cell adhesion between Nectin-4-expressing tumor cells and / or inhibiting the growth and / or clustering of Nectin-4-expressing tumor cells (e.g., three-dimensional or non-adherent tumor cell culture; assessed using a tumor spheroid assay) for use in the preparation of an antibody drug conjugate.

[0026] In some embodiments, antibodies (e.g., full length antibodies, antibody fragments) are provided that can inhibit nectin-4:nectin-1 interactions and / or nectin-4:nectin-4 interactions (e.g., the antibodies can inhibit the interaction of nectin-4 of a first cell with nectin-1 and / or nectin-4 of a second cell, where the cell may be a tumor cell).

[0027] In some embodiments, preparing an antibody drug conjugate comprises conjugating the antibody to a cytotoxic agent (eg, via a linker moiety, the linker moiety further comprising an intracellularly cleavable moiety).

[0028] In some embodiments, a method of preparing an antibody drug conjugate is provided, comprising conjugating an anti-Nectin-4 antibody of the present disclosure to a cytotoxic agent.

[0029] Also provided is an antibody drug conjugate comprising an anti-Nectin-4 antibody conjugated to a cytotoxic agent.

[0030] Also provided is a method of treating cancer comprising administering an antibody drug conjugate comprising an anti-Nectin-4 antibody conjugated to a cytotoxic agent.

[0031] The increased anti-tumor efficacy and larger therapeutic window provided by the anti-Nectin-4 antibodies of the present disclosure (e.g., especially when conjugated to camptothecin derivatives) offers the potential for improved treatment outcomes in individuals with tumors that are resistant to, unresponsive to, or progressed following treatment with compositions comprising anti-HER2 agents (e.g., trastuzumab, ADCs comprising trastuzumab). The improved therapeutic window offers the potential for combination treatment with other agents, particularly chemotherapeutic agents and / or anti-HER2 agents.

[0032] In some embodiments, there is provided a Nectin-4 binding agent conjugated to a cytotoxic agent, which may be a chemotherapeutic agent, and its use in treating a Nectin-4 expressing cancer, such as UC, breast cancer (e.g., TNBC), non-small cell lung cancer, pancreatic cancer, ovarian cancer, head and neck squamous cell carcinoma or esophageal cancer, wherein the binding agent is an antibody that binds to a human Nectin-4 polypeptide and can sensitize a tumor or tumor cells, particularly metastatic cancers, to the cytotoxic agent.

[0033] In some embodiments, there is provided a Nectin-4 binding agent conjugated to a cytotoxic agent, which may be a chemotherapeutic agent, and its use in treating a Nectin-4 expressing cancer, such as UC, breast cancer (e.g. TNBC), non-small cell lung cancer, pancreatic cancer, ovarian cancer, head and neck squamous cell carcinoma or esophageal cancer, wherein the binding agent is an antibody that binds to an epitope located at least in part within the VC1 bridging domain of human Nectin-4; e.g., the stretch of amino acids bridging the Ig-like C2 type 1 domain and the Ig-like V type domain, i.e., the amino acids bridging the Ig-like C2 type 1 domain and the Ig-like V type domain.

[0034] The feature of binding to the VC1 cross-linking domain of Nectin-4 can be suitably characterized as the ability to bind (e.g., at least partially) to (a) a human Nectin-4 polypeptide Ig-like V-type domain and (b) a human Nectin-4 polypeptide Ig-like C2-type 1 domain. In another embodiment, the feature of binding to the VC1 cross-linking domain of Nectin-4 can be characterized as retaining partial binding to a Nectin-4 polypeptide lacking an Ig-like V-type domain (e.g., a Nectin-4 polypeptide comprising an Ig-like C2-type 1 domain and an Ig-like C2-type 2 domain, but lacking the Ig-like V-type domain; the polypeptide of SEQ ID NO: 32), where the antibody may retain binding to a Nectin-4 protein lacking an Ig-like V-type domain at a reduced level compared to binding to a wild-type Nectin-4 protein), and further, the anti-Nectin-4 antibody may not bind to a Nectin-4 polypeptide lacking an Ig-like V-type domain and an Ig-like C2-type 1 domain, e.g., a polypeptide having the amino acid sequence of SEQ ID NO: 33, as appropriate. In another embodiment, the characteristic of binding to the VC1 cross-linking domain of nectin-4 can be characterized as exhibiting reduced binding to a mutant nectin-4 polypeptide comprising one or more amino acid substitutions at residues A72, G73, S195, K197, S199, L150, S152, Q234 and I236 (according to SEQ ID NO: 1), optionally to a mutant nectin-4 polypeptide comprising one or more amino acid substitutions at residues K197, S199 and / or Q234, as compared to binding to a wild-type human nectin-4 polypeptide, and optionally to a mutant nectin-4 polypeptide comprising one or more amino acid substitutions at residues K197 and / or S199, as compared to binding to a wild-type human nectin-4 polypeptide. Binding may be assessed by flow cytometry using cells engineered to express the nectin-4 polypeptide, and the fluorescence intensity level (e.g., MFI) determined.

[0035] In one embodiment, a Nectin-4 binding antibody or antibody fragment is provided which is a function-conservative variant of the antibody 5E7, 10B12, 6C11B or 6A7. In one embodiment, the Nectin-4 binding antibody comprises (i) a VH domain comprising an amino acid sequence having at least 70%, 80%, 85%, 90%, 95% or 98% identity to an amino acid sequence defined by a sequence selected from the group comprising SEQ ID NO: 6, 24, 42 or 50, where appropriate, each heavy chain framework region is replaced by a human heavy chain framework region, and / or (ii) a VL domain comprising an amino acid sequence having at least 70%, 80%, 85%, 90%, 95% or 98% identity to an amino acid sequence defined by a sequence selected from the group comprising SEQ ID NO: 7, 25, 43 or 51, where appropriate, each light chain framework region is replaced by a human light chain framework region.

[0036] In one embodiment, a Nectin-4 binding antibody or antibody fragment is provided, comprising: (i) a heavy chain variable region comprising the amino acid sequences of SEQ ID NOs: 8, 9 and 10 (Kabat H-CDR1, 2 and 3), and (ii) a light chain variable region comprising the amino acid sequences of SEQ ID NOs: 11, 12 and 13 (Kabat L-CDR1, 2 and 3).

[0037] In one embodiment, a Nectin-4-binding antibody or antibody fragment is provided, comprising: (i) a heavy chain variable region comprising the amino acid sequences of SEQ ID NOs: 14, 15 and 16 (H-CDR1, 2 and 3), and (ii) a light chain variable region comprising the amino acid sequences of SEQ ID NOs: 17, 18 and 13 (L-CDR1, 2 and 3).

[0038] In one embodiment, a Nectin-4 binding antibody or antibody fragment is provided, comprising: (i) a heavy chain variable region comprising the amino acid sequences of SEQ ID NOs: 19, 20 and 21 (H-CDR1, 2 and 3), and (ii) a light chain variable region comprising the amino acid sequences of SEQ ID NOs: 22, 18 and 23 (L-CDR1, 2 and 3).

[0039] In one embodiment, a Nectin-4 binding antibody or antibody fragment is provided, comprising: (i) a heavy chain variable region comprising the amino acid sequences of SEQ ID NOs: 44, 45 and 46 (H-CDR1, 2 and 3), and (ii) a light chain variable region comprising the amino acid sequences of SEQ ID NOs: 47, 48 and 49 (L-CDR1, 2 and 3).

[0040] In one embodiment, a Nectin-4 binding antibody or antibody fragment is provided, comprising: (i) a heavy chain variable region comprising the amino acid sequences of SEQ ID NOs: 52, 53 and 54 (H-CDR1, 2 and 3), and (ii) a light chain variable region comprising the amino acid sequences of SEQ ID NOs: 55, 56 and 57 (L-CDR1, 2 and 3).

[0041] In any embodiment herein, an anti-Nectin-4 antibody or antibody fragment, or an antibody-drug conjugate comprising such an antibody or fragment, can undergo intracellular internalization upon binding to Nectin-4 on the surface of a tumor cell.

[0042] In any embodiment herein, the anti-Nectin-4 antibody is conjugated to a cytotoxic agent. In any embodiment herein, the anti-Nectin-4 antibody conjugated to a cytotoxic agent is used in combination with an additional cytotoxic agent (e.g., a chemotherapeutic agent, a chemotherapeutic agent transported by P-glycoprotein (Pgp, the product of the human MDR1 gene), a platinum agent, a taxane), where the additional cytotoxic agent is administered separately from the anti-Nectin-4 antibody conjugated to a cytotoxic agent.

[0043] In one embodiment, a method of treating cancer and / or killing tumor cells in an individual in need thereof is provided, comprising administering to said individual a therapeutically effective amount of an antibody of the present disclosure that specifically binds to a human Nectin-4 polypeptide, wherein the antibody is optionally conjugated via a linker to a cytotoxic agent, which may be a camptothecin analog.

[0044] In one embodiment, the present invention provides a method of treatment that can be used for individuals with Nectin-4-expressing cancers regardless of the level of Nectin-4 expression in tumor cells.

[0045] In one aspect, the present invention provides a method of treatment that can be advantageously used in individuals whose tumor cells express P-glycoprotein (Pgp).

[0046] In one aspect, the present invention provides a method of treatment that can be advantageously used in individuals who have undergone prior treatment with chemotherapeutic agents (e.g., chemotherapeutic agents transported by P-glycoprotein (Pgp), platinum agents (e.g., oxaliplatin, cisplatin, carboplatin, nedaplatin, phenanthriplatin, picoplatin, satraplatin), taxanes (e.g., paclitaxel (Taxol™) and docetaxel (Taxotere™)).

[0047] In one aspect, the invention provides methods of treatment that can be advantageously used in individuals whose tumors or cancers are resistant, not responsive to, or have progressed following treatment with a composition comprising an anti-HER2 antibody (e.g., trastuzumab, an ADC comprising the heavy and light variable regions, CDRs, or polypeptide chains of trastuzumab).

[0048] In one embodiment, the present invention provides a method of treatment that can be used to mediate anti-tumor effects in individuals at low doses or doses lower than those used for conventional anti-Nectin-4 ADCs, e.g., fixed doses of less than 3 mg / kg body weight, less than 1.25 mg / kg body weight, less than 1 mg / kg body weight, less than 125 mg.

[0049] In one aspect, the invention provides a method of treatment that can be used in individuals with pre-existing neuropathy, diabetes or hyperglycemia, heart failure, eye conditions.

[0050] In one aspect, the present invention provides a method of treatment that can be used in individuals having a Nectin-4-expressing cancer characterized by low or moderate levels of tumor cell expression of Nectin-4 polypeptide (e.g., expression of Nectin-4 polypeptide in the tumor cell membrane).

[0051] In one embodiment, the anti-Nectin-4 antibody or antibody fragment is conjugated to a cytotoxic agent via an intracellularly cleavable (e.g., protease-cleavable) oligopeptide (e.g., di-, tri-, tetra- or pentapeptide). In one embodiment, the anti-Nectin-4 antibody or antibody fragment is conjugated to a cytotoxic agent (e.g., camptothecin derivative) via an intracellularly cleavable (e.g., protease-cleavable) di-, tri-, tetra- or pentapeptide and a self-eliminating spacer. In one embodiment, the anti-Nectin-4 antibody or antibody fragment is conjugated to a cytotoxic agent (e.g., camptothecin derivative) via an intracellularly cleavable (e.g., protease-cleavable) tetra- or pentapeptide and a self- or non-self-eliminating spacer.

[0052] In one aspect, the cytotoxic agent is a highly potent chemotherapeutic agent, which may be a cytotoxic agent selected from the group consisting of taxanes, anthracyclines, camptothecins, epothilones, mytomycins, combretastatins, vinca alkaloids, nitrogen mustards, maytansinoids, duocarmycins, tubulysins, dolastatins and auristatins, enediynes (e.g., calicheamicins, esperamicins, shishijimycins and namenamycins), pyrrolobenzodiazepines (e.g., pyrrolobenzodiazepine dimers and indolino-pyrrolobenzodiazepine dimers), amatoxins, and ethylenimines. In one embodiment, the cytotoxic agent is a DNA damaging agent, including, for example, DNA intercalating agents, such as agents that insert themselves into the DNA structure of a cell and bind to DNA, thereby causing DNA damage (e.g., daunorubicin). The compounds include topoisomerase inhibitors, i.e., chemical compounds that block the action of topoisomerase (topoisomerase I and II). Such compounds are used for various solid tumors and hematological malignancies, especially lymphomas. Topoisomerase I inhibitors include camptothecins, such as irinotecan (approved for the treatment of colon cancer), topotecan (approved for the treatment of ovarian and lung cancer), camptothecin, lamellarin D, indenoisoquinoline, indimitecan. Additional camptothecins include ciratecan, cositecan, exatecan, lurtotecan, gimatecan, belotecan, and rubitecan. Examples of topoisomerase II inhibitors include etoposide (VP-16), teniposide, doxorubicin, daunorubicin, mitoxantrone, amsacrine, ellipticines, aurintricarboxylic acid, and HU-331, a quinolone synthesized from cannabidiol.

[0053] An antibody may be functionalized with a linker-toxin of any one of Formulas I-XI.

[0054] In one embodiment, the cytotoxic agent is a camptothecin analogue, such as exatecan, Dxd or an SN-38 molecule.

[0055] In one aspect, the present invention provides a Nectin-4 binding antibody or antibody fragment of the disclosure conjugated (e.g., covalently linked) to a camptothecin, e.g., a camptothecin analog, exatecan or an exatecan derivative, a Dxd molecule, or an SN-38 molecule.

[0056] In any embodiment herein, a Nectin-4 binding antibody or antibody fragment of the present disclosure conjugated (e.g., covalently linked) to a camptothecin analog, such as exatecan or SN-38 molecule, can be characterized as comprising an antibody that specifically binds to a human Nectin-4 polypeptide in which one or more amino acid residues (e.g., cysteine, lysine, glutamine residues, unnatural amino acid residues) are functionalized via a linker with a molecule having the structure of compound 1 or 2, or with a linker-camptothecin molecule of formula I or II. In any embodiment herein, a Nectin-4 antibody or antibody fragment can be characterized as functionalized with a linker-camptothecin molecule having the structure of formula III, IV, V, VI, VII, VII, IX, X or XI, or with any of compounds 3-12.

[0057] In one embodiment, the nectin-4 antibody or antibody fragment conjugated to a camptothecin derivative is a nectin-4 antibody or antibody fragment conjugated to an exatecan molecule, e.g., a molecule having the structure of compound 1 (1a or 1b). In any embodiment, the cleavable linker, or immunoconjugate or ADC comprising a linker, can be characterized as releasing an exatecan molecule, e.g., a molecule having the structure of compound 1 (1a or 1b), e.g., upon enzymatic cleavage of the linker. In one embodiment, the nectin-4 antibody or antibody fragment conjugated to a camptothecin derivative is a nectin-4 antibody or antibody fragment conjugated to an SN-38 molecule, e.g., a molecule having the structure of compound 2. In one embodiment, the nectin-4 antibody or antibody fragment is conjugated to a SN-38 molecule, e.g., a molecule having the structure of compound 2, in which one or more amino acid residues (e.g., cysteine, lysine, glutamine or unnatural amino acid residues) are linked to the structure:

[0058] [ka] or

[0059] [ka] or

[0060] [ka] The present invention can be characterized as comprising an antibody that specifically binds to a human Nectin-4 polypeptide functionalized with a molecule having the formula:

[0061] In one embodiment, the Nectin-4 antibody or antibody fragment conjugated to a cytotoxic agent has formula (I): Ab-XZ Formula (I) [In the formula, Ab is an antibody or antibody fragment that specifically binds to a human nectin-4 polypeptide (e.g., an antibody or antibody fragment that binds to the VC1 cross-linking domain of human nectin-4; and / or that exhibits reduced binding to a mutant human nectin-4 polypeptide containing amino acid substitutions at residues K197 and / or S199 (according to SEQ ID NO:1) compared to binding to a wild-type human nectin-4 polypeptide), X is a linker molecule connecting Ab and Z (e.g. covalently linking each of Ab and Z), X comprises a moiety that is cleavable under physiological conditions, which may for example be intracellular conditions, optionally a protease cleavable di-, tri-, tetra- or pentapeptide, X may further comprise a self-eliminating or non-self-eliminating spacer system (Y') located between the cleavable moiety and Z, X may further comprise a spacer (Y) located between the Ab and the cleavable moiety; Z is a cytotoxic agent, Z may be a camptothecin analog, Z may be exatecan, and Z may be exatecan, where cleavage of the linker results in release of a compound having the structure of Compound 1 (exatecan). It can be defined as an immunoconjugate represented by:

[0062] In one embodiment, the Nectin-4 antibody or antibody fragment conjugated to a cytotoxic agent has formula (I): Ab-XZ Formula (I) [In the formula, Ab is an antibody or antibody fragment of the disclosure that specifically binds to a human Nectin-4 polypeptide, X is a linker molecule connecting Ab and Z (e.g., covalently binding each of Ab and Z), X comprises a valine-citrulline, valine-alanine, or phenylalanine-lysine dipeptide, X further comprises a self-eliminating or non-self-eliminating spacer system (Y') located between the cleavable moiety and Z, X further comprises a spacer (Y) located between the Ab and the cleavable moiety; Z is a cytotoxic agent, optionally a camptothecin analogue, optionally an exatecan molecule or an SN-38 molecule. It can be defined as an immunoconjugate represented by:

[0063] In one embodiment, there is provided a method of delivering or targeting a cytotoxic agent (which may be a camptothecin analog) to a tumor, releasing a cytotoxic agent (which may be a camptothecin analog, Dxd, exatecan) in a tumor (e.g., in a subject having cancer), and sensitizing a tumor or cancer to a cytotoxic agent (which may be a camptothecin analog), wherein the method comprises a compound represented by formula (I): Ab-XZ Formula (I) [In the formula, Ab is an antibody or antibody fragment that specifically binds to the human Nectin-4 polypeptide; X is a linker molecule connecting Ab and Z (e.g. covalently linking each of Ab and Z), X comprises a moiety that is cleavable under physiological conditions, which may for example be intracellular conditions, optionally a protease cleavable di-, tri-, tetra- or pentapeptide, X may further comprise a self-eliminating or non-self-eliminating spacer system (Y') located between the cleavable moiety and Z, X may further comprise a spacer (Y) located between the Ab and the cleavable moiety; Z is a cytotoxic agent, optionally a camptothecin analogue, optionally an exatecan molecule or an SN-38 molecule, and Z may be exatecan, where cleavage of the linker results in release of a compound having the structure of Compound 1 (exatecan). The method includes administering an immunoconjugate represented by the formula:

[0064] In one embodiment, the antibody or antibody fragment conjugated to a cytotoxic agent, which may be a camptothecin analog, has the formula (II): Ab-(X-(Z) n ) m Formula (II) [In the formula, Ab is an antibody or antibody fragment of the disclosure that specifically binds to a human Nectin-4 polypeptide, X is a linker molecule connecting Ab and Z, X comprises a moiety that is cleavable under physiological conditions, which may for example be intracellular conditions, optionally a protease cleavable di-, tri-, tetra- or pentapeptide, X may further comprise a self-eliminating or non-self-eliminating spacer system (Y') located between the cleavable moiety and Z, X may further comprise a spacer (Y) located between the Ab and the cleavable moiety, Z is a cytotoxic agent, optionally a camptothecin analogue, and Z may be an exatecan molecule or an SN-38 molecule, e.g., a molecule having the structure of compound 1 or 2; n is 1, m may be 4 to 8, or m may be an integer selected from 4, 5, 6, 7, or 8. It can be defined as an immunoconjugate represented by:

[0065] In one embodiment, the Nectin-4 antibody or antibody fragment conjugated to a cytotoxic agent, which may be a camptothecin analog, has the formula (II): Ab-(X-(Z) n ) m Formula (II) [In the formula, Ab is an antibody or antibody fragment of the disclosure that specifically binds to a human Nectin-4 polypeptide, X is a molecule connecting Ab and Z, X comprises a moiety that is cleavable under physiological conditions, which may for example be intracellular conditions, optionally a protease cleavable di-, tri-, tetra- or pentapeptide, X may further comprise a self-eliminating or non-self-eliminating spacer system (Y') located between the cleavable moiety and Z, X may further comprise a spacer (Y) located between the Ab and the cleavable moiety, Z is a cytotoxic agent, optionally a camptothecin analogue, Z may be a molecule comprising an exatecan molecule or an SN-38 molecule; n is 1 and at least 50%, 60%, 70%, 80%, 90%, 95%, 98% or 99% of the immunoconjugates in the composition have m (number of XZ moieties) that is between 2 and 4, between 4 and 8, optionally between 6 and 8. At least 50%, 60%, 70%, 80%, 90%, 95%, 98% or 99% of the immunoconjugates in the composition may have m that is, or is at least 4, 6, 7 or 8. The composition can be characterized as an immunoconjugate composition represented by:

[0066] In formula I or II, the (XZ) moiety can be characterized as having the structure of any of formulas III-XI or any of compounds 3-12, as appropriate.

[0067] In formula I or II, molecule X or spacer Y, as appropriate, can be defined as comprising a reactive group (R) or a residue for reaction of the reactive group (R) with a complementary reactive group (R') that is attached to an amino acid of an antigen binding protein (e.g., an antibody) or an amino acid of an antibody or antibody fragment.

[0068] In any embodiment herein, the exatecan molecule can be defined as being linked to the linker (X) via the amine at position 1 of the exatecan (when the exatecan molecule is part of the linker, the NH at position 1 can be 2 is replaced with NH). In one embodiment, exatecan is attached to the linker (X), for example to the carbonyl of the p-aminobenzyloxycarbonyl (PAB) self-elimination spacer moiety of X. In any embodiment herein, the SN-38 molecule can be defined as being attached to the linker (X) via the OH at position 9 (when the SN-38 molecule shown in compound 2 becomes part of the linker, the OH at position 9 is replaced with O).

[0069] In one embodiment, the Nectin-4 binding agent conjugated to Exatecan has one or more amino acid residues (e.g., cysteine ​​residues, glutamine residues) linked via a spacer (Y) to the following structure:

[0070] [ka] The present invention can be characterized as comprising an antibody that specifically binds to a human Nectin-4 polypeptide functionalized with a linker-exatecan molecule comprising:

[0071] In one embodiment, the Nectin-4 antibody or antibody fragment conjugated to Exatecan has one or more amino acid residues (e.g., cysteine ​​residues, glutamine residues) linked via a spacer (Y) to the following structure:

[0072] [ka] The present invention can be characterized as comprising an antibody that specifically binds to a human Nectin-4 polypeptide functionalized with a linker-exatecan comprising the following:

[0073] In one embodiment, the Nectin-4 antibody or antibody fragment conjugated to Exatecan has one or more amino acid residues (e.g., cysteine ​​residues, glutamine residues) linked via a spacer (Y) to the following structure:

[0074] [ka] The present invention can be characterized as comprising an antibody that specifically binds to a human Nectin-4 polypeptide functionalized with a linker-exatecan molecule comprising:

[0075] In one embodiment, the Nectin-4 antibody or antibody fragment conjugated to Exatecan has one or more amino acid residues (e.g., cysteine ​​residues, glutamine residues) linked via a spacer (Y) to the following structure:

[0076] [ka] The present invention can be characterized as comprising an antibody that specifically binds to a human Nectin-4 polypeptide functionalized with a linker-exatecan molecule comprising:

[0077] The spacer (Y) may be defined as being or comprising a substituted or unsubstituted alkyl or heteroalkyl chain, where Y may have a chain length of 2 to 40 atoms, optionally 2 to 30, 2 to 20, 4 to 40, 4 to 30 or 4 to 20 atoms, optionally one or more atoms may be other than carbon, such as oxygen, sulfur, nitrogen, or other atoms, optionally any carbon in the chain is substituted with alkoxy, hydroxyl, alkylcarbonyloxy, alkyl-S-, thiol, alkyl-C(O)S-, amine, alkylamine, amide, or alkylamide. For example, Y may comprise one or more ethylene oxide monomers, Y may comprise a polyethylene oxide moiety, Y may have the structure -(CH 2 CH 2 O) x - (wherein x is 1 to 12, optionally 1 to 8, optionally 1 to 6).

[0078] In one embodiment, the present invention provides treatments that show improved efficacy and / or improved (lower) drug resistance compared to existing anti-Nectin-4 ADC therapies (e.g., anti-Nectin-4 antibodies or antibody fragments conjugated to auristatins; enfortumab verdotin). In one embodiment, methods are provided for treating and / or preventing cancer and / or killing tumor cells in an individual in need thereof, the treatment comprising 2, 3, 4, 5, 6, 7, 8, 9 or 10 or more administrations of a Nectin-4 binding agent conjugated to a camptothecin derivative (e.g., exatecan or SN-38 molecule) at a frequency of 1-2 times per month (e.g., once every 2 weeks, once every 3 weeks, or once every 4 weeks).

[0079] In one aspect, the present invention provides a method of treating and / or preventing cancer and / or killing tumor cells in an individual in need thereof, comprising treating said individual with a Nectin-4 binding antibody or antibody fragment conjugated to a camptothecin molecule (e.g., an anti-Nectin-4 antibody or antibody fragment conjugated to one or more camptothecin moieties), where the camptothecin may be exatecan, Dxd or SN-38. In one embodiment, said individual has a Nectin-4 expressing tumor, and the tumor may be a HER2 expressing tumor or a HER2 negative tumor, such as a urothelial carcinoma, a breast cancer, a non-small cell lung cancer, a pancreatic cancer, an ovarian cancer, a head and neck squamous cell carcinoma or an esophageal cancer. In one embodiment, said individual has a Pgp expressing tumor. In one embodiment, the cancer or tumor is an advanced recurrent or metastatic cancer, optionally an advanced recurrent or metastatic urothelial carcinoma. In one embodiment, the cancer or tumor is a triple negative breast cancer (TNBC).

[0080] In one aspect, the present invention provides a method of treating cancer, killing tumor cells and / or delivering a cytotoxic agent to a tumor in an individual in need thereof, comprising administering to said individual a therapeutically effective amount of an antibody-drug conjugate comprising an anti-Nectin-4 antibody conjugated to compound 1, exatecan, via a cleavable linker, wherein cleavage of the linker may result in release of a compound having the structure of compound 1 (exatecan), wherein the cleavable linker may comprise a cleavable oligopeptide (e.g., di-, tri- or tetrapeptide, val-cit, val-phe, val-ala) and a self-immolative spacer (e.g., PAB), wherein said individual has cancer that has relapsed and / or progressed following treatment with a binding agent (optionally a Nectin-4 binding agent) conjugated via a linker (e.g., the linker is an intracellularly cleavable linker that releases the cytotoxic agent upon cleavage) to a cytotoxic agent capable of being transported by Pgp. In any embodiment, the cytotoxic agent capable of transport by Pgp is a camptothecin analog other than exatecan, the cytotoxic agent capable of transport by Pgp may be a pentacyclic camptothecin analog, a hexacyclic camptothecin, deruxtecan or Dxd, and cleavage of the linker may result in release of a camptothecin analog other than exatecan (e.g., Dxd having the structure of compound 13). In one embodiment, the binding agent conjugated via a linker to a cytotoxic agent capable of transport by Pgp includes an antibody that binds Nectin-4 conjugated via a linker to a compound having the structure of compound 13 (Dxd, deruxtecan), and the linker may include a cleavable glycine-containing oligopeptide linker, such as a glycine- and phenylalanine-containing oligopeptide linker, a GGFG linker. In one embodiment, the anti-Nectin-4 antibody conjugated to compound 1, exatecan, via a cleavable linker includes an antibody that binds to the VC1 cross-linking domain of human Nectin-4 polypeptide, such as an antibody of the present disclosure.

[0081] In one aspect of any embodiment herein, the individual has been pre-treated with radiation therapy, surgery, chemotherapy, and / or treatment with a biologic agent.

[0082] Compositions of the immunoconjugates of the present disclosure are also provided. Pharmaceutically acceptable compositions and kits are also provided that include the immunoconjugates of the present disclosure and typically one or more additional components, which may be active ingredients or inactive ingredients (e.g., various carriers) that facilitate the formulation, delivery, stability, or other characteristics of the composition. Methods for screening, testing, and making anti-nectin-4 antibodies and antibody fragments, and immunoconjugates or ADCs that include them, as well as tools and reagents for use in these methods are also provided.

[0083] These aspects are described more fully in the description of the invention provided herein, and additional aspects, features, and advantages will become apparent from the description of the invention provided herein. [Brief description of the drawings]

[0084] [Figure 1] Figure 1 shows the expression levels of HER2 and Nectin-4 polypeptides on the surface of SUM190 human breast cancer tumor cells as determined by FACS (MFI: mean fluorescence intensity). SUM190 tumor cells expressed HER2 at low to moderate levels (median fluorescence units 1777) and Nectin-4 at lower levels (median fluorescence units 991). [Diagram 2] Figure 2 shows the expression levels of HER2 and Nectin-4 polypeptides on the surface of SUM185 human breast cancer tumor cells as determined by FACS (MFI: mean fluorescence intensity). SUM185 cells expressed HER2 at medium to high levels (median fluorescence units 2880) and Nectin-4 at higher levels (median fluorescence units 4326). [Diagram 3]The right hand panel of Figure 3 shows the efficacy of N4 ADC1 (anti-nectin-4) in causing death of HER-2 and nectin-4 expressing SUM185 and SUM190 tumor cells. The two left hand panels show the efficacy of HER2 ADC1 (anti-Her2) in the same respective cells. N4 ADC1 had a 20-fold increase in potency compared to HER2 ADC1 in SUM190 cells, and also had higher comparative potency in SUM185 cells, which are characterized by lower nectin-4 surface expression (surface nectin-4 in SUM185 is approximately 4-fold lower than in SUM190). [Figure 4-A] FIG. 4A shows the MFI for binding of anti-nectin-4 antibodies to whole (wild type) nectin-4 protein assessed by flow cytometry using cells engineered to express nectin-4. mAbs 6 (5E7) and 7 (10B12) show a lower plateau than the other antibodies. FIG. 4B shows the MFI for binding of anti-nectin-4 antibodies to cells engineered to express modified nectin-4 (C1C2 construct) that has Ig-like C2 type 1 and Ig-like C2 type 2 domains and lacks the Ig-like V domain, assessed by flow cytometry. The left hand panel shows that mAbs 6 (5E7) and 7 (10B12) retain binding to the C1C2 construct. The right hand panel shows that the MFI of mAbs 6 and 7 is reduced compared to mAb 2, which binds fully to the C1C2 construct. [Figure 4-B] Same as above. [Diagram 5] FIG. 5 shows the domain structure of Nectin-4. Antibodies Enfortumab and N41 used as ADCs bind to the Ig-like V-type domain. Antibodies 1 to 5 obtained herein bind to the Ig-like C2 type 1 domain (C1 domain) and / or the Ig-like C2 type 2 domain (C2 domain), but do not bind to the Ig-like V-type domain. Antibodies 6 (5E7) and 7 (10B12), as well as antibodies 6CB11 and 6A7 obtained herein, bind to both the Ig-like V-type domain (V domain) and the Ig-like C2 type 1 domain (C1 domain). [Figure 6] Figure 6 shows the binding profiles of the different antibodies 1-7 and isotype control (IC) to SUM185 cells as assessed by flow cytometry. From this experiment, it appears that the C1 and / or C2 domain specific antibodies (mAbs 1-5) generally have binding profiles comparable to Enfortumab, whereas antibodies 6 and 7 (mAbs 6 and 7) have a different profile. [Figure 7-A] Figure 7A shows the internalization of each of antibodies 1-7 into SUM190 cells as luminescence (indicating cell viability) versus anti-Nectin-4 antibody concentration, compared to Enfortumab. Figure 7B shows the luminescence (indicating cell viability) in SUM185 cells for mAb6 compared to Enfortumab. mAb6 (5E7) was more efficient than Enfortumab at inducing internalization into SUM185 cells. [Figure 7-B] Same as above. [Figure 8-A]Figure 8A shows human breast cancer cell killing by mAb6(5E7) antibody conjugated to camptothecin analog Dxd (via GGFG-Dxd linker shown in Example 7) or exatecan [via (PEG(8U)-Val-Ala-PAB-exatecan) linker shown in Example 7] along with an isotype control antibody (IC) [all at equal drug-antibody ratio (DAR=8)] and Enhertu™ (trastuzumab deruxtecan (anti-HER2)] binding to the V domain. Figure 8B shows human breast cancer cell killing by mab6(5E7) conjugated to the same camptothecin analog-containing linker as in Figure 8A along with immune controls conjugated to camptothecin analogs, i.e., mAb3 conjugated to camptothecin analog-containing linkers at the same DAR, and Enhertu™. FIG. 8C shows the efficacy of "5E7-exatecan" [5E7 conjugated to the exatecan linker (PEG(8U)-Val-Ala-PAB-exatecan) shown in Example 7] in causing death of HER-2 and nectin-4 expressing SUM185, SUM190, MDA-MB-468 (TNBC) human tumor cells and MC38 (colon cancer) and B16F10 (melanoma) mouse tumor cells, and the EC50 value at which 5E7-exatecan can cause cell death. [Figure 8-B] Same as above. [Figure 8-C] Same as above. [Figure 9] Figure 9 shows the efficacy of a single dose of 3 mg / kg of mAb6 (5E7) antibody as a camptothecin ADC in a mouse model of human breast cancer, in comparison with the same doses of enfortumab, N41 and isotype control antibody (IC). Each antibody was conjugated with the same camptothecin analog (Dxd) and tetrapeptide-containing linker (GGFG) at an equal drug-antibody ratio (DAR=8). Only 5E7 was able to effectively control tumor growth. [Figure 10]Figure 10 shows the killing of SUM185 human breast cancer cells expressing relatively high levels of Nectin-4 by the mAb6 (5E7) antibody compared to Padcev™ (enfortumab vedotin) (enfortumab conjugated to the auristatin compound MMAE at DAR=4) and Enhertu™. This setting is used as a model for anti-HER2 resistance. [Figure 11-A] 11A and 11B show the binding of anti-nectin-4 antibodies to rat and cynomolgus monkey nectin-4 expressing CHO cell lines, respectively, as determined by flow cytometry. Enfortumab and mAbs 6 and 7 bind to rat nectin-4, but mAbs 1 to 5 do not. [Figure 11-B] Same as above. [Figure 12-A] 12A and 12B show the structure of human Nectin-4 protein with substitution shading, indicating the white regions corresponding to the C1 domain residues that are substituted in mutants 7 (12A) and 7bis (12B). [Figure 12-B] Same as above. [Figure 13-A] 13A and 13B show several views of the structure of human Nectin-4 protein with substitution shading, where the white areas corresponding to the residues substituted in mutants 1, 2, 3, 4, 5, 6, 7, 8 and 9 are indicated. [Figure 13-B] Same as above. [Figure 14-A] Figure 14A shows the luminescence in SUM190 cells (indicating cell viability) for 6C11B compared to antibody 5E7. Figure 14B shows the luminescence in SUM190 cells (indicating cell viability) for 6A7 compared to antibody 5E7. Both 6C11B and 6A7 were each as efficient as 5E7 in inducing internalization into SUM190 cells. [Figure 14-B] Same as above. [Figure 15-A]Figures 15A, 15B and 15c show the evolution of tumor growth over time (days after tumor implantation) in mice treated with ADC. Figures 15A and 15B show treatment with different antibodies conjugated to the same linker-payload at the same DAR, iv, at a dose of 3 mg / kg body weight. Figure 15C shows treatment with antibody 5E7, conjugated to a linker designed to release either Dxd or exatecan upon cleavage of the linker, iv, at a dose of 10 mg / kg body weight. [Figure 15-B] Same as above. [Figure 15-C] Same as above. [Figure 16-A] Figure 16A shows the luminescence (indicating cell viability) of cells treated with Padcev™ (enfortumab vedotin), antibody 5E7 conjugated to Dxd, or 5E7 conjugated to exatecan. The cells are MC-38 cells that endogenously express MDR1 p-glycoprotein and have been engineered to express nectin-4. ADCs with exatecan as payload were highly potent in reducing cell viability in this drug-resistant setting. FIG. 16B shows tumor growth (area under the curve) normalized to control antibody at 150 nM ADC for MC38 cells treated with Padcev™ (enfortumab vedotin), antibody 5E7 conjugated to Dxd, or 5E7 conjugated to exatecan in the presence or absence of the Pgp inhibitor cyclosporine, suggesting that the anti-tumor activity of Padcev™ and antibody 5E7 conjugated to Dxd is negatively affected by Pgp. [Figure 16-B] Same as above. [Figure 17-A]Figures 17A and 17B show the time course of tumor growth in mice treated with enfortumab vedotin, antibody 6A7 conjugated to deruxtecan, or 6A7 conjugated to exatecan in a model of MDR1 p-glycoprotein-expressing tumors, either once (Figure 17A) or three weekly injections (Figure 17B). Antibody 6A7 conjugated to exatecan was able to induce a significant reduction in tumor volume in this model of drug resistance. [Figure 17-B] Same as above. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0085] Introduction The present inventors provide herein a method for improving the delivery of cytotoxic agents to Nectin-4 positive tumors. In particular, the present invention arises from the observation that certain antibodies that bind to a site in the region of Nectin-4 that bridges the Ig-like V and Ig-like C2 type 1 domains, which are associated with cell-cell interactions, result in a three-fold increase in efficacy in anti-tumor activity compared to the gold standard anti-Ig-like V type domain ADC. The cell-cell interaction can be mediated by the interaction of Nectin-4 of a first cell with Nectin-1 and / or Nectin-4 of a second cell (Nectin-4:Nectin-1 or Nectin-4:Nectin-4 interaction). When prepared as ADCs with topoisomerase I inhibitors (camptothecin analogs Dxd and exatecan), antibodies binding to the above-mentioned sites on Nectin-4 demonstrated greater antitumor activity in vivo when compared with the gold standard antibody Enfortumab or comparator antibodies that bind to a different location on Nectin-4 bridging the Ig-like V and Ig-like C2 type 1 domains.

[0086] In general, the antibodies and fragments can be suitably used for their ability (or in methods of sensitizing) tumors to cytotoxic agents and / or for their ability (or in methods of suppressing) anti-cancer drug resistance. Thus, the antibodies and fragments of the present disclosure can be used (administered) in combination with a cytotoxic agent (e.g., a chemotherapeutic agent), where the cytotoxic agent is administered as a separately administered unconjugated agent, or in the same pharmaceutical formulation as the anti-Nectin-4 antibody, or as an immunoconjugate in which the cytotoxic agent is conjugated to the anti-Nectin-4 antibody.

[0087] One object of the present disclosure is an antibody (e.g., a full length antibody, an antibody fragment) that binds to an epitope of Nectin-4 that includes one, two or three residues selected from the group consisting of S195, K197 and S199 (according to SEQ ID NO:1).

[0088] One object of the present disclosure is an antibody (e.g., a full-length antibody, an antibody fragment) having reduced binding to a mutant nectin-4 polypeptide comprising a mutation at one or more (or all) residues selected from the group consisting of S195, K197 and S199 (according to SEQ ID NO: 1), wherein the mutant nectin-4 polypeptide may have the mutations S195A, K197T and S199A.

[0089] One object of the present disclosure is an antibody (e.g., a full-length antibody, an antibody fragment) with reduced binding to a mutant Nectin-4 polypeptide comprising mutations at one or more (or all) residues selected from the group consisting of S195, K197 and S199 (according to SEQ ID NO: 1), wherein the mutant Nectin-4 polypeptide may have mutations S195A, K197T and S199A, for use in the preparation of antibody drug conjugates.

[0090] One object of the present disclosure is a human nectin-4 polypeptide comprising a mutation at one or more (or all) residues selected from the group consisting of S195, K197 and S199 (according to SEQ ID NO: 1). The mutated human nectin-4 polypeptide can be a full-length nectin-4 polypeptide or a fragment thereof, such as an extracellular domain fragment, a VC domain fragment, a fragment comprising the V and C1 domains, or a fragment comprising at least 10, 20, 30, 50.100 or 200 consecutive amino acid residues of the nectin-4 polypeptide of SEQ ID NO: 1. The mutant nectin-4 polypeptide may comprise mutations at residues K197 and S199 (e.g., K197T and S199A), the mutant nectin-4 polypeptide may comprise mutations at residues S195, K197 and S199 (e.g., S195A, K197T and S199A), the mutant nectin-4 polypeptide may comprise mutations at residues A72, G73, K197 and S199 (e.g., A72P / G73N / K197T / S199A). Also provided are recombinant host cells that express (are engineered to express) such polypeptides, for example at the cell surface. The mutant polypeptides and / or host cells can be used in methods of making, testing, preparing or screening antibodies and / or antibody drug conjugates.

[0091] The reduced binding to a mutant Nectin-4 polypeptide can be compared to binding to a Nectin-4 polypeptide not having a mutation, for example a wild-type Nectin-4 polypeptide, such as a polypeptide comprising the amino acid sequence of SEQ ID NO:1.

[0092] One of the objects of the present disclosure is a Nectin-4 binding antibody or antibody fragment that is a function-conserving variant of the antibody 5E7, 10B12 or 6A7.One of the objects of the present disclosure is a Nectin-4 binding antibody or antibody fragment that competes with the antibody 5E7, 10B12 or 6A7 for binding to an epitope of Nectin-4.One of the objects of the present disclosure is a Nectin-4 binding antibody or antibody fragment that binds to the same site or epitope of Nectin-4 as the antibody 5E7, 10B12 or 6A7.One of the objects of the present disclosure is an antibody or antibody fragment that includes the heavy and light chain CDRs of the antibody 5E7, 10B12 or 6A7. One object of the present disclosure is an antibody or antibody fragment that binds Nectin-4 and comprises heavy and light chain CDRs having at least 70%, 80%, 85%, 90%, 95% or 98% sequence identity to the heavy and light chain CDRs of antibody 5E7, 10B12 or 6A7.

[0093] One of the objects of the present disclosure is a method for making ADC.When preparing ADC, it may be advantageous to link a cytotoxic agent (such as a topoisomerase inhibitor or a camptothecin analogue) to an antibody that binds to the above-mentioned site of nectin-4.In one of the objects, a method for making ADC is provided, which comprises conjugating a cytotoxic agent (Z) to an anti-nectin-4 antibody that binds to an epitope of nectin-4 that includes one, two or three residues selected from the group consisting of S195, K197 and S199, and / or has reduced binding to a mutant nectin-4 polypeptide with mutations S195A, K197T and S199A. The method may include contacting and / or reacting said anti-Nectin-4 antibody with a cytotoxic agent (Z) under suitable conditions such that an antibody-drug conjugate is formed, and isolating the antibody-drug conjugate, further, the anti-Nectin-4 antibody may be conjugated to the cytotoxic agent via a linker (X) connecting the antibody (Ab) and the cytotoxic agent (Z), further, the cytotoxic agent (Z) may be a topoisomerase I inhibitor, camptothecin, optionally a pentacyclic camptothecin analog, optionally a hexacyclic camptothecin analog, optionally exatecan, SN-38 or Dxd.

[0094] One of the objects of the present disclosure is an ADC comprising the Nectin-4 binding antibody or antibody fragment described herein conjugated to a cytotoxic agent, which further may be a topoisomerase I inhibitor, optionally a camptothecin analogue. When prepared as an ADC with a topoisomerase I inhibitor (camptothecin analogues Dxd and exatecan), the antibody bound to the above-mentioned site of Nectin-4 was highly potent in its ability to kill cancer cell lines expressing both Nectin-4 and P-glycoprotein, particularly HCT116, A375, MC38, A549, HT29 and MDA-MB-231 cell lines. Thus, such ADCs can be used with efficacy in cancer multidrug resistance, which is advantageous for treating Nectin-4 expressing cancers that are resistant to other drugs (e.g. auristatins, MMAE). One object of the present disclosure is the use of the immunoconjugate of the present disclosure for treating cancer, optionally urothelial cancer, optionally progressive recurrent or metastatic urothelial cancer, breast cancer, TNBC, non-small cell lung cancer, pancreatic cancer, ovarian cancer, head and neck squamous cell carcinoma or esophageal cancer.One object of the present disclosure is the use of the immunoconjugate of the present disclosure for treating cancer in an individual, said individual having relapsed and / or progressed after treatment with a nectin-4 binding agent conjugated to an auristatin or a cytotoxic agent capable of transport by Pgp, and the nectin-4 binding agent conjugated to the auristatin can be enfortumab vedotin. One of the objects of the present disclosure is the use of the immunoconjugate of the present disclosure to treat cancer in an individual, said individual having relapsed and / or progressed after treatment with an antibody that binds to HER2, optionally conjugated to a cytotoxic agent, optionally conjugated to a camptothecin analog, and the antibody may comprise the CDR and / or variable region of trastuzumab. In one embodiment, the individual has a Nectin-4 expressing cancer characterized by low or intermediate Nectin-4 expression in tumor cells, which may be determined by immunohistochemistry. In one embodiment, the individual has a Nectin-4 and HER2 expressing cancer. In one embodiment, the individual has a cancer characterized by tumor cells expressing low or intermediate levels of HER2 protein on their surface.In one embodiment, the individual has a cancer characterized by tumor cells expressing high levels of HER2 protein on the surface.In one embodiment, the individual has urothelial carcinoma, optionally progressive recurrent or metastatic urothelial carcinoma, breast cancer, TNBC, non-small cell lung cancer, pancreatic cancer, ovarian cancer, head and neck squamous cell carcinoma or esophageal cancer.In one embodiment, the individual has a cancer that has been pre-treated with a chemotherapeutic agent, optionally a chemotherapeutic agent transported by P-glycoprotein (Pgp), a platinum agent or a taxane, and / or has progressed after the pre-treatment.

[0095] definition As used herein, "a" or "an" may mean one or more. When used in the claims, when used with the word "comprising," the words "a" or "an" may mean one or more than one. As used herein, "another" may mean at least a second, or more than one.

[0096] Where "comprising" is used, this can be replaced with "consisting essentially of" or "consisting of," as appropriate.

[0097] "Nectin-4" and "Nectin-4 polypeptide" refer to a protein or polypeptide encoded by the NECTIN4 gene (see Uniprot Accession No. Q96NY8) or by a cDNA prepared from such a gene. Any naturally occurring isoform, allele, or variant is encompassed by the term Nectin-4 polypeptide (e.g., a Nectin-4 polypeptide that is 95%, 98%, or 99% identical to SEQ ID NO: 1, or to a contiguous sequence of at least 100, 200, 300, 400, or 500 amino acid residues thereof). The 510 amino acid residue sequence of authentic human Nectin-4 (isoform 1), including the 31 amino acid signal peptide, is shown below: MPLSLGAEMW GPEAWLLLLL LLASFTGRCP AGELETSDVV TVVLGQDAKL PCFYRGDSGE QVGQVAWARV DAGEGAQELA LLHSKYGLHV SPAYEGRVEQ PPPPRNPLDG SVLLRNAVQA DEGEYECRVS TFPAGSFQAR LRLRVLVPPL PSLNPGPALE EGQGLTLAAS CTAEGSPAPS VTWDTEVKGT TSSRSFKHSR SAAVTSEFHL VPSRSMNGQP LTCVVSHPGL LQDQRITHIL HVSFLAEASV RGLEDQNLWH IGREGAMLKC LSEGQPPPSY NWTRLDGPLP SGVRVDGDTL GFPPLTTEHS GIYVCHVSNE FSSRDSQVTV DVLDPQEDSG KQVDLVSASV VVVGVIAALL FCLLVVVVVL MSRYHRRKAQ QMTQKYEEEL TLTRENSIRR LHSHHTDPRS QPEESVGLRA EGHPDSLKDN SSCSVMSEEP EGRSYSTLTT VREIETQTEL LSPGSGRAEE EEDQDEGIKQ AMNHFVQENG TLRAKPTGNG IYINGRGHLV (SEQ ID NO: 1)

[0098] SEQ ID NO:1 corresponds to the UniProt KB identifier Q96NY8-1, the disclosure of which is incorporated herein by reference.

[0099] Certain aspects of the present disclosure provide anti-Nectin-4 antibodies that bind to human Nectin-4, or homologs thereof, including, but not limited to, mammalian Nectin-4 proteins and Nectin-4 orthologs from other species, such as non-human primates, macaca fascicularis.

[0100] The term "HER2" (also known as HER2 / neu and ErbB-2) refers to "human epidermal growth factor receptor 2." This term includes variants and isoforms of HER2.

[0101] The terms "immunoconjugate" and "antibody conjugate" are used interchangeably and refer to an antigen-binding agent, e.g., an antibody bound to a polypeptide, or an antibody conjugated to another molecule (e.g., a camptothecin derivative, an exatecan molecule, an SN-38 molecule). When the immunoconjugate comprises an antigen-binding agent conjugated to a therapeutic agent, e.g., a cytotoxic or anticancer agent, the immunoconjugate may also be referred to as an "antibody drug conjugate" or "ADC". Examples of cytotoxic agents include camptothecins, taxanes, anthracyclines, camptothecins, epothilones, mitomycins, combretastatins, vinca alkaloids, nitrogen mustards, maytansinoids, calicheamycins, duocarmycins, tubulysins, dolastatins and auristatins, enediynes, pyrrolobenzodiazepines, and ethylenimines.

[0102] As used herein, "treatment" and "treating" generally refer to obtaining a desired pharmacological and physiological effect. The effect may be preventative in that it prevents or partially prevents the disease, its symptoms or conditions, and / or may be therapeutic in that it partially or completely cures the disease, conditions, symptoms or adverse effects caused by the disease. The term "treatment" as used herein encompasses any treatment of disease in a mammal, particularly a human, and includes (a) preventing the onset of the disease in a subject who may be predisposed to the disease but has not yet been diagnosed with the disease, e.g., preventive early asymptomatic intervention, (b) inhibiting the disease, e.g., arresting its onset, or relieving the disease, e.g., causing regression of the disease and / or its symptoms or conditions, e.g., amelioration of damage or cure, such as in a subject who has been diagnosed with the disease. Optionally, the treatment may cause (e.g., may be characterized as a method for causing) a reduction in tumor burden, a reduction in size and / or number of lesions, a reduction or delay in cancer progression (e.g., an increase in progression-free survival), a delay or prevention of cancer metastasis, and / or an increase in survival. Optionally, the treatment may cause (e.g., may be characterized as a method for causing) stable disease, partial response, or complete response in the subject according to standard criteria, which may be, for example, RECIST criteria.

[0103] Whenever "treatment of cancer" or the like is mentioned in connection with a Nectin-4 binding agent (e.g., an antibody or antibody fragment), (a) a method for the treatment of cancer, comprising the step of administering (for at least one treatment) a Nectin-4-binding agent to an individual, a mammal, in particular a human, in need of such treatment, in a dose (therapeutically effective amount) that allows for the treatment of cancer, optionally in the doses (amounts) defined herein; (b) use of a Nectin-4 binding agent for the treatment of cancer; (c) a Nectin-4 binding agent for use in the treatment of cancer (especially in humans); (d) use of a Nectin-4 binding agent for the manufacture of a pharmaceutical preparation for the treatment of cancer; (e) a method of using a Nectin-4 binding agent for the manufacture of a pharmaceutical preparation for the treatment of cancer, the method comprising admixing the Nectin-4 binding agent with a pharma- ceutically acceptable carrier; (f) a pharmaceutical preparation comprising an effective dose of a Nectin-4-binding agent suitable for the treatment of cancer; (g) Any combination of (a), (b), (c), (d), (e) and (f), depending on patentable subject matter in the country in which the application is filed. Includes:

[0104] The term "biopsy" as used herein is defined as the removal of tissue for the purpose of examination, such as to establish a diagnosis. Examples of types of biopsy include application of suction, e.g., by a needle attached to a syringe; removal of a piece of tissue by an instrument; removal using a suitable instrument via an endoscope; surgical excision, e.g., of the entire lesion, etc.

[0105] The term "antibody" as used herein refers to polyclonal and monoclonal antibodies. Depending on the type of constant domain in the heavy chain, antibodies are assigned to one of five major classes, namely IgA, IgD, IgE, IgG, and IgM. Some of these are further divided into subclasses or isotypes, e.g., IgG1, IgG2, IgG3, IgG4, etc. An exemplary immunoglobulin (antibody) structural unit comprises a tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one "light" chain (about 25 kDa) and one "heavy" chain (about 50-70 kDa). The N-terminus of each chain defines a variable region of about 100-110 amino acids or more that is primarily responsible for antigen recognition. The variable light chain (VLC) is a tetramer that is composed of two identical pairs of polypeptide chains, each pair having one "light" chain (about 25 kDa) and one "heavy" chain (about 50-70 kDa). The N-terminus of each chain defines a variable region of about 100-110 amino acids or more that is primarily responsible for antigen recognition. L ) and variable heavy chain (V HThe terms "antibody" and "antibody" refer to these light and heavy chains, respectively. The heavy chain constant domains corresponding to the different classes of immunoglobulins are termed "alpha", "delta", "epsilon", "gamma" and "mu", respectively. The subunit structures and three-dimensional configurations of the different classes of immunoglobulins are well known. IgG is the exemplary class of antibody used herein because it is the most common antibody in the physiological situation and is the most easily made in a laboratory setting. The antibody may be a monoclonal antibody. Particular examples of antibodies are humanized, chimeric, human, or otherwise suitable for humans. "Antibody" also includes any fragment or derivative of any of the antibodies described herein.

[0106] The amino acid residues of an antibody which are responsible for antigen-binding are sometimes referred to as hypervariable region. The hypervariable regions generally comprise amino acid residues from the "complementarity determining regions" or "CDRs" [e.g., residues 24-34 (L1), 50-56 (L2), and 89-97 (L3) in the light chain variable domain and 31-35 (H1), 50-65 (H2), and 95-102 (H3) in the heavy chain variable domain; Kabat et al. 1991] and / or amino acid residues from the "hypervariable loops" [e.g., residues 26-32 (L1), 50-52 (L2), and 91-96 (L3) in the light chain variable domain and 26-32 (H1), 53-55 (H2), and 96-101 (H3) in the heavy chain variable domain; Chothia and Lesk, J. Mol. Biol 1987;196:901-917], or a similar system for determining essential amino acids responsible for antigen binding. Typically, the numbering of amino acid residues in this region is performed by the method described in Kabat et al., supra. Phrases such as "Kabat position", "variable domain residue numbering in Kabat" and "according to Kabat" herein refer to this numbering system for the heavy chain variable domain or the light chain variable domain. When using the Kabat numbering system, the actual linear amino acid sequence of the peptide may contain fewer or additional amino acids corresponding to shortening or insertion into the FR or CDR of the variable domain. For example, a heavy chain variable domain may contain a single amino acid insertion after residue 52 of CDR H2 (residue 52a according to Kabat) and inserted residues after heavy chain FR residue 82 (e.g., residues 82a, 82b, and 82c, etc. according to Kabat). The Kabat numbering of residues can be determined for a given antibody by alignment in the region of homology of the sequence of the antibody with the "standard" Kabat numbering sequence.

[0107] The term "specifically binds to" means that the antibody can bind to a binding partner, such as Nectin-4, preferably in a competitive binding assay, when assessed using either a recombinant form of the protein, an epitope therein, or a native protein present on the surface of an isolated target cell. Competitive binding assays and other methods for determining specific binding are well known in the art. For example, binding can be detected via physical methods such as radiolabeling, mass spectrometry, or direct or indirect fluorescent labeling, for example, detected using cytofluorometry (e.g., FACScan). Binding that exceeds the amount seen with a control, i.e., a non-specific agent, indicates that the agent binds to the target.

[0108] When an antibody is said to "compete with" a particular monoclonal antibody, this means that the antibody competes with the monoclonal antibody in a binding assay using either a recombinant molecule (e.g., Nectin-4) or a surface-expressed molecule (e.g., Nectin-4). For example, if a test antibody reduces the binding of an antibody having a heavy chain variable region of either SEQ ID NO: 6 or 24 and a light chain variable region of SEQ ID NO: 7 or 25, respectively, to a Nectin-4 polypeptide or a Nectin-4-expressing cell in a binding assay, the test antibody is said to "compete with" such antibody, respectively.

[0109] The term "internalization" is used interchangeably with "intracellular internalization" and refers to the molecular, biochemical and cellular events associated with the process of transferring a molecule from the extracellular surface of a cell to the intracellular surface of a cell. The processes responsible for intracellular internalization of molecules are well known and may involve, among others, the internalization of extracellular molecules (e.g., hormones, antibodies, and small organic molecules); membrane-associated molecules (e.g., cell surface receptors); and complexes of membrane-associated molecules bound to extracellular molecules (e.g., ligands bound to transmembrane receptors or antibodies bound to membrane-associated molecules). Thus, "inducing and / or increasing internalization" includes events that initiate intracellular internalization and / or increase the rate and / or extent of intracellular internalization.

[0110] The term "affinity" as used herein means the strength of binding of an antibody to an epitope. The affinity of an antibody is indicated by the dissociation constant Kd, defined as [Ab] x [Ag] / [Ab-Ag], where [Ab-Ag] is the molar concentration of the antibody-antigen complex, [Ab] is the molar concentration of unbound antibody, and [Ag] is the molar concentration of unbound antigen. The affinity constant K a is defined by 1 / Kd. Methods for determining the affinity of monoclonal antibodies can be found in Harlow, et al., Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1988), Coligan et al., eds., Current Protocols in Immunology, Greene Publishing Assoc. and Wiley Interscience, NY, (1992, 1993), and Muller, Meth. Enzymol. 92:589-601 (1983), which are incorporated herein by reference in their entirety. One standard method well known in the art for determining the affinity of monoclonal antibodies is the use of surface plasmon resonance (SPR) screening (e.g., by analysis using a BIAcore™ SPR analyzer).

[0111] In the present context, a "determinant" refers to a site of interaction or binding on a polypeptide.

[0112] The term "epitope" refers to an antigenic determinant, a location or region of an antigen to which an antibody binds. A protein epitope may include amino acid residues directly involved in binding and those that are effectively blocked by a specific antigen-binding antibody or peptide, i.e., amino acid residues within the "footprint" of an antibody. An epitope is the simplest form or smallest structural part in a complex antigen molecule that can be associated with, for example, an antibody or a receptor. An epitope may be a linear epitope or a conformational / structural epitope. The term "linear epitope" is defined as an epitope composed of amino acid residues that are contiguous in a linear sequence of amino acids (primary structure). The term "conformation or structural epitope" is defined as an epitope composed of amino acid residues that represent separate portions of a linear sequence of amino acids that are not all contiguous and therefore are in close proximity to each other due to folding of the molecule (secondary, tertiary and / or quaternary structure). Conformational epitopes depend on a three-dimensional structure. Thus, the term "conformation" is often used interchangeably with "structure".

[0113] The term "agent" is used herein to refer to a chemical compound, a mixture of chemical compounds, a biopolymer, or an extract made from biological material. The term "therapeutic agent" refers to an agent that has biological activity.

[0114] The terms "Fc domain," "Fc portion," and "Fc region" refer to a C-terminal fragment of an antibody heavy chain, e.g., derived from about amino acid (aa) 230 to about aa 450 of the human gamma (gamma) heavy chain or the corresponding sequences in other types of antibody heavy chains (e.g., alpha, delta, epsilon, and mu of human antibodies), or naturally occurring allotypes thereof. Unless otherwise specified, the generally accepted Kabat amino acid numbering for immunoglobulins is used throughout this disclosure (see Kabat et al. (1991) Sequences of Protein of Immunological Interest, 5th ed., United States Public Health Service, National Institute of Health, Bethesda, MD).

[0115] "Framework" or "FR" residues, as used herein, refer to the regions of an antibody variable domain excluding the regions defined as the CDRs. Each antibody variable domain framework can be further subdivided into contiguous regions (FR1, FR2, FR3 and FR4) separated by the CDRs.

[0116] The terms "isolated," "purified," or "biologically pure" refer to material that is substantially or essentially free from components that normally accompany the material as found in its native state. Purity and homogeneity are typically determined using analytical chemistry techniques such as polyacrylamide gel electrophoresis or high performance liquid chromatography. A protein that is the predominant species present in a preparation is substantially purified.

[0117] The terms "polypeptide," "peptide," and "protein" are used interchangeably herein to refer to a polymer of amino acid residues. These terms apply to amino acid polymers in which one or more amino acid residues are artificial chemical mimetics of a corresponding naturally occurring amino acid, as well as to naturally occurring and non-naturally occurring amino acid polymers.

[0118] The term "recombinant," when used in reference to, for example, a cell, or a nucleic acid, protein, or vector, indicates that the cell, nucleic acid, protein, or vector has been modified by the introduction of a heterologous nucleic acid or protein, or the alteration of a native nucleic acid or protein, or that the cell is derived from a cell so modified. Thus, for example, a recombinant cell expresses genes that are not found in the native (non-recombinant) form of the cell, or expresses native genes that are otherwise aberrantly expressed, under-expressed, or not expressed at all.

[0119] In the present context, the term an antibody that "binds" to a polypeptide or epitope denotes an antibody that binds to said determinant with specificity and / or affinity.

[0120] The term "identity" or "identical", when used in the context of the sequences of two or more polypeptides, refers to the degree of sequence relatedness between the polypeptides, as determined by the number of matches between strings of two or more amino acid residues. "Identity" measures the percent of exact matches between the smaller of two or more sequences, with gap alignments (if any), as processed by a particular mathematical model or computer program (i.e., "algorithm"). The identity of related polypeptides can be readily calculated by known methods. Such methods include, but are not limited to, those described in Computational Molecular Biology, Lesk, AM, ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Smith, DW, ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part 1, Griffin, AM, and Griffin, HG, eds., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M. Stockton Press, New York, 1991; and Carillo et al., SIAM J. Applied Math. 48, 1073 (1988).

[0121] Methods for determining identity are designed to show the greatest match between the sequences tested. Methods for determining identity are described in publicly available computer programs. Computer program methods for determining identity between two sequences include the GCG program package, including GAP (Devereux et al., Nucl. Acid. Res. 12, 387 (1984); Genetics Computer Group, University of Wisconsin, Madison, Wis.), BLASTP, BLASTN, and FASTA (Altschul et al., J. Mol. Biol. 215, 403-410(1990)). The BLASTX program is available from the National Center for Biotechnology Information (NCBI) and other sources (BLAST Manual, Altschul et al. NCB / NLM / NIH Bethesda, Md. 20894, Altschul et al., supra). The well-known Smith Waterman algorithm can also be used to determine identity.

[0122] As used herein, "alkyl" refers to a straight or branched hydrocarbon chain that includes a fully saturated (no double or triple bonds) hydrocarbon group. An alkyl group can have, for example, 1 to 20 carbon atoms (whenever expressed herein, a numerical range such as "1 to 20" refers to each integer in the given range, e.g., "1 to 20 carbon atoms" means that an alkyl group can consist of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc., up to 20 carbon atoms, although this definition also encompasses occurrences of the term "alkyl" where no numerical range is specified). The alkyl group of a compound is "C 1 ~C 4 By way of example only, "C 1 ~C 4"Alkyl" indicates that 1 to 4 carbon atoms are present in the alkyl chain, i.e., the alkyl chain is selected from methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, and t-butyl. Typical alkyl groups include, but are in no way limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tertiary butyl, pentyl, and hexyl. Alkyl groups may be substituted or unsubstituted.

[0123] As used herein, the term "heteroalkyl" refers to a straight- or branched-chain alkyl group that contains one or more heteroatoms, i.e., elements other than carbon (including, but not limited to, oxygen, sulfur, nitrogen, phosphorus), replacing one or more carbon atoms.

[0124] Whenever a group is described as being "substituted," the group is substituted with one or more of the indicated substituents. When no substituents are indicated, it is meant that the indicated "substituted" group can be substituted with one or more groups individually and independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heteroalkyl, aryl, heteroaryl, heteroalicyclyl, aralkyl, heteroaralkyl, (heteroalicyclyl)alkyl, hydroxy, alkoxy, aryloxy, acyl, mercapto, alkylthio, arylthio, cyano, halogen, thiocarbonyl, carbamyl, thiocarbamyl, amido, sulfonamido, sulfonamido, carboxy, isocyanato, thiocyanato, isothiocyanato, nitro, silyl, sulfenyl, sulfinyl, sulfonyl, haloalkyl, haloalkoxy, trihalomethanesulfonyl, trihalomethanesulfonamido, amino, mono- and di-substituted amino groups, and protected derivatives thereof.

[0125] Where the number of substituents is not specified (e.g., haloalkyl), one or more substituents may be present. For example, "haloalkyl" may include one or more of the same or different halogens. As another example, "C 1 ~C 3 The "alkoxyphenyl" may include one or more of the same or different alkoxy groups containing 1, 2 or 3 atoms.

[0126] Reference to a "compound" or "formula" having a particular number (e.g., "compound 1," "compound 2," "formula I," or "formula II") refers to all compounds derived from the particular number or formula, unless the context clearly dictates otherwise. For example, compound 1 includes reference to compounds 1a and 1b.

[0127] Nectin-4 binding antibodies and antibody fragments The hypervariable region, heavy and light chain CDRs, heavy and light chain variable regions, and antibodies comprising them, such as full-length antibodies or antibody fragments, can bind to human Nectin-4 expressed on the surface of cells, such as tumor cells. In one embodiment, Nectin-4 binding by the antibody is mediated by a single antigen-binding domain or two identical antigen-binding domains, where each antigen-binding domain may comprise a VH and VL domain pair or a single variable domain (e.g., sdAb).

[0128] When used as either immunoconjugates or unconjugated ("naked") antibodies (e.g., optionally in combination with a separately administered cytotoxic agent) in therapy for the elimination of Nectin-4-expressing tumor cells, Nectin-4-binding antibodies (e.g., full-length antibodies, antibody fragments) or proteins, conjugates or complexes comprising such antibodies may advantageously inhibit cell-cell interactions mediated by Nectin-4, as determined, for example, by assessing cell cluster formation of Nectin-4-expressing cells (e.g., by assessing tumor spheroid formation or growth in a three-dimensional cell culture system) and / or by assessing anchorage-independent growth of Nectin-4-expressing cells. When used in therapy for the elimination of Nectin-4-expressing tumor cells, either as an immunoconjugate with a cytotoxic agent or as an unconjugated ("naked") antibody combined with a separately administered cytotoxic agent, the Nectin-4-binding antibody may advantageously be able to sensitize the tumor to the cytotoxic agent, e.g., the antibody may enhance the ability of the cytotoxic agent to inhibit the proliferation or cause death of tumor cells, e.g., to inhibit the proliferation or cause death of tumor cells in clusters (e.g., spheroids), or to inhibit the formation or growth of tumor cell clusters (e.g., spheroids). When used as an immunoconjugate in therapy for the elimination of Nectin-4-expressing tumor cells, the anti-Nectin-4 immunoconjugate, when conjugated to a cytotoxic molecule disclosed herein, may advantageously be able to cause the death of Nectin-4-expressing tumor cells.

[0129] Tumor cells that express Pgp may have reduced sensitivity to certain cytotoxic agents. Antibodies and cytotoxic agents (whether or not the cytotoxic agent is conjugated to the antibody) can be tested, where appropriate, using cells (e.g., tumor cells) that express Pgp.

[0130] Tumor spheroids are generally less sensitive to chemotherapy, in part due to the protection provided by their structure, but also due to their slower growth rate, and as a result may be useful for evaluating the antitumor effect of antibodies or immunoconjugates.Antibodies or immunoconjugates can be tested for their ability to inhibit spheroid formation in a concentration-dependent manner or to prevent spheroid formation of cancer cells.Antibodies or immunoconjugates can be tested for their ability to modify spheroid formation in different cancer cell lines, for example, using real-time digital photography.

[0131] The antibody or immunoconjugate can be characterized, for example, as being capable of maintaining (or improving) the maintenance of cancer cells as single cells, which can render the cells more sensitive to cytotoxic agents (e.g., chemotherapy). Promotion of the maintenance of cancer cells as single cells to improve sensitivity to chemotherapy can be tested in vitro by adding different chemotherapeutic agents (e.g., doxorubicine, cisplatin, paclitaxel, camptothecin, or camptothecin analogs) at different concentrations, either separately or in combination, in the presence of the antibody or immunoconjugate, and may be compared to an antibody or immunoconjugate that binds to the Ig-like V domain or the Ig-like C2 type 1 or 2 domain alone. Maintenance of cancer cells as single cells to improve sensitivity to chemotherapy can also be tested in vitro, for example by adding different immunoconjugates targeting different domains of Nectin-4, for example with different toxins, where the IC50 of chemotherapy or ADCs whose antibodies bind to the VC1 domain of Nectin-4 is lower, or the dose of ADCs whose antibodies bind to the VC1 domain of Nectin-4 is lower, used to control tumor growth. Sensitivity to chemotherapy can be assessed as cell viability, cell proliferation or cytotoxicity, and can be monitored using different readouts, for example CTG by luminescence, Incucyte or confluence using caspase 3 / 7 or Annexin V. In one embodiment, the anti-Nectin-4 antibody or antibody fragment binds to wild-type human Nectin-4 polypeptide, for example a polypeptide having the amino acid sequence of SEQ ID NO: 1, as well as modified human Nectin-4 polypeptide having the amino acid sequence of SEQ ID NO: 32 (a Nectin-4 protein containing Ig-like C2 type 1 and 2 domains but lacking the Ig-like V type domain.The antibody may retain partial binding to a polypeptide lacking an Ig-like V-type domain, and the antibody may retain binding to a nectin-4 protein lacking an Ig-like V-type domain at a reduced level compared to binding to a wild-type nectin-4 protein, for example the reduced level is between 5-50%, optionally 5-30%, optionally 5-25%, optionally 5-15% of binding to wild-type nectin-4. Further, the anti-nectin-4 antibody may not bind to a nectin-4 polypeptide lacking both an Ig-like V-type domain and an Ig-like C2-type 1 domain, for example a polypeptide having the amino acid sequence of SEQ ID NO: 33. Binding may be assessed by flow cytometry using cells engineered to express the nectin-4 polypeptide and the fluorescence intensity level (e.g. MFI) determined.

[0132] In one embodiment, the anti-Nectin-4 antibody or antibody fragment does not bind to any of human Nectin 1 protein, human Nectin 2 protein, human Nectin 3 protein and human PVR protein. Each nectin or PVR protein can be defined as being expressed on the surface of a cell.

[0133] In one embodiment, the anti-Nectin-4 antibody or antibody fragment is A Nectin-4 polypeptide having the amino acid sequence of SEQ ID NO:1, and Nectin-4 polypeptide having the amino acid sequence of SEQ ID NO: 32 (at a reduced level compared to binding to SEQ ID NO: 1, which may be between 5-50% as appropriate) and the anti-Nectin-4 antibody or antibody fragment binds to A polypeptide having the amino acid sequence of SEQ ID NO: 37, A polypeptide having the amino acid sequence of SEQ ID NO: 38, A polypeptide having the amino acid sequence of SEQ ID NO:39, and A polypeptide having the amino acid sequence of SEQ ID NO:40 does not bind to any of the

[0134] Furthermore, the anti-Nectin-4 antibody or antibody fragment may not bind to a polypeptide having the amino acid sequence of SEQ ID NO:33.

[0135] Furthermore, the anti-Nectin-4 antibody or antibody fragment may bind to the rat Nectin-4 polypeptide (eg, the amino acid sequence of SEQ ID NO:35).

[0136] In one embodiment, the anti-Nectin-4 antibody or antibody fragment binds to the VC1 cross-linking domain, epitope or determinant of Nectin-4.

[0137] In one embodiment, the anti-nectin-4 antibody or antibody fragment binds to human nectin-4 at one, two, three, four or five or more residues selected from the group consisting of A72, G73, S195, K197, S199, L150, S152, Q234 and I236 (according to SEQ ID NO: 1). In one embodiment, the anti-nectin-4 antigen binding protein or antibody binds to human nectin-4 at one, two or three residues selected from the group consisting of K197, S199 and Q234, optionally residues K197 and / or S199. In one embodiment, the anti-nectin-4 antibody or antibody fragment binds to residue K197 of human nectin-4. In one embodiment, the anti-nectin-4 antibody or antibody fragment binds to residue S199 of human nectin-4. In one embodiment, the anti-nectin-4 antibody or antibody fragment binds to residue Q234 of human nectin-4. Binding can be determined, for example, by assessing whether the antibody or antibody fragment has reduced or lost binding to a mutant Nectin-4 polypeptide (e.g., expressed on the surface of a cell) in which the residues have been replaced by different residues.

[0138] In one embodiment, the anti-Nectin-4 antibody or antibody fragment can bind to both the Ig-like V-type domain and the Ig-like C2-type 1 domain, for example, to a determinant or epitope on the Ig-like V-type domain and a determinant or epitope on the Ig-like C2-type 1 domain.

[0139] In one embodiment, the anti-Nectin-4 antibody or antibody fragment retains at least partial binding to a modified Nectin-4 polypeptide comprising an Ig-like C2-type 1 domain but lacking an Ig-like V-type domain, such as a Nectin-4 polypeptide lacking all or a portion of the amino acid sequence of SEQ ID NO: 3. Partial binding can be characterized as retaining binding, but at a reduced level (e.g., as assessed by flow cytometry) compared to binding to a wild-type human Nectin-4 polypeptide having the amino acid sequence of residues of SEQ ID NO: 1. A Nectin-4 polypeptide can be defined as being expressed on the surface of a cell (e.g., a host cell engineered to express the polypeptide).

[0140] Antibodies can be produced by various techniques known in the art. Typically, antibodies are produced by immunization of a non-human animal, preferably a mouse, with an immunogen comprising a Nectin-4 polypeptide, preferably a human Nectin-4 polypeptide. The Nectin-4 polypeptide may comprise the full-length sequence of the human Nectin-4 polypeptide, or a fragment or derivative thereof, typically an immunogenic fragment, i.e., a portion of the polypeptide comprising an epitope exposed on the surface of a cell expressing the Nectin-4 polypeptide, such as an epitope recognized by the 5E7, 10B12, 6C11B or 6A7 antibody. The Nectin-4 polypeptide may be defined as comprising or consisting of the VC1 cross-linking domain, or a fragment or subsequence thereof. Such a fragment typically contains at least about 7 consecutive amino acids of the mature polypeptide sequence, and even more preferably at least about 10 consecutive amino acids thereof. The fragment typically is essentially derived from the extracellular domain of the receptor. In one embodiment, the immunogen comprises a wild-type human Nectin-4 polypeptide in a lipid membrane, typically on the surface of a cell. In a specific embodiment, the immunogen comprises intact cells, particularly intact human cells, which may be treated or lysed. In another preferred embodiment, the polypeptide is a recombinant Nectin-4 polypeptide. In a specific embodiment, the immunogen comprises intact Nectin-4-expressing cells.

[0141] Immunizing a non-human mammal with an antigen can be carried out in any manner known in the art for stimulating the production of antibodies in mice (see, e.g., E. Harlow and D. Lane, Antibodies: A Laboratory Manual., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1988), the entire disclosure of which is incorporated herein by reference).

[0142] Antibodies can also be produced by selection of combinatorial immunoglobulin libraries, for example as disclosed in (Ward et al. Nature, 341 (1989) p. 544, the disclosure of which is incorporated herein by reference in its entirety).

[0143] Identification of one or more antibodies that compete with monoclonal antibody 5E7, 10B12, 6C11B or 6A7 for binding to Nectin-4 can be readily determined using any one of a variety of immunological screening assays in which antibody competition can be assessed. Many such assays are routinely performed and well known in the art (see, e.g., U.S. Patent No. 5,660,827, incorporated herein by reference).

[0144] For example, if the test antibodies being examined are obtained from different source animals or are of different Ig isotypes, a simple competition assay may be used in which the control (e.g., 5E7, 10B12, 6C11B or 6A7) and the test antibody are mixed (or pre-adsorbed) and applied to a sample containing a Nectin-4 polypeptide. Protocols based on Western blotting and the use of surface plasmon resonance (e.g., Biacore™) analysis are suitable for use in such competition studies.

[0145] In certain embodiments, a control antibody (e.g., 5E7, 10B12, 6C11B or 6A7) is premixed with various amounts of test antibody (e.g., about 1:10 or about 1:100) for a certain period of time before being applied to the Nectin-4 antigen sample. In other embodiments, the control and various amounts of test antibody can be simply mixed during exposure to the Nectin-4 antigen sample. As long as it is possible to distinguish between bound and free antibodies (e.g., by using a separation or washing technique that removes unbound antibodies) and between 5E7, 10B12, 6C11B or 6A7 and the test antibody (e.g., by using a species-specific or isotype-specific secondary antibody, or by specifically labeling 5E7, 10B12, 6C11B or 6A7 with a detectable label), it can be determined whether the test antibody reduces the binding of 5E7, 10B12, 6C11B or 6A7 to the antigen. Binding of the (labeled) control antibody in the absence of a completely unrelated antibody can serve as a high control value. A low control value can be obtained by incubating a labeled (5E7, 10B12, 6C11B or 6A7) antibody with an unlabeled antibody of the exact same type (5E7, 10B12, 6C11B or 6A7), where competition can occur and reduce binding of the labeled antibody. The test antibody can reduce binding of 5E7, 10B12, 6C11B or 6A7 to the Nectin-4 antigen by at least about 50%, such as at least about 60%, or more preferably at least about 80% or 90% (e.g., about 65-100%), for example, at any ratio between about 1:10 and about 1:100 of 5E7, 10B12, 6C11B or 6A7:test antibody. Such a test antibody may reduce the binding of 5E7, 10B12, 6C11B or 6A7 to the Nectin-4 antigen by at least about 90% (eg, about 95%).

[0146] Competition can also be evaluated, for example, by flow cytometry tests. In such tests, cells with a given nectin-4 polypeptide can be incubated first with, for example, 5E7, 10B12, 6C11B or 6A7, and then with a test antibody labeled with a fluorescent dye or biotin. An antibody is said to compete with 5E7, 10B12, 6C11B or 6A7 if the binding obtained after preincubation with a saturating amount of 5E7, 10B12, 6C11B or 6A7 is about 80%, preferably about 50%, about 40% or less (e.g., about 30%, 20% or 10%) of the binding obtained by the antibody without preincubation with 5E7, 10B12, 6C11B or 6A7 (measured by the average of fluorescence). Alternatively, an antibody is said to compete with 5E7, 10B12, 6C11B or 6A7 if the binding obtained with a labeled 5E7, 10B12, 6C11B or 6A7 antibody (with a fluorescent dye or biotin) to cells preincubated with a saturating amount of the test antibody is about 80%, preferably about 50%, about 40% or less (e.g., about 30%, 20% or 10%) of the binding obtained in the absence of preincubation with the test antibody.

[0147] A simple competitive assay can also be used in which the test antibody is pre-adsorbed and applied to a surface on which the Nectin-4 antigen is immobilized at a saturating concentration. The surface in the simple competitive assay is preferably a Biacore™ chip (or other medium suitable for surface plasmon resonance analysis). Here, a control antibody (e.g., 5E7, 10B12, 6C11B or 6A7) is contacted with the surface at a saturating concentration of Nectin-4, and the surface binding of Nectin-4 and the control antibody is measured. This binding of the control antibody is compared to the binding of the control antibody to the Nectin-4-containing surface in the absence of the test antibody. In the test assay, a significant reduction in the binding of the control antibody to the Nectin-4-containing surface in the presence of the test antibody indicates that the test antibody recognizes substantially the same region of Nectin-4 as the control antibody, and thus the test antibody "cross-reacts" with the control antibody. The test antibody may, for example, reduce the binding of a control (e.g., 5E7, 10B12, 6C11B or 6A7) antibody to the Nectin-4 antigen by at least about 30% or more, preferably about 40%. Such a test antibody may reduce the binding of a control antibody (e.g., 5E7, 10B12, 6C11B or 6A7) to the Nectin-4 antigen by at least about 50% (e.g., at least about 60%, at least about 70% or more). It will be understood that the order of the control and test antibodies may be reversed, i.e., the control antibody may be bound to the surface first, and then the test antibody may be contacted with the surface in a competitive assay. Preferably, the antibody with a higher affinity for the Nectin-4 antigen is bound to the surface first, since it is expected that the reduction in binding seen for the second antibody (assuming the antibodies are cross-reacting) will be greater. Further examples of such assays are provided, for example, in Saunal (1995) J. Immunol. Methods 183: 33-41, the disclosure of which is incorporated herein by reference.

[0148] The antibody may bind to Nectin-4-expressing tumor cells from one or more individuals with cancer characterized by Nectin-4-positive tumor cells, i.e., individuals who are candidates for treatment with one of the methods described herein using anti-Nectin-4 antibodies. Thus, once an antibody that specifically recognizes cellular Nectin-4 is obtained, it may be tested for its ability to bind to Nectin-4-positive cells (e.g., cancer cells) as appropriate. It may be tested for its ability to bind to tumor cells expressing high levels of Nectin-4 polypeptide on their surface, and / or tumor cells expressing low levels of Nectin-4 polypeptide on their surface as appropriate. In particular, before treating a patient with one of the present antibodies, the antibody may be tested for its ability to bind to malignant cells obtained from the patient, for example, in a blood sample or tumor biopsy, in order to maximize the chances that the therapy will benefit the patient.

[0149] In one embodiment, the antibody is verified in an immunoassay that tests its ability to bind to Nectin-4 expressing cells, such as malignant cells. For example, blood samples or tumor biopsies are performed and tumor cells are collected. The ability of a given antibody to bind to cells is then evaluated using standard methods well known to those skilled in the art. To evaluate the binding of the antibody to cells, the antibody may be directly or indirectly labeled. When indirectly labeled, a secondary labeled antibody is typically added.

[0150] Determining whether an antibody binds within an epitope region can be carried out by means known to those skilled in the art. As an example of such a mapping / characterization method, the epitope region for an anti-nectin-4 antibody can be determined by epitope "footprinting" using chemical modification of exposed amines / carboxyls in the nectin-4 protein. One specific example of such a footprinting technique is the use of HXMS (hydrogen-deuterium exchange detected by mass spectrometry), in which hydrogen / deuterium exchange, binding, and back-exchange of receptor and ligand protein amide protons occurs, while backbone amide groups involved in protein binding are protected from back-exchange and therefore remain deuterated. At this stage, relevant regions can be identified by digestive proteolysis, fast microbore high performance liquid chromatography separation, and / or electrospray ionization mass spectrometry. See, for example, Ehring H, Analytical Biochemistry, Vol. 267 (2) pp. 252-259 (1999); Engen, JR and Smith, DL (2001) Anal. Chem. 73, 256fA-265A. Another example of a suitable epitope identification technique is nuclear magnetic resonance epitope mapping (NMR), in which the positions of signals in two-dimensional NMR spectra of free antigen and antigen complexed with an antigen-binding peptide, such as an antibody, are typically compared. The antigen is typically selectively isotopically labeled with 15N, so that only signals corresponding to the antigen are seen in the NMR spectrum, and signals from the antigen-binding peptide are not seen in the NMR spectrum. Antigen signals originating from amino acids involved in the interaction with the antigen-binding peptide typically shift in position in the spectrum of the complex compared to the spectrum of the free antigen, and the amino acids involved in binding can be identified as such.See, e.g., Ernst Schering Res Found Workshop. 2004; (44): 149-67, Huang et al., Journal of Molecular Biology, Vol. 281 (1) pp. 61-67 (1998), and Saito and Patterson, Methods, 1996 Jun; 9 (3): 516-24.

[0151] Epitope mapping / characterization can also be performed using mass spectrometry. See, for example, Downard, J Mass Spectrom. 2000 Apr ;35 (4): 493-503 and Kiselar and Downard, Anal Chem. 1999 May 1;71 (9): 1792-1801. Protease digestion techniques can also be useful in the context of epitope mapping and identification. Antigenic determinant-associated regions / sequences can be determined by protease digestion, for example, using trypsin in a ratio of about 1:50 to nectin-4 or overnight digestion at pH 7-8, followed by analysis by mass spectrometry (MS) for peptide identification. Peptides protected from trypsin cleavage by anti-nectin-4 binders can then be identified by comparison of samples subjected to trypsin digestion with samples incubated with the antibody followed by digestion, for example, by trypsin (thereby revealing a footprint for the binder). Other enzymes, such as chymotrypsin, pepsin, etc., can additionally or alternatively be used in similar epitope characterization methods. Furthermore, enzyme digestion can provide a rapid method to analyze whether potential antigenic determinant sequences are present within regions of the Nectin-4 polypeptide that are not surface exposed and therefore most likely not relevant in terms of immunogenicity / antigenicity.

[0152] Site-directed mutagenesis is another technique useful for elucidating binding epitopes. For example, in "alanine scanning", each residue in a protein segment is replaced with an alanine residue and the results for binding affinity are measured. If the mutation causes a significant decrease in binding affinity, it is most likely involved in binding. Monoclonal antibodies specific for structural epitopes (i.e., antibodies that do not bind to unfolded proteins) can be used to demonstrate that the alanine substitutions do not affect the overall folding of the protein. See, for example, Clackson and Wells, Science 1995; 267: 383-386, and Wells, Proc Natl Acad Sci USA 1996; 93: 1-6.

[0153] Electron microscopy can also be used for epitope "footprinting." For example, Wang et al., Nature 1992; 355: 275-278 used the coordinated application of cryo-electron microscopy, 3D image reconstruction, and X-ray crystallography to determine the physical footprint of Fab fragments on the capsid surface of native cowpea mosaic virus.

[0154] Other forms of "label-free" assays for epitope evaluation include surface plasmon resonance (SPR, BIACORE™) and reflectance interferometry (RifS).See, for example, Faegerstam et al., Journal Of Molecular Recognition 1990; 3:208-14; Nice et al., J. Chromatogr. 1993; 646:159-168; Leipert et al., Angew. Chem. Int. Ed. 1998; 37: 3308-3311; Kroeger et al., Biosensors and Bioelectronics 2002; 17:937-944.

[0155] It should also be noted that antibodies that bind to the same or substantially the same epitope as an antibody may be identifiable in one or more of the exemplary competition assays described herein.

[0156] In the immunization and production of antibodies in vertebrates or cells, or in the creation of a library of candidate antibodies or antibody sequences, a specific selection step may be carried out to isolate the claimed antibody. In this regard, in a specific embodiment, a method for producing such an antibody is provided, comprising: (a) immunizing a non-human mammal with an immunogen comprising a Nectin-4 polypeptide or preparing a library of antibodies or antibody sequences, and (b) preparing antibodies from said immunized animals or from said library of antibodies or sequences, and (c) selecting an antibody from step (b) that can bind to Nectin-4, optionally selecting an antibody from step (b) that can bind to the VC1 cross-linking domain of Nectin-4. Optionally, selecting antibodies capable of binding to the VC1 cross-linking domain of Nectin-4 from step (b) can be carried out by any suitable method, including but not limited to those described herein (e.g., epitope mapping / characterization methods, testing whether the antibody has reduced binding to a Nectin-4 mutant, testing whether the antibody binds to a Nectin-4 protein modified to lack the Ig-like V domain, etc.).

[0157] In one embodiment, the antibody has a titer of 1×10 for human Nectin-4, as determined, for example, by surface plasmon resonance (SPR) screening (e.g., by analysis using a BIAcore™ SPR analyzer). -8 M or less, 1×10 as appropriate -9 The average dissociation constant (K D In a more specific exemplary embodiment, the antibody may have a nucleotide sequence of about 1×10 for Nectin-4. -8 M ~ approx. 1×10 -10 M, or approximately 1 x 10 -9 M ~ approx. 1×10 -11An anti-Nectin-4 antibody having a KD of M is provided.

[0158] In one embodiment, an antibody of the present disclosure that binds to Nectin-4 can inhibit cell-cell interactions mediated by Nectin-4, e.g., as determined by assessing cell clustering and / or anchorage-independent growth of Nectin-4-expressing cells. For example, Nectin-4-expressing tumor cells can be contacted with an antibody that binds Nectin-4 to assess whether the antibody reduces cell-cell adhesion between Nectin-4-expressing tumor cells and / or inhibits the growth and / or clustering of Nectin-4-expressing tumor cells (e.g., as assessed using three-dimensional or non-adherent tumor cell culture; tumor spheroid assays).

[0159] In one embodiment, an antibody of the present disclosure that binds to Nectin-4 can inhibit cell-cell interactions mediated by Nectin-4, as determined by assessing spheroid formation by Nectin-4-expressing tumor cells. Determining whether an antibody can inhibit spheroid formation can include, for example, culturing Nectin-4-expressing tumor cells in three-dimensional or non-adherent tumor cell culture (e.g., in a tumor spheroid assay) in the presence of an antibody that binds to Nectin-4, and assessing whether the antibody inhibits spheroid formation.

[0160] In one embodiment, a method is provided for identifying or selecting an antibody for use in preparing or manufacturing an immunoconjugate (e.g., an antibody drug conjugate) or for use in treating cancer (e.g., in combination with a chemotherapeutic agent or as an ADC), comprising contacting an antibody that binds Nectin-4 with Nectin-4-expressing tumor cells (e.g., in three-dimensional or non-adherent tumor cell culture; in a tumor spheroid assay) and assessing whether the antibody inhibits clustering (e.g., spheroid formation) and / or anchorage-independent growth of Nectin-4-expressing tumor cells. The method may include selecting the antibody for use in treating cancer based on a determination that the antibody can inhibit clustering and / or anchorage-independent growth of Nectin-4-expressing tumor cells.

[0161] In one embodiment, a method is provided for identifying or selecting an antibody for use in preparing or manufacturing an immunoconjugate (e.g., an antibody drug conjugate) or for use in treating cancer (e.g., in combination with a chemotherapeutic agent or as an ADC), comprising contacting an antibody that binds to Nectin-4 with Nectin-4-expressing tumor cells (e.g., cells in a three-dimensional or non-adherent tumor cell culture; tumor spheroid assay) and assessing whether the antibody inhibits spheroid formation by Nectin-4-expressing tumor cells. The method may include selecting the antibody for use in treating cancer based on a determination that the antibody can inhibit spheroid formation by Nectin-4-expressing tumor cells.

[0162] In any of the above methods, the tumor cells may express Pgp(MDR1).

[0163] In any of the above methods, the method may further comprise the step of conjugating the antibody, preferably via a linker moiety, to a cytotoxic agent (e.g., a camptothecin analogue) either before or after assessing inhibition of tumor or tumor cell growth, thereby producing the immunoconjugates herein.

[0164] In one embodiment, selecting an antibody for use in preparing or manufacturing an immunoconjugate (e.g., an antibody drug conjugate) or for use in treating a cancer (e.g., a Nectin-4 positive cancer) involves contacting a cell (e.g., a tumor cell) that expresses a Nectin-4 polypeptide on its surface with an antibody drug conjugate that binds Nectin-4, and determining the ability of the antibody drug conjugate to cause death of the cell (e.g., potency, IC 50 In one embodiment, the selected antibody is more potent (e.g., has a lower IC) in causing cell death compared to an antibody drug conjugate having the VH and VL of the antibody enfortumab. 50 ) (when each ADC has the same linker-cytotoxic drug and drug:antibody ratio). The antibody drug conjugate may comprise an antibody that binds Nectin-4 conjugated to a camptothecin analog.

[0165] In one embodiment, a method is provided that can be used to select and / or identify an antibody suitable for use in the methods herein. The method can also be advantageously used as a "bioassay" to test and / or monitor the quality or activity of an antibody drug conjugate during the manufacturing process of the antibody drug conjugate. In one example, the method includes, for example, the steps of: (i) providing an antibody that inhibits cluster formation and / or anchorage-independent growth of Nectin-4-expressing tumor cells, where the antibody is conjugated to a cytotoxic agent; and (ii) contacting a cell expressing a Nectin-4 polypeptide on its surface with the antibody drug conjugate of step (i), and measuring the ability of the antibody drug conjugate to cause cell death (e.g., potency, IC 50The antibody drug conjugate may optionally be compared to a standard antibody drug conjugate composition for a predetermined efficacy or potency (e.g., a predetermined IC 50 If it is determined that the antibody drug conjugate is capable of causing cell death, with the antibody drug conjugate being compared to a specific antibody value (e.g., for further processing in manufacturing, for filling into containers such as vials or syringes, for use in the treatment of cancer, etc.).

[0166] "IC" for binding in activity assays (e.g., ability to cause cell death) 50 " (or E.C. 50 ) refers to the inhibitory or effective concentration of anti-Nectin-4 antibody that produces 50% of the maximal response or effect on a desired activity.

[0167] The assay herein may be particularly useful for antibodies that bind to the VC1 cross-linking domain.For example, in one embodiment, a method is provided for making, identifying or testing a nectin-4-binding antibody or an antibody drug conjugate comprising such a nectin-4-binding antibody, comprising contacting an antibody or antibody drug conjugate (or a sample from a production batch thereof) that exhibits reduced binding to a mutant nectin-4 polypeptide comprising a mutation at residues K197 and / or S199 compared to the binding between the antibody and a wild-type nectin-4 polypeptide with a cell expressing nectin-4, optionally a wild-type nectin-4 polypeptide, on its surface, and evaluating the ability of the antibody or antibody drug conjugate to undergo intracellular internalization, induce intracellular internalization of the antibody-nectin-4 complex, and / or cause the death of the cell.

[0168] In some embodiments, a method is provided for testing an antibody that binds to the VC1 cross-linking domain of Nectin-4, comprising: (i) contacting the antibody with cells expressing Nectin-4 on their surface (the cells may express Pgp) in the presence of a cytotoxic agent, where the antibody may be conjugated to a cytotoxic agent, and (ii) evaluating the ability of the antibody or conjugated antibody to cause death of the cells, optionally evaluating whether the antibody or conjugated antibody in the presence of the cytotoxic agent increases cell death compared to cell death observed in the presence of the cytotoxic agent alone. In one embodiment, the cells express Pgp and the cytotoxic agent is a camptothecin analog, optionally exatecan.

[0169] In some embodiments, methods are provided for testing an ADC comprising an antibody that binds the VC1 cross-linking domain of Nectin-4 conjugated to a cytotoxic agent (e.g., a camptothecin analog, exatecan), comprising: (i) contacting the ADC with a cell expressing Nectin-4 on its surface (the cell may express Pgp) in the presence of the cytotoxic agent; and (ii) assessing the ability of the ADC to cause death of the cell, optionally compared to a reference ADC, and optionally compared to cell death observed in the presence of the cytotoxic agent alone.

[0170] In one aspect of any embodiment, the antibody prepared according to the method is a monoclonal antibody.In another aspect, the non-human animal used to produce the antibody is a mammal, such as rodent, cow, pig, poultry, horse, rabbit, goat or sheep.Antibody of the present invention can be defined as any antibody other than antibody 5E7, 10B12, 6C11B or 6A7, or derivative thereof, including, for example, the whole or part of each heavy and light chain CDR or antigen-binding region.

[0171] DNA encoding an antibody that binds to an epitope present in the Nectin-4 polypeptide is isolated from the hybridoma and placed into an expression vector, which is then transfected into a host cell, such as Escherichia coli (E. coli) cells, monkey COS cells, Chinese Hamster Ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin proteins, resulting in the synthesis of monoclonal antibodies in the recombinant host cell. As described elsewhere herein, such DNA sequences can be modified for any of a number of purposes, for example, to humanize the antibody, to produce fragments or derivatives, or to modify the antibody sequence, for example, at the antigen-binding site, to optimize the binding specificity of the antibody. In one embodiment, an isolated nucleic acid sequence encoding the light and / or heavy chain of the antibody, as well as a recombinant host cell containing such nucleic acid (e.g., in its genome), is provided.

[0172] In one embodiment, the anti-Nectin-4 antibody is an antibody that is a function-conserving variant of an antibody having the heavy and light chain CDRs or variable regions of the antibody 5E7, 10B12, 6C11B or 6A7. A "function-conserving variant" is a variant in which a given amino acid residue in a protein (e.g., an antibody or antibody fragment) is altered without changing the overall conformation and function of the polypeptide, including but not limited to replacing an amino acid with one that has similar properties (e.g., polarity, hydrogen bonding ability, acidicity, basicity, hydrophobicity, aromaticity, etc.). Amino acids other than those shown to be conserved may differ in a protein, and thus the percent protein or amino acid sequence similarity between any two proteins of similar function may vary, for example, the similarity may be 70%-99%, as determined according to an alignment scheme such as by a clustering method based on the MEGALIGN algorithm. "Function-conservative variants" also include polypeptides that have at least 60% amino acid identity, preferably at least 75%, more preferably at least 85%, even more preferably at least 90%, and even more preferably at least 95% amino acid identity, as determined by BLAST or FASTA algorithms, and that have the same or substantially similar properties or functions as the native, reference or parent protein to which it is being compared.

[0173] The antibody can be evaluated and / or selected based on binding to the VC1 cross-linking domain of the nectin-4 polypeptide as a membrane-anchored nectin-4 polypeptide lacking an Ig-like V domain, for example, at the cell surface. In one aspect, the antibody binds to an antigenic determinant present in the Ig-like V domain and an antigenic determinant present in the C2 type 1 domain of the nectin-4 polypeptide, for example, present on a protein expressed at the cell surface. In one embodiment, the determinant is not entirely present in the Ig-like V domain and is not entirely present in the Ig-like C2 type 1 domain. In one embodiment, the antibody has a partial reduction in binding to a membrane-anchored nectin-4 polypeptide lacking an Ig-like V domain (i.e., a nectin-4 polypeptide having the amino acid sequence shown in SEQ ID NO: 32) compared to a wild-type membrane-bound nectin-4 polypeptide.

[0174] In one embodiment, a method for testing and / or producing an anti-Nectin-4 antibody (e.g., an antibody suitable for use in an immunoconjugate with a cytotoxic agent), comprising: (a) providing multiple antibodies that bind to the Nectin-4 protein; (b) assessing whether the antibody binds to an antibody against the VC1 cross-linking domain of Nectin-4; and (c) optionally selecting an antibody (e.g., from those evaluated in step (b)) that binds to an antibody against the VC1 cross-linking domain of Nectin-4; Optionally, step (b) comprises determining whether the antibody has a partially reduced binding to a membrane-anchored Nectin-4 polypeptide lacking an Ig-like V domain and / or whether the antibody is a mutant Nectin-4 polypeptide comprising one or more amino acid substitutions (e.g., at residues A72, G73, S195, K197, S199, L150, S152, Q234 and I236), optionally comprising one or more amino acid substitutions at residues K197, S199 and / or 1236. or Q234; optionally, a mutant nectin-4 polypeptide comprising substitutions S195A / K197T / S199A, optionally, a mutant nectin-4 polypeptide comprising substitutions A72P / G73N / K197T / S199A, or optionally, a mutant nectin-4 polypeptide comprising substitutions L150S / S152A / Q234R / I236S.

[0175] In one embodiment, a method for testing and / or producing an anti-Nectin-4 antibody (e.g., an antibody suitable for use in an immunoconjugate with a cytotoxic agent, which may be a camptothecin analogue), comprising: (a) providing multiple antibodies that bind to the Nectin-4 protein; (b) assessing whether the antibodies cause inhibition of cluster formation and / or anchorage-independent growth of Nectin-4-expressing tumor cells; and (c) optionally selecting antibodies (e.g., from those assessed in step (b)) that cause inhibition of cluster formation and / or anchorage-independent growth of Nectin-4-expressing tumor cells; Optionally, step (b) may further comprise evaluating whether the antibody binds and / or selecting an antibody that binds to the antibody against the VC1 cross-linking domain of Nectin-4.

[0176] In one embodiment, a method for testing and / or producing an anti-Nectin-4 antibody (e.g., an antibody suitable for use in an immunoconjugate with a cytotoxic agent, which may be a camptothecin analogue), comprising: (a) providing multiple antibodies that bind to the Nectin-4 protein; (b) assessing whether the antibody is capable of reducing cell-cell adhesion between Nectin-4-expressing tumor cells and / or inhibiting the growth and / or clustering of Nectin-4-expressing tumor cells (e.g., as assessed using three-dimensional or non-adherent tumor cell cultures; tumor spheroid assays); and (c) optionally selecting an antibody (e.g., from those assessed in step (b)) that is capable of reducing cell-cell adhesion between Nectin-4-expressing tumor cells and / or inhibiting the growth and / or clustering of Nectin-4-expressing tumor cells. Optionally, step (b) may further comprise evaluating whether the antibody binds and / or selecting an antibody that binds to the antibody against the VC1 cross-linking domain of Nectin-4.

[0177] In one embodiment, a method for testing and / or producing an anti-Nectin-4 antibody (e.g., an antibody suitable for use in an immunoconjugate with a cytotoxic agent, which may be a camptothecin analogue), comprising: (a) providing multiple antibodies that bind to the Nectin-4 protein; (b) assessing whether the antibody is capable of inhibiting cell-cell interactions mediated by Nectin-4, e.g., by assessing cell cluster formation and / or anchorage-independent growth of Nectin-4-expressing cells; and (c) optionally selecting antibodies (e.g., from those evaluated in step (b)) that are capable of inhibiting cell-cell interactions mediated by Nectin-4. A method is provided that includes:

[0178] In one embodiment, a method for testing and / or producing an anti-Nectin-4 antibody (e.g., an antibody suitable for use in an immunoconjugate with a cytotoxic agent, which may be a camptothecin analogue), comprising: (a) providing one or more antibodies that bind to Nectin-4 protein; (b) assessing whether the antibody can sensitize tumors (e.g., metastatic cancers, Nectin-4-expressing tumors) to cytotoxic agents (e.g., agent (Z) disclosed herein, camptothecin analogs); and (c) optionally selecting an antibody (e.g., from step (b)) capable of sensitizing the tumor to a cytotoxic agent (e.g., agent (Z), a camptothecin analogue disclosed herein); The method includes: Optionally, step (b) may further comprise contacting each antibody with tumor cells, which may be Pgp-expressing tumor cells (e.g., in a three-dimensional tumor cell culture, in a tumor spheroid assay) in the presence of a cytotoxic agent, and determining whether the antibody enhances the ability of the cytotoxic agent to cause tumor cell death compared to the cytotoxic agent in the absence of the antibody. Optionally, step (b) may further comprise evaluating whether the antibody binds and / or selecting an antibody that binds to the antibody against the VC1 cross-linking domain of Nectin-4.

[0179] In one embodiment, a method of testing and / or manufacturing an ADC (e.g., an ADC comprising an anti-Nectin-4 antibody that binds the VC1 cross-linking domain conjugated to a topoisomerase I inhibitor, a camptothecin analog, exatecan, comprising: (a) providing an ADC comprising an anti-Nectin-4 antibody that binds to the VC1 cross-linking domain, conjugated to a topoisomerase I inhibitor, optionally a camptothecin analog, and optionally exatecan; (b) contacting the ADC with Pgp-expressing tumor cells and assessing whether the antibody is capable of inducing the death of Pgp-expressing tumor cells (e.g., potency in inducing cell death, IC 50 (including determining (c) optionally, selecting an ADC if it is capable of inducing the death of Pgp-expressing tumor cells; Optionally, step (b) may comprise determining whether the ADC is capable of causing death of Pgp-expressing tumor cells compared to a topoisomerase I inhibitor alone (in the absence of antibody). Optionally, step (c) may comprise selecting the ADC if it is capable of causing increased death of Pgp-expressing tumor cells compared to a topoisomerase I inhibitor alone (in the absence of antibody).

[0180] In one embodiment, a method for selecting or testing an immunoconjugate or testing the suitability of a topoisomerase inhibitor for use in an anti-Nectin-4 immunoconjugate (e.g., for use in combination with an anti-Nectin-4 antibody, for use in an immunoconjugate by conjugation to an anti-Nectin-4 antibody), comprising: (a) providing an anti-Nectin-4 antibody, where the antibody may bind to the VC1 cross-linking domain of Nectin-4; (b) providing a topoisomerase inhibitor (e.g., one or more agents to be evaluated separately in step c) and conjugating the agent to the antibody of (a) (e.g., if more than one is to be evaluated, conjugating each agent separately); (c) assessing whether the topoisomerase inhibitor-conjugated antibody of step (b) is capable of causing the death of Pgp-expressing tumor cells; and Optionally, selecting an immunoconjugate or a topoisomerase inhibitor for use in an immunoconjugate if the ability to cause cell death is enhanced by the topoisomerase inhibitor conjugated antibody as compared to an immunoconjugate comprising a reference or comparative topoisomerase inhibitor conjugated antibody, as appropriate. The comparison or reference can include a different topoisomerase inhibitor and / or a different anti-Nectin-4 antibody.

[0181] In one embodiment, there is provided a method of selecting or testing the suitability of a chemotherapeutic or cytotoxic agent for use with an anti-Nectin-4 antibody that binds to the VC1 cross-linking domain of Nectin-4 (e.g., for use in combination with an anti-Nectin-4 antibody, for use in an immunoconjugate by conjugation to an anti-Nectin-4 antibody), comprising: (a) providing an anti-nectin-4 antibody that binds to the VC1 cross-linking domain of nectin-4; (b) providing a cytotoxic or chemotherapeutic agent (e.g., one or more agents to be evaluated separately in step c); (c) assessing whether the antibody can sensitize tumors (e.g., Pgp-expressing tumors, tumors derived from metastatic cancers, Nectin-4-expressing tumors) to drugs; and (d) Optionally, selecting an agent whose anti-tumor activity is enhanced by the antibody (e.g., for use in combination with an anti-Nectin-4 antibody, for use in an immunoconjugate by conjugation to an anti-Nectin-4 antibody). The method includes: Optionally, step (c) may further comprise contacting the antibody with tumor cells (e.g., Pgp-expressing cells, cells in a three-dimensional tumor cell culture in a tumor spheroid assay) in the presence of the agent, and determining whether the antibody enhances the ability of the cytotoxic agent to cause tumor cell death compared to the cytotoxic agent in the absence of the antibody. Optionally, step (a) may further comprise evaluating whether the antibody binds and / or selecting an antibody that binds to the antibody against the VC1 cross-linking domain of Nectin-4.

[0182] In any of the above methods of producing an antibody, the method may further comprise a step of evaluating the binding affinity of the antibody to a human Nectin-4 polypeptide, e.g., evaluating the 1:1 binding fit and / or the dissociation rate or off rate [kd(1 / s)] as determined in an SPR monovalent binding affinity assay.

[0183] The tested, selected and / or produced antibodies can then be used for further evaluation, for further processing, for production in quantity, for conjugation to a cytotoxic agent, for formulation or filling into containers or vials, for use in the treatment of cancer. In one embodiment, an antibody or conjugated antibody drug produced by the method is provided.

[0184] In one example, screening or testing of antibodies may involve the use of mutant Nectin-4 polypeptides to characterize and / or direct the selection of antibodies. For example, a method for producing or testing an antibody that binds to Nectin-4 may include: (a) providing a plurality of antibodies that bind to the Nectin-4 polypeptide; (b) contacting each of said antibodies with a mutant Nectin-4 polypeptide comprising a mutation at one, two, three, four or five or more residues selected from the group consisting of A72, G73, S195, K197, S199, L150, S152, Q234 and I236, or, optionally, at residues K197 and / or S199, or, optionally, at one, two or three residues selected from the group consisting of K197, S199 and Q234 (according to SEQ ID NO: 1), and assessing the binding between the antibody and the mutant Nectin-4 polypeptide compared to the binding between the antibody and a wild-type Nectin-4 polypeptide comprising the amino acid sequence of SEQ ID NO: 1; (c) optionally selecting antibodies that have reduced binding to the mutant Nectin-4 polypeptide compared to the binding between the antibody and a wild-type Nectin-4 polypeptide comprising the amino acid sequence of SEQ ID NO:1 (e.g., for further evaluation, for conjugation to a cytotoxic agent, for further processing, manufacture in quantity, for use in treatment); The mutant Nectin-4 polypeptide may comprise substitutions S195A / K197T / S199A, substitutions A72P / G73N / K197T / S199A, and / or substitutions L150S / S152A / Q234R / I236S.

[0185] Advantageously, the antibody can be identified and selected based on binding to the same region or epitope on the surface of the nectin-4 polypeptide as any of the antibodies described herein.In one aspect, the antibody binds to substantially the same epitope as any of the antibodies 5E7, 10B12, 6C11B or 6A7.In one embodiment, the antibody binds to an epitope of nectin-4 that at least partially overlaps with or includes at least one residue in the epitope bound by the antibodies 5E7, 10B12, 6C11B or 6A7.The residue bound by the antibody can be defined as present on the surface of the nectin-4 polypeptide, for example, on the nectin-4 polypeptide expressed on the surface of a cell.

[0186] The binding of an anti-nectin-4 antibody to a specific site on nectin-4 can be assessed by measuring the binding of the anti-nectin-4 antibody to cells transfected with a nectin-4 mutant, compared to the ability of the anti-nectin-4 antibody to bind to a wild-type nectin-4 polypeptide (e.g., SEQ ID NO: 1). The present disclosure provides mutant nectin-4 polypeptides that allow characterization of the binding site of antibodies, including antibodies that bind to the VC domain. In one embodiment, mutant nectin-4 polypeptides containing the mutations set forth in the mutants of Table 2, nucleic acids encoding such mutants, and recombinant host cells expressing the foregoing are provided. In one embodiment, there is provided a mutant Nectin-4 polypeptide comprising a mutation at one, two, three, four or five or more residues selected from the group consisting of A72, G73, S195, K197, S199, L150, S152, Q234 and I236, or optionally at residues K197 and / or S199, or optionally at one, two or three residues selected from the group consisting of K197, S199 and Q234 (according to SEQ ID NO: 1), a nucleic acid encoding such a mutant, and a recombinant host cell expressing the foregoing. A reduced binding between an anti-Nectin-4 antibody and a mutant Nectin-4 polypeptide (e.g., a mutant in Table 2) means that there is a reduced binding affinity (e.g., measured by known methods such as FACS testing of cells expressing a particular mutant or by Biacore testing of binding to the mutant polypeptide) and / or a reduced total binding capacity of the anti-Nectin-4 antibody (e.g., evidenced by a reduced Bmax in a plot of anti-Nectin-4 antibody concentration versus polypeptide concentration). A significant reduction in binding indicates that the mutated residue is either directly involved in binding to the anti-Nectin-4 antibody or is in close proximity to the binding protein in which the anti-Nectin-4 antibody binds to Nectin-4.

[0187] In some embodiments, a significant reduction in binding means that the binding affinity and / or binding capacity between an anti-nectin-4 antibody and a mutant nectin-4 polypeptide is reduced by more than 40%, more than 50%, more than 55%, more than 60%, more than 65%, more than 70%, more than 75%, more than 80%, more than 85%, more than 90% or more than 95% compared to the binding between the antibody and a wild-type nectin-4 polypeptide. In certain embodiments, the binding is reduced below the detection limit. In some embodiments, a significant reduction in binding is evidenced when the binding of an anti-nectin-4 antibody to a mutant nectin-4 polypeptide is less than 50% (e.g., less than 45%, 40%, 35%, 30%, 25%, 20%, 15% or 10%) of the binding observed between an anti-nectin-4 antibody and a wild-type nectin-4 polypeptide.

[0188] In some embodiments, anti-Nectin-4 antibodies are provided that exhibit significantly reduced binding to mutant Nectin-4 polypeptides (e.g., mutants in Table 2) in which residues in a segment containing amino acid residues bound by antibodies 5E7, 10B12, 6C11B, or 6A7 are substituted with different amino acids compared to binding to wild-type Nectin-4 polypeptides that do not contain such substitutions (e.g., the polypeptide of SEQ ID NO: 1).

[0189] In one embodiment, the anti-nectin-4 antibody binds to an epitope located on or within the VC1 bridging domain of nectin-4. In one embodiment, the anti-nectin-4 antibody competes with antibody 5E7, 10B12, 6C11B or 6A7 for binding to an epitope on the VC1 bridging domain of nectin-4.

[0190] In one embodiment, the anti-Nectin-4 antibody has reduced binding, and optionally lost binding, to a Nectin-4 polypeptide having a mutation at one, two or three residues selected from the group consisting of K197 (e.g., a K197T substitution), S199 (e.g., an S199A substitution) and Q234 (e.g., a Q234R substitution), based on SEQ ID NO:1.

[0191] In one embodiment, the antibody further has reduced binding to a mutant nectin-4 polypeptide comprising mutations at one or more (or all) residues selected from the group consisting of S195, K197 and S199 (according to SEQ ID NO: 1), and the mutant nectin-4 polypeptide may have mutations S195A, K197T and S199A.

[0192] In one embodiment, the antibody further has reduced binding to a mutant nectin-4 polypeptide comprising mutations at one or more (or all) residues selected from the group consisting of A72, G73, K197 and S199 (according to SEQ ID NO: 1), and the mutant nectin-4 polypeptide may have mutations A72P, G73N, K197T and S199A.

[0193] In one embodiment, the antibody further has reduced binding to a mutant Nectin-4 polypeptide comprising mutations at one or more (or all) residues selected from the group consisting of L150, S152, Q234 and I236 (according to SEQ ID NO: 1), and the mutant Nectin-4 polypeptide may have mutations L150S, S152A, Q234R and I236S.

[0194] In one embodiment, the antibody further has reduced binding to a mutant nectin-4 polypeptide comprising a mutation at one or more (or all) residues selected from the group consisting of A72, G73, S195, K197, S199, L150, S152, Q234 and I236 (according to SEQ ID NO: 1), and the mutant nectin-4 polypeptide may have the mutations A72P, G73N, S195A, K197T, S199A, L150S, S152A, Q234R and I236S.

[0195] In each case, the reduction or loss of binding can be defined as relative to the binding between the antibody and a wild-type Nectin-4 polypeptide comprising the amino acid sequence of SEQ ID NO:1.

[0196] In one embodiment, the anti-Nectin-4 antibody binds to an epitope of Nectin-4 comprising amino acid residues (e.g., 1, 2, 3, 4 or 5 residues) selected from the group consisting of A72, G73, S195, K197, S199, L150, S152, Q234 and I236, or optionally 1, 2 or 3 residues selected from the group consisting of K197, S199 and Q234 (according to SEQ ID NO: 1).

[0197] In one embodiment, the anti-Nectin-4 antibody binds to an epitope of Nectin-4 comprising amino acid residues (e.g., 1, 2 or 3 residues) selected from the group consisting of S195, K197 and S199 (according to SEQ ID NO:1).

[0198] In one embodiment, the anti-Nectin-4 antibody binds to an epitope of Nectin-4 that includes amino acid residues (e.g., 1, 2, 3 or 4 residues) selected from the group consisting of A72, G73, K197 and S199.

[0199] In one embodiment, the anti-Nectin-4 antibody binds to an epitope of Nectin-4 comprising amino acid residues (e.g., 1, 2, 3 or 4 residues) selected from the group consisting of L150, S152, Q234 and I236.

[0200] In one embodiment, the anti-nectin-4 antibody binds to an epitope located on or within the VC1 bridging domain of nectin-4. In one embodiment, the anti-nectin-4 antibody competes with antibody 5E7, 10B12, 6C11B or 6A7 for binding to an epitope on the VC1 bridging domain of human nectin-4 protein.

[0201] In one embodiment, the VH region of an antibody of the disclosure is selected from the group consisting of IGHV1-18, IGHV1-2, IGHV1-24, IGHV1-3, IGHV1-45, IGHV1-46, IGHV1-58, IGHV1-69, IGHV1-8, IGHV2-26, IGHV2-5, IGHV2-70, IGHV2-70D, IGHV3-11, IGHV3-13, IGHV3-15, IGHV3-20, IGHV3-21, IGHV3-23, IGHV3-23D, IGHV3-30, IGHV3-30-3, IGHV3-30-5, IGHV3-33, IGHV3-43, IGHV3-43D, IGHV3-48, IGHV3-49, IGHV3-54, IGHV3-64, IGHV3-64D, IGHV3-66, IGHV3-7, IGHV3-72, IGHV3-73, IGHV3-74, IGHV3-9, IGHV3-NL1, IGHV4-28, IGHV4-30-1, IGHV4-30-2, IGHV4-30-4, IGHV4-31, IGHV4-34, IGHV4-38-2, IGHV The VH region of an antibody of the disclosure may comprise an amino acid sequence having at least about 80%, 85%, 90%, 95%, 97%, 98% or 99% identity to an amino acid sequence encoded by a gene of a human V gene group selected from the group consisting of IGHV4-39, IGHV4-4, IGHV4-59, IGHV4-61, IGHV5-10-1, IGHV5-51, IGHV6-1, and IGHV7-4-1. The VH region of an antibody of the disclosure may comprise a VH that comprises an amino acid sequence derived from said gene (e.g., CDRs and / or human framework regions, e.g., according to Kabat numbering).

[0202] In one embodiment, the VL region of an antibody of the disclosure is selected from the group consisting of IGKV1-12, IGKV1-13, IGKV1-16, IGKV1-27, IGKV1-33, IGKV1-39, IGKV1-5, IGKV1-6, IGKV1-8, IGKV1-9, IGKV1-NL1, IGKV1D-12, IGKV1D-13, IGKV1D-16, IGKV1D-17, IGKV1D-33, IGKV1D-39, IGKV1D43, IGKV1D8, IGKV2-24, IGKV2-28, IGKV2-29, IGKV2-30, IGKV2-40, IGKV2-50, IGKV2-60, IGKV2-70, IGKV2-80, IGKV2-90, IGKV2-100, IGKV2-110, IGKV2-120, IGKV2-130, IGKV2-140, IGKV2-150, IGKV2-160, IGKV2-170, IGKV2-180, IGKV2-190, IGKV2-200, IGKV2-210, IGKV2-220, IGKV2-230, IGKV2-240, IGKV2-250, IGKV2-260, IGKV2-270, IGKV2-280, IGKV2-290, IGKV2-300, IGKV2-310, IGKV2-32 V2D-26, IGKV2D-28, IGKV2D-29, IGKV2D-30, IGKV2D-40, IGKV3-11, IGKV3-15, IGKV3-20, IGKV3D-11, IGKV3D-15, IGKV3D-20, IGKV3D-7, IGKV4-1, IGKV5-2, IGKV6-21 and IGKV6D-21. The VL region of the antibody of the disclosure may comprise a VL comprising amino acid sequences from said genes (e.g., CDRs and / or human framework regions, e.g., according to Kabat numbering).

[0203] An exemplary anti-Nectin-4 VH and VL pair of the present disclosure is that of antibody 5E7, the amino acid sequence of the heavy chain variable region of which is set forth below (SEQ ID NO:6) and the amino acid sequence of the light chain variable region of which is set forth below (SEQ ID NO:7). In a specific embodiment, an antibody is provided that binds essentially the same epitope or determinant as monoclonal antibody 5E7, which may comprise the hypervariable region of antibody 5E7. In any embodiment herein, antibody 5E7 may be characterized by its amino acid sequence and / or the nucleic acid sequence encoding it. In one embodiment, the monoclonal antibody is a Fab or F(ab') of 5E7. 2The antibody or antibody fragment further comprises a portion of the heavy chain variable region of 5E7. Also provided is an antibody or antibody fragment comprising the heavy chain variable region of 5E7. In one embodiment, the antibody or antibody fragment comprises the three CDRs of the heavy chain variable region of 5E7. Also provided is an antibody or antibody fragment further comprising the variable light chain variable region of 5E7 or one, two or three CDRs of the light chain variable region of 5E7. Optionally, the HCDR1, 2, 3 and LCDR1, 2, 3 sequences can be defined as being all (or each independently) according to the Kabat numbering system, the Chotia numbering system, the IMGT numbering system, or any other suitable numbering system. Optionally, any one or more of the light or heavy chain CDRs can contain one, two, three, four or five or more amino acid modifications (e.g., substitutions, insertions or deletions).

[0204] In one embodiment, the anti-Nectin-4 antibody or antibody fragment has a VH domain having at least about 60%, 70% or 80% sequence identity, optionally at least about 85%, 90%, 95%, 97%, 98% or 99% identity to the VH domain of SEQ ID NO:6. H In another embodiment, the anti-Nectin-4 antibody comprises a VL domain having at least about 60%, 70% or 80% sequence identity, optionally at least about 85%, 90%, 95%, 97%, 98% or 99% identity to the VL domain of SEQ ID NO:7. L Includes the domain.

[0205] The VH and VL may comprise (e.g., may be modified to incorporate) a human acceptor framework. In one embodiment, an anti-Nectin-4 antibody of the present disclosure comprises a VH CDR1, CDR2 and / or CDR3 (e.g., according to Kabat numbering) of a heavy chain variable region having the amino acid sequence of SEQ ID NO: 6. In one embodiment, an anti-Nectin-4 antibody of the present disclosure comprises a VL CDR1, CDR2 and / or CDR3 (e.g., according to Kabat numbering) of a light chain variable region having the amino acid sequence of SEQ ID NO: 7. In one embodiment, an anti-Nectin-4 antibody of the present disclosure comprises a VH comprising Kabat CDR1, CDR2 and / or CDR3 of a heavy chain variable region having the amino acid sequence of SEQ ID NO: 6, and a VL comprising Kabat CDR1, CDR2 and / or CDR3 of a light chain variable region having the amino acid sequence of SEQ ID NO: 7. 5E7 VH: QVQLQQPGAELVKPGASVKLSCKASGYIFTSYWMHWVKQRPGQGLEWIGEIDPSDSYTNYNQKFKGKATLTLDKSSSTTYMQLSSLTSEDSAVYYCVRGYGNYGDYWGQGTTLTVSS (sequence number 6) 5E7 VL: DVVMTQAAFSNPVTLGTSASISCRSSKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNLASGVPDRFSSSGSGTDFTLRISRVEAEDVGVYYCAQNLELPWTFGGGTKLEIK (SEQ ID NO: 7) 5E7 CDR: Kabat: CDR-H1 SYWMH (SEQ ID NO: 8) CDR-H2 EIDPSDSYTNYNQKFKG (SEQ ID NO: 9) CDR-H3 GYGNYGDY (SEQ ID NO: 10) CDR-L1 RSSKSLLHSNGITYLY (SEQ ID NO: 11) CDR-L2 QMSNLAS (SEQ ID NO: 12) CDR-L3 AQNLELPWT (SEQ ID NO: 13) IMGT: CDR-H1 GYIFTSYW (SEQ ID NO: 14) CDR-H2 IDPSDSYT (SEQ ID NO: 15) CDR-H3 VRGYGNYGDY (SEQ ID NO: 16) CDR-L1 KSLLHSNGITY (SEQ ID NO: 17) CDR-L2 QMS (SEQ ID NO: 18) CDR-L3 AQNLELPWT (SEQ ID NO: 13) Chothia: CDR-H1 GYIFTSY (SEQ ID NO: 19) CDR-H2 PSDS (SEQ ID NO: 20) CDR-H3 YGNYGD (SEQ ID NO: 21) CDR-L1 SKSLLHSNGITY (SEQ ID NO: 22) CDR-L2 QMS (SEQ ID NO: 18) CDR-L3 NLELPW (SEQ ID NO: 23)

[0206] In one embodiment, the anti-Nectin-4 antibody may comprise, for example, a heavy chain variable region comprising the amino acid sequences of SEQ ID NOs: 8 to 10, and a light chain variable region comprising the amino acid sequences of SEQ ID NOs: 11 to 13. The anti-Nectin-4 antibody may comprise, for example, the amino acid sequence: SYWMH (SEQ ID NO: 8) or a sequence of at least 4 consecutive amino acids thereof, where appropriate, one or more of these amino acids may be substituted with different amino acids, HCDR1; the amino acid sequence: EIDPSDSYTNYNQKFKG (SEQ ID NO: 9) or a sequence of at least 4, 5, 6, 7, 8, 9 or 10 consecutive amino acids thereof, where appropriate, one or more of these amino acids may be substituted with different amino acids, HCDR2; the amino acid sequence: GYGNYGDY (SEQ ID NO: 10) or a sequence of at least 4, 5 or 6 consecutive amino acids thereof, where appropriate, one or more of these amino acids may be substituted with different amino acids, HCDR3; the amino acid sequence: RSSKS The CDRs may include an LCDR1 region comprising the amino acid sequence: LLHSNGITYLY (SEQ ID NO: 11) or a sequence of at least 4, 5, 6, 7, 8, 9 or 10 consecutive amino acids thereof, where appropriate, one or more of these amino acids may be replaced by different amino acids; an LCDR2 region comprising the amino acid sequence: QMSNLAS (SEQ ID NO: 12) or a sequence of at least 4, 5 or 6 consecutive amino acids thereof, where appropriate, one or more of these amino acids may be replaced by different amino acids; and / or an LCDR3 region comprising the amino acid sequence: AQNLELPWT (SEQ ID NO: 13) or a sequence of at least 4, 5, 6, 7 or 8 consecutive amino acids thereof, where appropriate, one or more of these amino acids may be deleted or replaced by different amino acids. The CDR positions may be according to Kabat numbering.

[0207] Another exemplary anti-Nectin-4 VH and VL pair of the present disclosure is that of antibody 10B12, the amino acid sequence of the heavy chain variable region of which is set forth below (SEQ ID NO:24) and the amino acid sequence of the light chain variable region of which is set forth below (SEQ ID NO:25). In a specific embodiment, an antibody is provided that binds essentially the same epitope or determinant as monoclonal antibody 10B12, which may comprise the hypervariable region of antibody 10B12. In any embodiment herein, antibody 10B12 may be characterized by its amino acid sequence and / or the nucleic acid sequence encoding it. In one embodiment, the monoclonal antibody is a Fab or F(ab') of 10B12. 2 The antibody or antibody fragment further comprises a portion thereof. An antibody or antibody fragment comprising the heavy chain variable region of 10B12 is also provided. In one embodiment, the antibody or antibody fragment comprises the three CDRs of the heavy chain variable region of 10B12. An antibody or antibody fragment further comprises one, two or three CDRs of the variable light chain variable region of 10B12 or the light chain variable region of 10B12. The HCDR1, 2, 3 and LCDR1, 2, 3 sequences can be defined, as appropriate, all together (or each independently) as being according to the Kabat numbering system, the Chotia numbering system [e.g., the antibody has the CDR-H1 amino acid sequence GYTFTSY (SEQ ID NO:26)], the IMGT numbering system [e.g., the antibody has the CDR-H1 amino acid sequence GYTFTSYW (SEQ ID NO:27)], or any other suitable numbering system. Optionally, any one or more of the light or heavy chain CDRs may contain one, two, three, four or five or more amino acid modifications (e.g., substitutions, insertions or deletions).

[0208] In one embodiment, the anti-Nectin-4 antibody or antibody fragment has a VH domain having at least about 60%, 70% or 80% sequence identity, optionally at least about 85%, 90%, 95%, 97%, 98% or 99% identity to the VH domain of SEQ ID NO:24. HIn another embodiment, the anti-Nectin-4 antibody comprises a VL domain having at least about 60%, 70% or 80% sequence identity, optionally at least about 85%, 90%, 95%, 97%, 98% or 99% identity to the VL domain of SEQ ID NO:25. L Includes the domain.

[0209] The VH and VL may comprise (e.g., may be modified to incorporate) a human acceptor framework. In one embodiment, an anti-Nectin-4 antibody of the present disclosure comprises a VH CDR1, CDR2 and / or CDR3 (e.g., according to Kabat numbering) of a heavy chain variable region having the amino acid sequence of SEQ ID NO: 24. In one embodiment, an anti-Nectin-4 antibody of the present disclosure comprises a VL CDR1, CDR2 and / or CDR3 (e.g., according to Kabat numbering) of a light chain variable region having the amino acid sequence of SEQ ID NO: 25. In one embodiment, an anti-Nectin-4 antibody of the present disclosure comprises a VH comprising Kabat CDR1, CDR2 and / or CDR3 of a heavy chain variable region having the amino acid sequence of SEQ ID NO: 24, and a VL comprising Kabat CDR1, CDR2 and / or CDR3 of a light chain variable region having the amino acid sequence of SEQ ID NO: 25. 10B12 VH: QVQLQQPGAELVKPGASVKLSCKASGYTFTSYWMHWVKQRPGQGLEWIGEIDPSDSYTNYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSAVYYCVRGYGNYGDYWGQGTTLTVSS (SEQ ID NO: 24) 10B12 VL: DIVMTQAAFSNPVTLGTSASISCRSSKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNLASGVPDRFSSSGSGTDFTLRISRVEAEDVGVYYCAQNLELPWTFGGGTKLEIK (SEQ ID NO: 25)

[0210] Another exemplary anti-Nectin-4 VH and VL pair of the present disclosure is that of antibody 6C11B, the amino acid sequence of the heavy chain variable region of which is set forth below (SEQ ID NO:42) and the amino acid sequence of the light chain variable region of which is set forth below (SEQ ID NO:43). In a specific embodiment, an antibody is provided that binds essentially the same epitope or determinant as monoclonal antibody 6C11B, which may comprise the hypervariable region of antibody 6C11B. In any embodiment herein, antibody 6C11B may be characterized by its amino acid sequence and / or the nucleic acid sequence encoding it. In one embodiment, the monoclonal antibody is a Fab or F(ab') of 6C11B. 2 The antibody or antibody fragment further comprises a portion of the heavy chain variable region of 6C11B. An antibody or antibody fragment further comprises a variable light chain variable region of 6C11B or one, two or three CDRs of the light chain variable region of 6C11B. The HCDR1, 2, 3 and LCDR1, 2, 3 sequences can be optionally all (or each independently) specified as being in the Kabat numbering system, the Chotia numbering system, the IMGT numbering system, or any other suitable numbering system. Optionally, any one or more of the light or heavy chain CDRs can contain one, two, three, four or five or more amino acid modifications (e.g., substitutions, insertions or deletions).

[0211] In one embodiment, the anti-Nectin-4 antibody or antibody fragment has a VH domain having at least about 60%, 70% or 80% sequence identity, optionally at least about 85%, 90%, 95%, 97%, 98% or 99% identity to the VH domain of SEQ ID NO:42. H In another embodiment, the anti-Nectin-4 antibody comprises a VL domain having at least about 60%, 70% or 80% sequence identity, optionally at least about 85%, 90%, 95%, 97%, 98% or 99% identity to the VL domain of SEQ ID NO:43. L Includes the domain.

[0212] The VH and VL may comprise (e.g., may be modified to incorporate) a human acceptor framework. In one embodiment, an anti-Nectin-4 antibody of the present disclosure comprises a VH CDR1, CDR2 and / or CDR3 (e.g., according to Kabat numbering) of a heavy chain variable region having the amino acid sequence of SEQ ID NO: 42. In one embodiment, an anti-Nectin-4 antibody of the present disclosure comprises a VL CDR1, CDR2 and / or CDR3 (e.g., according to Kabat numbering) of a light chain variable region having the amino acid sequence of SEQ ID NO: 43. In one embodiment, an anti-Nectin-4 antibody of the present disclosure comprises a VH comprising Kabat CDR1, CDR2 and / or CDR3 of a heavy chain variable region having the amino acid sequence of SEQ ID NO: 42, and a VL comprising Kabat CDR1, CDR2 and / or CDR3 of a light chain variable region having the amino acid sequence of SEQ ID NO: 43. 6C11B VH: EVQLQQSGPELVKPGASVKISCKTSGYTFTEYTIHWVKQNHGKSLEWIGRINPKNGDIIHNQNFMGKATLTVDKSSSTAYMELRSLTSEDSAVCYCARSGYGSSYGFAYWGQGTLVTVSA (SEQ ID NO:42) 6C11B VL: DIVMTQSPTSLVVSLGQRATISCRASQSVTTPRYSYMHWYQQKPGQPPKLLIKYASNLESGVPARFSGSGSGTDFTLNIHPVEEEDTATYYCQHSWEIPYTFGGGTKLEIK (SEQ ID NO: 43) 6C11B CDR: Kabat: CDR-H1 EYTIH (SEQ ID NO: 44) CDR-H2 RINPKNGDIIHNQNFMG (SEQ ID NO: 45) CDR-H3 SGYGSSYGFAY ​​(SEQ ID NO: 46) CDR-L1 RASQSVTTPRYSYMH (SEQ ID NO: 47) CDR-L2 YASNLES (SEQ ID NO: 48) CDR-L3 QHSWEIPYT (SEQ ID NO: 49)

[0213] Anti-Nectin-4 antibodies include, for example, the amino acid sequence: EYTIH (SEQ ID NO: 44) or a sequence of at least 4 consecutive amino acids thereof, where appropriate, one or more of these amino acids may be substituted by different amino acids; HCDR1; amino acid sequence: RINPKNGDIIHNQNFMG (SEQ ID NO: 45) or a sequence of at least 4, 5, 6, 7, 8, 9 or 10 consecutive amino acids thereof, where appropriate, one or more of these amino acids may be substituted by different amino acids; HCDR2; amino acid sequence: SGYGSSYGFAY ​​(SEQ ID NO: 46) or a sequence of at least 4, 5 or 6 consecutive amino acids thereof, where appropriate, one or more of these amino acids may be substituted by different amino acids; HCDR3; amino acid sequence: RA The CDRs may include an LCDR1 region comprising the amino acid sequence: SQSVTTPRYSYMH (SEQ ID NO: 47) or a sequence of at least 4, 5, 6, 7, 8, 9 or 10 consecutive amino acids thereof, where appropriate, one or more of these amino acids may be replaced by different amino acids; an LCDR2 region comprising the amino acid sequence: YASNLES (SEQ ID NO: 48) or a sequence of at least 4, 5 or 6 consecutive amino acids thereof, where appropriate, one or more of these amino acids may be replaced by different amino acids; and / or an LCDR3 region comprising the amino acid sequence: QHSWEIPYT (SEQ ID NO: 49) or a sequence of at least 4, 5, 6, 7 or 8 consecutive amino acids thereof, where appropriate, one or more of these amino acids may be deleted or replaced by different amino acids. The CDR positions may be according to Kabat numbering.

[0214] Another exemplary anti-Nectin-4 VH and VL pair of the present disclosure is that of antibody 6A7, the amino acid sequence of the heavy chain variable region of which is set forth below (SEQ ID NO:50) and the amino acid sequence of the light chain variable region of which is set forth below (SEQ ID NO:51). In a specific embodiment, an antibody is provided that binds essentially the same epitope or determinant as monoclonal antibody 6A7, which may comprise the hypervariable region of antibody 6A7. In any embodiment herein, antibody 6A7 may be characterized by its amino acid sequence and / or the nucleic acid sequence encoding it. In one embodiment, the monoclonal antibody is a Fab or F(ab') of 6A7. 2 The antibody or antibody fragment further comprises a portion of the heavy chain variable region of 6A7. An antibody or antibody fragment further comprises a portion of the heavy chain variable region of 6A7. In one embodiment, the antibody or antibody fragment comprises three CDRs of the heavy chain variable region of 6A7. An antibody or antibody fragment further comprises one, two or three CDRs of the variable light chain variable region of 6A7 or the light chain variable region of 6A7. The HCDR1, 2, 3 and LCDR1, 2, 3 sequences can be defined as follows, all together (or each independently) according to the Kabat numbering system, the Chotia numbering system, the IMGT numbering system, or any other suitable numbering system. Optionally, any one or more of the light or heavy chain CDRs can contain one, two, three, four or five or more amino acid modifications (e.g., substitutions, insertions or deletions).

[0215] In one embodiment, the anti-Nectin-4 antibody or antibody fragment has a VH domain having at least about 60%, 70% or 80% sequence identity, optionally at least about 85%, 90%, 95%, 97%, 98% or 99% identity to the VH domain of SEQ ID NO:50. H In another embodiment, the anti-Nectin-4 antibody comprises a VL domain having at least about 60%, 70% or 80% sequence identity, optionally at least about 85%, 90%, 95%, 97%, 98% or 99% identity to the VL domain of SEQ ID NO:51. L Includes the domain.

[0216] The VH and VL may comprise (e.g., are modified to incorporate) a human acceptor framework. In one embodiment, an anti-Nectin-4 antibody of the present disclosure comprises a VH CDR1, CDR2 and / or CDR3 (e.g., according to Kabat numbering) of a heavy chain variable region having the amino acid sequence of SEQ ID NO: 50. In one embodiment, an anti-Nectin-4 antibody of the present disclosure comprises a VL CDR1, CDR2 and / or CDR3 (e.g., according to Kabat numbering) of a light chain variable region having the amino acid sequence of SEQ ID NO: 51. In one embodiment, an anti-Nectin-4 antibody of the present disclosure comprises a VH comprising Kabat CDR1, CDR2 and / or CDR3 of a heavy chain variable region having the amino acid sequence of SEQ ID NO: 50, and a VL comprising Kabat CDR1, CDR2 and / or CDR3 of a light chain variable region having the amino acid sequence of SEQ ID NO: 51. 6A7 VH: QVQLKESGAELVKPGASVKLSCKASGYTFTSYWMHWVKQRPGHGLEWVGEIDPSDSYTNYNQKFKGKATLTIDKSSSTVYMQLSSLTSEDSAVYYCARSGNYDAMDYWGQGTSVTVSA (SEQ ID NO:50) 6A7 VL: DIVMTQAAFSSAVTLGTSASISCRSSKSLLHSNGITYLYWYLQKPGQSPHFLIYQMSNLASGVPDRFTSSGSGTDFTLRISRVEAEDVGVYYCAQNLELPWTFGGGTKLEIK (SEQ ID NO: 51) 6A7 CDR: Kabat: CDR-H1 SYWMH (SEQ ID NO:52) CDR-H2 EIDPSDSYTNYNQKFKG (SEQ ID NO: 53) CDR-H3 SGNYDAMDY (SEQ ID NO:54) CDR-L1 RSSKSLLHSNGITYLY (SEQ ID NO:55) CDR-L2 QMSNLAS (SEQ ID NO:56) CDR-L3 AQNLELPWT (SEQ ID NO:57)

[0217] The anti-Nectin-4 antibody may, for example, comprise the amino acid sequence: SYWMH (SEQ ID NO: 52) or a sequence of at least four consecutive amino acids thereof, optionally in which one or more of these amino acids may be substituted by a different amino acid; HCDR1; comprises the amino acid sequence: EIDPSDSYTNYNQKFKG (SEQ ID NO: 53) or a sequence of at least 4, 5, 6, 7, 8, 9 or 10 consecutive amino acids thereof, optionally in which one or more of these amino acids may be substituted by a different amino acid; HCDR2; comprises the amino acid sequence: SGNYDAMDY (SEQ ID NO: 54) or a sequence of at least 4, 5 or 6 consecutive amino acids thereof, optionally in which one or more of these amino acids may be substituted by a different amino acid; HCDR3; comprises the amino acid sequence: RSS The CDRs may include an LCDR1 region comprising the amino acid sequence: KSLLHSNGITYLY (SEQ ID NO: 55) or a sequence of at least 4, 5, 6, 7, 8, 9 or 10 consecutive amino acids thereof, where appropriate, one or more of these amino acids may be replaced by different amino acids; an LCDR2 region comprising the amino acid sequence: QMSNLAS (SEQ ID NO: 56) or a sequence of at least 4, 5 or 6 consecutive amino acids thereof, where appropriate, one or more of these amino acids may be replaced by different amino acids; and / or an LCDR3 region comprising the amino acid sequence: AQNLELPWT (SEQ ID NO: 57) or a sequence of at least 4, 5, 6, 7 or 8 consecutive amino acids thereof, where appropriate, one or more of these amino acids may be deleted or replaced by different amino acids. The CDR positions may be according to Kabat numbering.

[0218] In any embodiment, the defined variable region, FR and / or CDR sequences of an antibody or antibody fragment (e.g., 10B12, 6C11B, 6A7 or 5E7) may contain one or more sequence modifications, e.g., substitutions (1, 2, 3, 4, 5, 6, 7, 8 or more sequence modifications). In one embodiment, the substitutions are conservative modifications.

[0219] Antibody fragments and derivatives (included in the term "antibody" or "antibodies" as used in this application unless otherwise stated or clearly contradicted by the context) can be produced by techniques known in the art. A "fragment" comprises a portion of an intact antibody, generally the antigen binding site or variable region. Examples of antibody fragments include Fab, Fab', Fab'-SH, F(ab')2, and Fv fragments; diabodies; any antibody fragment that is a polypeptide having a primary structure consisting of one uninterrupted sequence of contiguous amino acid residues (referred to herein as a "single-chain antibody fragment" or "single-chain polypeptide"), such as, but not limited to, (1) a single-chain Fv molecule, (2) a single-chain polypeptide containing only one light chain variable domain, or a fragment thereof containing the three CDRs of a light chain variable domain, and not containing the associated heavy chain molecule, and (3) a single-chain polypeptide containing only one heavy chain variable region, or a fragment thereof containing the three CDRs of a heavy chain variable region, and not containing the associated light chain molecule; and multispecific antibodies formed from antibody fragments. Nanobodies, domain antibodies, single domain antibodies or "dAbs", among others.

[0220] The anti-Nectin-4 antibody or antibody fragment (e.g., variable region and / or CDR) may be embodied as a multispecific (e.g., bispecific) antibody or protein, as appropriate. For example, a multispecific protein may comprise the hypervariable region (e.g., VH and VL) of an antibody of any embodiment herein, and the hypervariable region (e.g., VH and VL) of a different antibody, e.g., an antibody that binds to an antigen of interest other than Nectin-4.

[0221] Also included are the antibodies or antibody fragments of the present disclosure expressed by cells, and methods of treating cancer using such antibodies or antibody fragments. For example, cells expressing chimeric antigen receptors (CARs) can be constructed. CARs typically comprise an extracellular single-chain antibody (scFv) fused with an intracellular signaling domain of the T cell antigen receptor complex zeta chain, and are engineered to have the ability to modify antigen recognition based on the specificity of monoclonal antibodies when expressed in effector cells such as T cells or NK cells. In one embodiment, genetically engineered immune cells are provided that express and have a Nectin-4-specific chimeric immune receptor on the cell surface membrane, comprising an intracellular signaling domain, a transmembrane domain (TM), and a Nectin-4-specific extracellular domain (e.g., a domain derived from or including an antibody or antibody fragment of the present disclosure, or a variable heavy and light chain region of an antibody of the present disclosure). Also provided are plasmid expression vectors containing the Nectin-4-specific chimeric immune receptor, a DNA construct encoding the receptor, and the construct in an orientation suitable for expression.

[0222] In one embodiment, the antibody is humanized. "Humanized" forms of antibodies are certain chimeric immunoglobulins, immunoglobulin chains or fragments thereof (e.g., Fv, Fab, Fab', F(ab')2, or other antigen-binding subsequences of antibodies) that contain minimal sequence derived from mouse immunoglobulin. For the most part, humanized antibodies are human immunoglobulins (recipient antibodies) in which residues from the recipient complementarity determining regions (CDRs) are replaced with residues from the CDRs of the original antibody (donor antibody) while retaining the desired specificity, affinity, and capacity of the original antibody.

[0223] In some cases, Fv framework residues of the human immunoglobulin may be replaced with corresponding non-human residues. Furthermore, humanized antibodies can contain residues that are found neither in the recipient antibody nor in the imported CDR or framework sequences. These modifications are made to further refine and optimize antibody performance. In general, a humanized antibody can comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of the original antibody and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence. A humanized antibody also optimally comprises at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. For further details, see Jones et al., Nature, 321, pp. 522 (1986); Reichmann et al, Nature, 332, pp. 323 (1988); Presta, Curr. Op. Struct. Biol., 2, pp. 593 (1992); Verhoeyen et Science, 239, pp. 1534; and U.S. Pat. No. 4,816,567, the disclosures of which are incorporated herein by reference in their entireties.

[0224] The selection of human variable domains, both light and heavy, used to generate humanized antibodies is very important to reduce antigenicity. In the so-called "best-fit" method, the sequence of the variable domain of an antibody is screened against the entire library of known human variable domain sequences. The human sequence that is closest to the mouse sequence is then accepted as the human framework (FR) for the humanized antibody (Sims et al., J. Immunol. 151, pp. 2296 (1993); Chothia and Lesk, J. Mol. 196, 1987, pp. 901). Another method uses a specific framework derived from the consensus sequence of all human antibodies of a particular subgroup of light or heavy chains. The same framework can be used for several different humanized antibodies (Carter et al., PNAS 89, pp. 4285 (1992); Presta et al., J. Immunol., 151, p. 2623 (1993)).

[0225] It is further important that the antibody is humanized while retaining high affinity for Nectin-4 and other favorable biological properties. To this end, in a preferred method, humanized antibodies are prepared by a process of analysis of various conceptual humanized products using parental sequences and three-dimensional models of parental and humanized sequences. Three-dimensional immunoglobulin models are generally available and are familiar to those skilled in the art. Computer programs are available that illustrate and display possible three-dimensional structures of selected immunoglobulin candidate sequences. Examination of these displays allows analysis of the possible role of the residues in the functioning of the immunoglobulin candidate sequence, i.e., analysis of residues that affect the ability of the immunoglobulin candidate to bind to an antigen. In this regard, FR residues can be selected and combined from the consensus and import sequences to achieve desired antibody characteristics, such as improved affinity for the target antigen. In general, CDR residues are directly and most substantially involved in influencing antigen binding. In one example, the FR of the humanized antibody chain is derived from a human variable region that has at least about 60% overall sequence identity, preferably at least about 70% or 80% overall sequence identity, with the variable region of a non-human donor (e.g., 5E7, 10B12, 6C11B or 6A7 antibody). The humanized heavy and / or light chain variable region may share at least about 60%, 70% or 80% overall sequence identity with the respective heavy and / or light chain variable region of a non-human donor (e.g., 5E7, 10B12, 6C11B or 6A7 antibody). Another method of making a "humanized" monoclonal antibody is to use a XenoMouse (Abgenix, Fremont, CA) as the mouse used for immunization. A XenoMouse is a mouse host in which immunoglobulin genes have been replaced with functional human immunoglobulin genes. Thus, the antibody produced by this mouse or in a hybridoma made from the B cells of this mouse is already humanized. The XenoMouse is described in US Pat. No. 6,162,963, which is incorporated herein by reference in its entirety.Human antibodies may also be produced according to a variety of other techniques, such as by using for immunization other transgenic animals engineered to express human antibody repertoires (Jakobovitz et al., Nature 362 (1993) 255), or by selection of antibody repertoires using phage display methods. Such techniques are known to those of skill in the art and can be implemented from the monoclonal antibodies disclosed in the present application.

[0226] Advantageously, the antibody of the present disclosure can be used in a method for preparing an antibody conjugate. In one embodiment, the method for preparing an antibody conjugate comprises conjugating a cytotoxic agent (Z) to an anti-Nectin-4 antibody or antibody fragment of the present disclosure. In one embodiment, the cytotoxic agent (Z) can be defined as being conjugated to the antibody or fragment via a linker (X). X is a linker connecting the antibody or fragment (Ab) and the cytotoxic agent (Z), e.g., when conjugated, X is a residue of the linker following the covalent linkage to one or both of Ab and Z.

[0227] In an embodiment herein, a method for preparing an antibody-drug conjugate comprises contacting and / or reacting an anti-Nectin-4 antibody or antibody fragment (Ab) of the present disclosure with a cytotoxic agent (Z). The contacting can be carried out under suitable conditions such that an antibody-drug conjugate of an embodiment of the present disclosure is formed or obtained. Z may be included in a compound comprising, for example, a cytotoxic agent (Z) and a linker (X) or a portion of a linker (X), and thus the step comprises contacting an anti-Nectin-4 antibody or antibody fragment of the present disclosure with a compound comprising a cytotoxic agent (Z) and a linker (X) or a portion of a linker (X). The method can optionally provide for isolating or recovering the formed antibody-drug conjugate, and optionally further processing the composition for use as a medicament, and optionally formulating the antibody (e.g., with a pharmaceutical excipient) for administration to a human subject.

[0228] The method of making an ADC may include conjugating an antibody or antibody fragment to 2, 3, 4, 5, 6, 7 or 8 molecules of a cytotoxic agent. The resulting composition may be characterized by a DAR between 2 and 4, between 4 and 6, between 6 and 8. The method may include conjugating an antibody to 4 molecules of a cytotoxic agent. The method may further include evaluating the DAR, and if the DAR corresponds to a predetermined specification (e.g., a DAR or DAR range disclosed herein, i.e., a DAR of about 2, 4, 6, or 8, etc.), further processing the composition for use as a medicament, and optionally formulating the antibody (e.g., with a pharmaceutical excipient) for administration to a human subject.

[0229] In some embodiments, the linker (X)-(Z) elements are prepared and isolated prior to forming the antibody drug conjugate by contacting (and reacting) a compound comprising (X) and (Z) with (Ab).

[0230] In some embodiments, the method comprises: (a) contacting and / or reacting a linker (X) or a portion of a linker (X) with (Ab) to form an Ab-X conjugate; and (b) contacting and / or reacting Ab-X of step (a) with a cytotoxic agent (Z), or a compound comprising a second portion of the linker (X) and (Z), to form an antibody-drug conjugate. Includes.

[0231] For example, X may represent a molecule comprising a moiety that is cleavable under physiological conditions, which may be, for example, intracellular conditions. In one embodiment, X represents a molecule comprising (i) a spacer (Y), (ii) a cleavable moiety, and (iii) an optional self-eliminating or non-self-eliminating spacer system (Y'). The cleavable moiety may be, for example, an oligopeptide (e.g., a di-, tri-, tetra- or pentapeptide). The spacer Y may be located between Ab and the cleavable moiety, and the spacer system (Y') may be located between the cleavable moiety and Z.

[0232] In some embodiments, the linker X or spacer Y can be defined as comprising a reactive group (R), as appropriate, that can react (e.g., under suitable conditions, which may be after deprotection) with an amino acid of the antibody or a complementary reactive group (R') attached to an amino acid of the antibody. R can be a group reactive with a free amino, hydroxyl, sulfhydryl or carboxyl group on an antibody. For example, R can be a group of the following structure, which is reactive with a thiol group (also referred to as a sulfhydryl group) on an antibody:

[0233] [ka] It may be a maleimido-N-yl group having the formula:

[0234] In some embodiments, the linker X or spacer Y, as appropriate, can be defined as comprising the residue of a reactive group R reacting with an amino acid of the antibody or a complementary reactive group (R') attached to an amino acid of the antibody. R can also be the residue of a group reactive with a free amino, hydroxyl, sulfhydryl or carboxyl group on the antibody and reacting with said free amino, hydroxyl, sulfhydryl or carboxyl group.

[0235] In any embodiment, prior to the step of contacting and / or reacting the anti-Nectin-4 antibody or antibody fragment with a compound (e.g., a linker and / or a cytotoxic agent), the method includes a step of preparing, selecting or providing an anti-Nectin-4 antibody or antibody fragment. In one embodiment, this step includes preparing, selecting or providing an anti-Nectin-4 antibody or antibody fragment, and determining or testing whether the antibody or antibody fragment has the characteristics of an anti-Nectin-4 antibody or antibody fragment of the present disclosure.

[0236] For example, anti-nectin-4 antibodies or antibody fragments can be tested for their ability to bind to the VC1 cross-linking domain of nectin-4. Antibodies or antibody fragments determined to bind to the VC1 cross-linking domain of nectin-4 are then contacted and / or reacted with a compound (e.g., a linker (X) and / or a cytotoxic agent (Z)). For example, anti-nectin-4 antibodies or antibody fragments can be tested for their ability to bind to a mutant nectin-4 polypeptide (e.g., a mutant nectin-4 polypeptide containing substitutions at residues Q234, K197 and / or S199). Antibodies or antibody fragments determined to have reduced or lost binding to a mutant nectin-4 polypeptide (e.g., compared to binding to a wild-type nectin-4 polypeptide) are then contacted and / or reacted with a compound (e.g., a linker (X) and / or a cytotoxic agent (Z)).

[0237] In another example, anti-Nectin-4 antibodies or antibody fragments can be tested for their ability to reduce cell-cell adhesion between Nectin-4-expressing tumor cells (e.g., adherent tumor cells) and / or for their ability to inhibit the growth of Nectin-4-expressing tumor cells (e.g., in a tumor spheroid formation assay, in a three-dimensional cell culture). Antibodies or antibody fragments determined to have the ability to reduce cell-cell adhesion between Nectin-4-expressing tumor cells and / or determined for their ability to inhibit the growth of Nectin-4-expressing tumor cells (e.g., adherent tumor cells) are then contacted and / or reacted with a compound (e.g., a linker (X) and / or a cytotoxic agent (Z)).

[0238] In another example, an anti-Nectin-4 antibody or antibody fragment can be tested for the ability to sensitize a tumor to a cytotoxic agent (e.g., cytotoxic agent Z, or a cytotoxic agent of the same drug class as Z, e.g., a camptothecin drug). An antibody or antibody fragment determined to have the ability to sensitize a tumor to a cytotoxic agent is then contacted and / or reacted with a compound (e.g., a linker (X) and / or a cytotoxic agent (Z)).

[0239] Optionally, the method can include any two or more antibody testing steps prior to contacting the antibody with the compound (eg, the linker (X) and / or the cytotoxic agent (Z)).

[0240] As further described herein, some well-known methods for conjugating cytotoxic agents to antibodies involve multiple reaction steps in which an antibody is first modified with a linker or portion of a linker, followed by a reaction in which the cytotoxic agent is conjugated to the antibody-linker composition.

[0241] In one embodiment, there is provided a method for preparing an antibody conjugate, comprising the steps of: (i) culturing a host cell transformed with an expression vector containing a polynucleotide encoding the antibody; obtaining an anti-Nectin-4 antibody by harvesting and purifying the antibody of interest from the culture obtained in the preceding step; (ii) contacting an anti-Nectin-4 antibody or antibody fragment with a compound (L) that comprises (a) a first reactive group capable of reacting with an amino acid of the antibody (e.g., a side chain or glycan of the amino acid, or a group attached to the amino acid or glycan of the amino acid), and (b) a second reactive group (R') to obtain a modified antibody that comprises one or more amino acids functionalized with compound (L); and (iii) reacting the modified antibody of step (i) with a compound comprising: (a) a reactive group (R) complementary to the reactive group (R'); (b) an amino acid unit (e.g., a di-, tri-, tetra- or pentapeptide) that is cleaved by an intracellular peptidase or protease enzyme; (c) optionally a non-self-eliminating or self-eliminating spacer (Y'); and (d) a cytotoxic agent (Z). The compound of step (ii) may further comprise a spacer (Y) disposed between R and the amino acid unit.

[0242] Optionally, the process of obtaining anti-Nectin-4 antibodies may further include the steps of preparing antibody-producing cells by immunizing an animal by injecting an antigen, taking blood and assaying its antibody titer to determine when to remove the spleen; preparing myeloma cells; fusing the antibody-producing cells with myelomas; screening a group of hybridomas that produce the desired antibodies; splitting the hybridomas into single-cell clones (cloning); culturing the hybridomas or raising animals transplanted with hybridomas to produce large amounts of monoclonal antibodies; and / or testing the monoclonal antibodies so produced for biological activity and binding specificity or assaying them for their properties as labeling reagents, etc.

[0243] Optionally, the step of obtaining an anti-Nectin-4 antibody can further include the step of preparing a cell library.

[0244] In one embodiment, R and R' are capable of undergoing a Click reaction or cycloaddition, where R comprises or is an alkyne moiety and R' comprises or may be an azide moiety, or R' comprises or is an alkyne moiety and R comprises or is an azide moiety, and the reaction in step (ii) is a 1,3-dipolar cycloaddition.

[0245] In one embodiment, the reaction in step (i) is carried out in the presence of a catalyst, which may be an enzyme (e.g., transglutaminase).

[0246] In one embodiment, step (i) comprises modifying the anti-nectin-4 antibody or antibody fragment before contacting the anti-nectin-4 antibody or antibody fragment with compound (L). For example, the antibody or antibody fragment can be modified by reacting or contacting it with an enzyme capable of modifying antibody glycosylation (e.g., at Kabat residue N297). In one example, the modification comprises deglycosylation of the antibody glycan having a core N-acetylglucosamine in the presence of an endoglycosidase to obtain an antibody comprising a core N-acetylglucosamine substituent, wherein the core N-acetylglucosamine and the core N-acetylglucosamine substituent may be fucosylated. Examples of endoglycosidases include EndoS, EndoA, EndoE, Endo18A, EndoF, EndoM, EndoD, EndoH, EndoT and EndoSH and / or combinations thereof.

[0247] The antigen binding protein (e.g., antibody) molecule and the cytotoxic agent (e.g., camptothecin derivative molecule) are connected by a linker. In such embodiments, the immunoconjugate may be, for example, of formula (II): Ab-(X-(Z) n ) m Formula (II) [In the formula, Ab is an anti-nectin-4 antibody or antibody fragment, X is a residue of a linker connecting Ab and Z, e.g., a linker following a covalent linkage to one or both of Ab and Z; Z is a cytotoxic agent, such as a camptothecin analog, and Z may include the structure of compound 1 or 2 (exatecan or SN-38 molecule); n is 1 or 2, When n is 1, m may be 1 to 8, or m may be an integer selected from among 1 to 8 or 1 to 6, m may be an integer selected from among 1 to 4, m may be 2 or 4; m may be 2, 3, 4, 5, 6, 7 or 8; when n is 2, m may be 1 to 4, or m may be an integer selected from among 1 to 4 or 1 to 3, m may be an integer selected from among 1 to 4, m may be 2 or 4; m may be 1, 2, 4 or 4. Where appropriate, "n" may be defined to represent the degree of branching or polymerization. "n" and "m" may be defined to represent averages in a composition comprising multiple antibodies.

[0248] In one embodiment, X represents a molecule comprising a moiety that is cleavable under physiological conditions, which may be, for example, intracellular conditions. In one embodiment, X represents a molecule comprising (i) a spacer (Y), (ii) a cleavable moiety, and (iii) an optional self-eliminating or non-self-eliminating spacer system (Y'). The spacer Y may be located between the Ab and the cleavable moiety, and the spacer system (Y') may be located between the cleavable moiety and Z. The molecule X or the spacer Y may be defined as comprising a reactive group (R) or a residue for reaction of the reactive group R with an amino acid of the antibody or a complementary reactive group (R') attached to an amino acid of the antibody, as appropriate.

[0249] The variable m is the -X-(Z) n In a composition comprising multiple anti-Nectin-4 ADCs, the number "m", which is the number of -XZ moieties per antibody molecule, can vary. Thus, in an exemplary composition comprising multiple immunoconjugates of the formulas herein, m represents the number of -X-(Z) moieties per Ab. n m is the average number of moieties, in which case m can also be referred to as the average drug loading or drug:antibody ratio (DAR). The average drug loading or DAR is advantageously between 1 and about 8 (-X-(Z) n) moieties. "n", the number of Z moieties attached to moiety X, can be, for example, 1 or 2. Typically, n is 1. In some embodiments, n is 1, m represents the average drug loading, and m is between 2 and 8. In some embodiments, n is 1, m represents the average drug loading, and m is between 2 and 6. In some embodiments, n is 1, m represents the average drug loading, and m is between 4 and 8. In some embodiments, n is 1, m represents the average drug loading, and m is between 6 and 8, optionally about 6, 7 or 8. In some embodiments, n is 1, m represents the average drug loading, and m is between 4 and 6, optionally about 4, 5 or 6.

[0250] The number of (-XZ) moieties per Ab can be characterized by conventional means such as mass spectrometry, ELISA assay, and HPLC. The quantitative distribution of the immunoconjugate with respect to m can also be determined. In some cases, separation, purification, and characterization of homogeneous immunoconjugates with a certain value of m, which are distinguished from immunoconjugates with other drug loads, can be achieved by means such as reverse-phase HPLC or electrophoresis.

[0251] In one embodiment, the anti-Nectin-4 composition used in the treatment method of the present disclosure has formula (I): Ab-(X-(Z) n ) m Formula (II) [In the formula, Ab is an anti-Nectin-4 antigen-binding protein (e.g., an antibody or antibody fragment); X is a molecule connecting Ab and Z, e.g., a residue of a linker following a covalent linkage to one or both of Ab and Z; Z is a cytotoxic agent, optionally a topoisomerase inhibitor, optionally a camptothecin analogue, optionally an exatecan or SN-38 molecule, e.g., a camptothecin analogue, including a molecule having the structure of Compound 1 or 2; n is 1 or 2, At least 50%, 60%, 70%, 80%, 90%, 95%, 98% or 99% of the immunoconjugates in the antibody sample have m (number of XZ moieties) that is 2 or 4, at least 2, between 2 and 4, at least 4, between 4 and 6, or between 4 and 8, where n is 1 and at least 50%, 60%, 70%, 80%, 90%, 95%, 98% or 99% of the immunoconjugates in the antibody sample have m (number of XZ moieties) that is 2 or 4, at least 2, between 2 and 4, at least 4, between 4 and 6, or between 4 and 8] The immunoconjugate is characterized as comprising a plurality of immunoconjugates represented by:

[0252] In one embodiment, the anti-Nectin-4 composition used in the treatment method of the present disclosure has formula (I): Ab-(X-(Z) n ) m Formula (II) [In the formula, Ab is an anti-Nectin-4 antigen-binding protein (e.g., an antibody or antibody fragment); X is a molecule connecting Ab and Z, e.g., a residue of a linker following a covalent linkage to one or both of Ab and Z; Z is a camptothecin analog, including an exatecan or SN-38 molecule, e.g., a molecule containing the structure of compound 1 or 2; n is 1, At least 50%, 60%, 70%, 80%, 90%, 95%, 98% or 99% of the immunoconjugates in the antibody sample have m (the number of XZ moieties) that is 6, at least 6, between 6 and 8, or 8. The immunoconjugate is characterized as comprising a plurality of immunoconjugates represented by:

[0253] It will be appreciated that a variety of methods can be used to covalently link a linker comprising a cytotoxic agent to an antibody or antigen-binding protein, either non-specifically or specifically to a particular amino acid residue. The linker (X) can include a moiety that is cleavable under physiological conditions, which may be intracellular conditions, for example, as shown in the Examples, such that cleavage of the linker releases the cytotoxic agent (e.g., Compound 1, Compound 2, Compound 13, etc.) into the intracellular environment. The linker can be attached to a chemically reactive group on the antibody molecule, such as a free amino, imino, hydroxyl, thiol, or carboxyl group (e.g., at the N- or C-terminus, the epsilon amino group of one or more lysine residues, the free carboxylic acid group of one or more glutamic or aspartic acid residues, or the sulfhydryl group of one or more cysteinyl residues), carbohydrate, or generally any reactive group that has been introduced or engineered into the antibody. The site at which the linker is attached may be a natural residue in the amino acid sequence of the antibody molecule, or may be introduced into the antibody molecule, for example, by recombinant DNA techniques (e.g., by introducing a cysteine ​​or protease cleavage site into the amino acid sequence, i.e., by introducing a non-natural amino acid residue) or by protein biochemistry (e.g., reduction, pH adjustment or proteolysis by glycomodification, which is the enzymatic modification of amino acid-linked glycans).

[0254] In some embodiments, the linker (X) comprises a peptide residue comprising an amino acid selected from phenylalanine, glycine, valine, lysine, citrulline, serine, glutamic acid, and aspartic acid, and the linker (X) may comprise a tetrapeptide residue.

[0255] In certain embodiments, an intermediate that is a precursor of the linker (X) is reacted with a cytotoxic agent (Z) under appropriate conditions. In certain embodiments, a reactive group on the cytotoxic agent and / or intermediate is used. In some embodiments, the product of the reaction of the cytotoxic agent with the intermediate, or a derivatized cytotoxic agent, is then reacted with an antibody molecule under appropriate conditions. In other embodiments, a precursor of the linker (X) is first reacted with an antibody molecule under appropriate conditions to obtain an antibody bound to the precursor of the linker (X), and then the antibody is reacted with a molecule comprising a cytotoxic agent (Z).

[0256] In some embodiments, the linker (X) is cleavable by a cleavage agent present in the intracellular environment (e.g., in a lysosome or endosome or caveolea). The linker can include, for example, a peptidyl linker or amino acid unit that is cleaved by an intracellular peptidase or protease enzyme, including but not limited to a lysosomal or endosomal protease. In some embodiments, the peptidyl linker moiety is at least 2 amino acids long or at least 3 amino acids long. Cleavage agents can include cathepsin B and D and plasmin, all of which are known to hydrolyze dipeptide drug derivatives, resulting in the release of active drugs inside target cells. Peptidyl linkers that are cleavable by enzymes present in cells are most typical. In a specific embodiment, the peptidyl linker cleavable by an intracellular protease is a Val-Cit linker or a Phe-Lys linker (see, for example, U.S. Patent No. 6,214,345, which describes the synthesis of doxorubicin with a valine-citrulline linker). The valine-citrulline (Val-Cit) element has the structure shown below:

[0257] [ka] may have the following structure:

[0258] In another specific embodiment, the peptidyl linker cleavable by an intracellular protease is a valine-alanine (Val-Ala) linker. The val-ala element has the structure shown below:

[0259] [ka] may have the following structure:

[0260] In another specific embodiment, the peptidyl linker cleavable by an intracellular protease is a glycine-containing oligopeptide linker, e.g., a glycine- and phenylalanine-containing oligopeptide linker, optionally a GGF, DGGF, (D-)D-GGF, EGGF, SGGF, KGGF, DGGFG, DDGGFG, KDGGFG, GGFGGGF GGFG, GGFGG or GGFGGG linker (see, e.g., U.S. Pat. No. 6,835,807, the disclosure of which is incorporated herein by reference), where "(D-)D represents D-aspartic acid.

[0261] In some embodiments, the linker may function to act as a spacer or stretcher to distance the antibody from Z to avoid interference with the antibody's ability to bind to Nectin-4 and / or inhibit cell-cell interactions mediated by Nectin-4. The linker may comprise a spacer unit (Y) and / or a spacer or spacer system (Y'). Thus, the spacer Y may be located between the Ab and the cleavable moiety. The spacer system (Y') may be located between the cleavable moiety and Z. The molecule X or the spacer Y may be defined as comprising a reactive group (R) or a residue of reaction of the reactive group R with an amino acid of the antibody or a complementary reactive group (R') attached to an amino acid of the antibody, as appropriate. The spacer Y can be, for example, a molecule that forms a bond (e.g., via its reactive group R) with an amino acid of the antibody, such as a sulfur atom, a primary or secondary amino group, or a carbohydrate group of the antibody, and this spacer or stretcher (Y) links the antibody to a cytotoxic agent (Z) or a cleavable amino acid unit (e.g., a peptidyl linker, a cleavable di-, tri-, tetra- or pentapeptide) which may further have a self-eliminating and / or non-self-eliminating spacer (Y') linking it to Z. Thus, when the spacer (Y) is linked at one end to an amino acid unit (e.g., a cleavable di-, tri-, tetra- or pentapeptide), the cleavable amino acid unit can be directly linked to Z or can include a further spacer (Y'), such as a non-self-eliminating or self-eliminating spacer linking the amino acid unit to Z.

[0262] The spacer (Y) may be defined as being or comprising a substituted or unsubstituted alkyl or heteroalkyl chain, where Y may have a chain length of from 2 to 100 atoms, optionally from 2 to 40, 2 to 30, 2 to 20, 4 to 40, 4 to 30 or 4 to 20 atoms, where optionally one or more of the atoms may be other than carbon, for example oxygen, sulfur, nitrogen or other atoms, and where optionally any carbon of the chain is substituted by alkoxy, hydroxyl, alkylcarbonyloxy, alkyl-S-, thiol, alkyl-C(O)S-, amine, alkylamine, amide, or alkylamide.

[0263] Spacer (Y) can be optionally defined as including a stability enhancing moiety. For example, spacer Y can include an orthogonal poly-ethylene glycol (PEG) moiety or a polysarcosine (poly-N-methylglycine or PSAR) moiety in a linker design (see, for example, WO 2019 / 081455, WO 2015 / 057699 and WO 2016 / 059377, the disclosures of which are incorporated herein by reference).

[0264] In some specific embodiments, the spacer (Y) may comprise one or more ethylene oxide monomers, Y may comprise a polyethylene oxide moiety, Y may comprise between 1 and 24, optionally between 1 and 12, optionally between 1 and 8, optionally between 1 and 6 polyethylene oxide moieties, and Y may have the structure -(CH 2 CH 2 O) x -wherein x is 1 to 12, optionally 1 to 8, optionally 1 to 6.

[0265] One example of a suitable stability enhancing moiety, the spacer chain Y, can include a stability enhancing moiety disclosed in PCT Publication No. WO2015 / 057699 or WO2019 / 081455. For example, the spacer chain Y can include an orthogonal connector moiety and a stability enhancing moiety. The stability enhancing moiety can be a PEG homopolymer, or generally any single molecular weight homopolymer (e.g., a PEG or polysarcosine homopolymer) linked to an orthogonal connector moiety. The homopolymer can have, for example, 1-4, 1-6, 1-8, 1-10, 1-12, at least 6, 8 or 10, or 6-12, 6-24, 6-72 units of PEG or other monomers. The term orthogonal connector refers to a branched linker unit component that connects a linker moiety (e.g., a chain of spacer Y) to a homopolymeric unit and to a cytotoxic agent (Z) via a linker [e.g., a cleavable oligopeptide (Pep) and a spacer Y'] such that the homopolymeric unit is in a parallel (not serial) arrangement to the cytotoxic agent (the homopolymer is parallel to the Pep-Y'-Z moiety). The orthogonal connector moiety may be, for example, one or more natural or unnatural amino acids that may be selected from glutamic acid, lysine, and glycine. The amino acid orthogonal connector moiety may be located at the end of the spacer chain Y such that the orthogonal connector moiety amino acid residue is connected to an amino acid residue of the peptidyl linker [e.g., (Pep) in formula V or VI] via a peptide bond between the α-carboxyl group of one amino acid and the α-amino group of the other amino acid. Y may, for example, be linked to the orthogonal connector moiety by a peptide bond between the orthogonal connector moiety and the α-amino group of the other amino acid.

[0266] [ka] [In the formula, R 1 and R 2 Unlike, R 1 and R 2 one of R is H or an inert group, 1 and R 2The other of Z is a functionalizing reactive group, which is reactive for covalent bonding to a bondable group of the orthogonal connector moiety under reaction conditions in which the inert group is non-reactive, and may be the same or different. 1 and Z 2 is an optional spacer, n is 1 or more, and k is 2 or more] may include the result of a reaction with a moiety of

[0267] In another example, the spacer Y is a group disclosed in U.S. Patent Application Publication No. 2017 / 0072068A1, the disclosure of which is incorporated herein by reference, such as a group represented by formula (E):

[0268] [ka] [In the formula, a is 0 or 1, R 1 is hydrogen, C 1 ~C 24 Alkyl group, C 3 ~C 24 Cycloalkyl groups, C2-C24 (hetero)aryl groups, C3-C24 alkyl (hetero)aryl groups and C 3 ~C 24 (hetero)arylalkyl groups, 1 ~C 24 Alkyl group, C 3 ~C 24 Cycloalkyl groups, C 2 ~C 24 (Hetero)aryl groups, C 3 ~C 24 Alkyl(hetero)aryl groups and C 3 ~C 24 (Hetero)arylalkyl groups are O, S and NR 3 and optionally substituted and optionally interrupted by one or more heteroatoms selected from R 3 is hydrogen and C 1 ~C 4or a salt thereof, wherein the group of formula E or a salt thereof is located between said first and second ends of spacer chain Y.

[0269] In this embodiment, the spacer Y can include -(succinimid-3-yl-N)-CH2CH2-C(=O)-, -(succinimid-3-yl-N)-CH2CH2CH2-C(=O)-, -(succinimid-3-yl-N)-CH2CH2CH2CH2-C(=O)-, -(succinimid-3-yl-N)-CH2CH2CH2CH2-C(=O)-, -(succinimid-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-.

[0270] Optionally, such a spacer Y can further include the following structure: -NH-(CH2CH2-O)n-CH2CH2-C(=O)-, where n is an integer from 1 to 6, preferably from 2 to 4. Such structures include, for example, -NH-CH 2 CH 2 -O-CH 2 CH 2 -C(=O)-, -NH-CH 2 CH 2 -O-CH 2 CH 2 -O-CH 2 CH 2 -C(=O)-, -NH-CH 2 CH 2 -O-CH 2 CH 2 -O-CH 2 CH 2 -O-CH 2 CH 2 -C(=O)-, -NH-CH 2 CH 2 -O-CH 2 CH 2 -O-CH 2 CH 2 -O-CH 2 CH 2 -O-CH 2 CH 2 -C(=O)-, -NH-CH 2 CH 2 -O-CH 2 CH 2 -O-CH2 CH 2 -O-CH 2 CH 2 -O-CH 2 CH 2 -O-CH 2 CH 2 -C(=O)-, -NH-CH 2 CH 2 -O-CH 2 CH 2 -O-CH 2 CH 2 -O-CH 2 CH 2 -O-CH 2 CH 2 -O-CH 2 CH 2 -O-CH 2 CH 2 -O-CH 2 CH 2 -C(=O)- is exemplified.

[0271] The spacer or spacer system (Y') located between the amino acid unit (e.g., a cleavable di-, tri-, tetra- or pentapeptide) and Z may be a self-eliminating or non-self-eliminating spacer. The spacer Y' may, for example, comprise a substituted or unsubstituted alkyl or heteroalkyl chain, Y having a chain length of 2 to 30 atoms, optionally 2 to 20, 4 to 20, 2 to 10 or 4 to 20 atoms, optionally one or more atoms may be other than carbon, e.g. oxygen, sulfur, nitrogen or other atoms, optionally any carbon of the chain is substituted with alkoxy, hydroxyl, alkylcarbonyloxy, alkyl-S-, thiol, alkyl-C(O)S-, amine, alkylamine, amide, or alkylamide. In one embodiment, Y' comprises a p-aminobenzyloxycarbonyl group. In one embodiment, Y' is a non-self-elimination spacer and comprises the structure -(CH2)nC(=O)-, where n is an integer from 0 to 5, connected to the cleavable moiety by -O- or a single bond. For example, Y' can be or include a -C(=O)-, -OC(=O)-, -O-CH2-C(=O)-, -O-CH2CH2-C(=O)-, -O-CH2CH2CH2-C(=O)-, -O-CH2CH2CH2CH2-C(=O)-, -O-CH2CH2CH2CH2-C(=O)-, -O-CH2CH2CH2CH2CH2-C(=O)-, HO-O-CH2-C(=O)-, -CH2-C(=O)-, -CH2CH2CH2-C(=O)-, -CH2CH2CH2-C(=O)-, -CH2CH2CH2CH2-C(=O)-, -CH2CH2CH2CH2-C(=O)-, -CH2CH2CH2CH2-C(=O)-, -CH2-O-CH2-C(=O)- or -CH2CH2-O-CH2-C(=O)- group.

[0272] A "self-elimination" spacer unit allows the release of the drug moiety without a separate hydrolysis step. When a self-elimination spacer is used, after cleavage or transformation of the amino acid unit, the side of the spacer linked to the amino acid unit becomes unblocked, resulting in the eventual release of one or more moieties Z. Self-elimination spacer systems can be, for example, those described in WO 02 / 083180 and WO 2004 / 043493, the disclosures of which are incorporated herein by reference in their entirety, as well as other self-elimination spacers known to those skilled in the art. In certain embodiments, the spacer unit of the linker comprises a p-aminobenzyl unit. In one such embodiment, p-aminobenzyl alcohol is attached to the amino acid unit via an amide bond, resulting in a carbamate, methyl carbamate, or carbonate between the benzyl alcohol and the cytotoxic agent. In one embodiment, the spacer unit can be, for example, a structure:

[0273] [ka] and p-aminobenzyloxycarbonyl (PAB) having the formula:

[0274] Examples of self-eliminating spacer units include, but are not limited to, aromatic compounds that are electronically similar to p-aminobenzyl alcohol (see, for example, US Patent Application Publication No. 2005 / 0256030A1), such as 2-aminoimidazole-5-methanoi derivatives (Hay et al. (1999) Bioorg. Med. Chem. Lett. 9:2237) and ortho- or para-aminobenzyl acetals. Spacers that can be used may undergo cyclization upon amide bond hydrolysis, such as substituted and unsubstituted 4-aminobutyric acid amides (Rodrigues et al.. Chemistry Biology, 1995, 2, 223) and 2-aminophenylpropionic acid amides (Amsberry, et al., J. Org. Chem., 1990, 55. 5867). Elimination of amine-containing drugs substituted at the a-position of glycine (Kingsbury, et al., J. Med. Chem., 1984, 27, 1447) is also an example of a self-eliminating spacer. p-Aminobenzyl self-eliminating spacers (e.g., PAB) are particularly suitable for use with Phe-Lys, Val-Ala or Val-Cit cleavable dipeptide units (PAB is placed between the dipeptide and the camptothecin derivative (Z)).

[0275] A "non-self-eliminating" spacer unit is one in which some or all of the spacer unit remains attached to the moiety Z after enzymatic (e.g., proteolytic) cleavage of the antibody-moiety of interest conjugate. Examples of non-self-eliminating spacer units suitable for use as a spacer between a Gly-Gly-Phe-Gly amino acid unit and an exatecan molecule include, but are not limited to, -O-CH 2 -C(=O)-, HO-O-CH 2 -C(=O)-, -CH 2 CH 2 -C(=O)-, -CH 2 CH 2 CH 2 -C(=O)-, -CH 2 -O-CH 2-C(=O)- and -CH 2 CH 2 -O-CH 2 -C(=O)-(e.g., GGFG-CH 2 CH 2 -O-CH 2 -C(=O)-exatecan unit). The use of such a spacer between the GGFG amino acid unit and exatecan results in the release of a molecule having the structure of compound 13. Other examples of non-self-eliminating spacer units include, but are not limited to, glycine spacer units and glycine-glycine spacer units. Other known combinations of peptide spacers susceptible to sequence-specific enzymatic cleavage can be used as well. For example, enzymatic cleavage of an antibody-moiety of interest conjugate containing a glycine-glycine spacer unit by tumor cell-associated proteases can result in the release of the glycine-glycine-drug moiety from the remainder of the antibody-moiety of interest conjugate. In one such embodiment, the glycine-glycine-drug moiety is then subjected to a separate hydrolysis step in the tumor cell, thereby cleaving the glycine-glycine spacer unit from the drug moiety.

[0276] Exemplary linker-cytotoxic drug moieties (XZ) can include any of the structures shown in Formulas III and IV below.

[0277] [ka] [ka]

[0278] The spacers (Y) and (Y') are, as appropriate, linear or branched C 1 ~C 20 Alkylene group, C 2 ~C 20 Alkenylene group, C 2 ~C 20 Alkynylene group, C 3 ~C 20 Cycloalkylene group, C5 ~C 20 Cycloalkenylene group, C 8 ~C 20 Cycloalkynylene group, C 7 ~C 20 Alkyl arylene group, C 7 ~C 20 Aryl alkylene group, C 8 ~C 20 Arylalkenylene groups and C 9 ~C 20 arylalkynylene groups, wherein the alkylene, alkenylene, alkynylene, cycloalkylene, cycloalkenylene, cycloalkynylene, alkylarylene, arylalkylene, arylalkenylene, and arylalkynylene groups are independently selected from the group consisting of O, S, and NR 1 and R 1 is hydrogen, C 1 ~C 24 Alkyl group, C 2 ~C 24 Alkenyl group, C 2 ~C 24 Alkynyl groups and C 3 ~C 24 cycloalkyl groups, wherein the alkyl groups, alkenyl groups, alkynyl groups, and cycloalkyl groups are optionally substituted.

[0279] The spacers (Y) and (Y') are suitably 1 ~C 10 Alkylene-, -C 1 ~C 10 Heteroalkylene-, -C 3 ~C 8 Carbocyclo-, -O-(C 1 ~C 8 Alkyl)-, -arylene-, -C 1 ~C 10 Alkylene-arylene-, -arylene-C 1 ~C 10 Alkylene-, -C 1 ~C 10Alkylene-(C 3 ~C 8 Carbocyclo)-, -(C 3 ~C 8 Carbocyclo)-C 1 ~C 10 Alkylene-, -C 3 ~C 8 Heterocyclo-, -C 1 ~C 10 Alkylene-(C 3 ~C 8 Heterocyclo)-, -(C 3 ~C 8 Heterocyclo)-C 1 ~C 10 Alkylene-, -C 1 ~C 10 Alkylene-C(=O)-, -C 1 ~C 10 Heteroalkylene-C(=O)-, -C 3 ~C 8 Carbocyclo-C(=O)-, -O-(C 1 ~C 8 Alkyl)-C(=O)-, -arylene-C(=O)-, -C 1 ~C 10 Alkylene-arylene-C(=O)-, -arylene-C 1 ~C 10 Alkylene-C(=O)-, -C 1 ~C 10 Alkylene-(C 3 ~C 8 Carbocyclo)-C(=O)-, -(C 3 ~C 8 Carbocyclo)-C 1 ~C 10 Alkylene-C(=O)-, -C 3 ~C 8 Heterocyclo-C(=O)-, -C 1 ~C 10 Alkylene-(C 3 ~C 8 Heterocyclo)-C(=O)-, -(C 3 ~C 8 Heterocyclo)-C 1 ~C 10 Alkylene-C(=O)-, -C 1 ~C 10Alkylene-NH-, -C 1 ~C 10 Heteroalkylene-NH-, -C 3 ~C 8 Carbocyclo-NH-, -O-(C 1 ~C 8 Alkyl)-NH-, -Arylene-NH-, -C 1 ~C 10 Alkylene-arylene-NH-, -arylene-C 1 ~C 10 Alkylene-NH-, -C 1 ~C 10 Alkylene-(C 3 ~C 8 Carbocyclo)-NH-, -(C 3 ~C 8 Carbocyclo)-C 1 ~C 10 Alkylene-NH-, -C 3 ~C 8 Heterocyclo-NH-, -C 1 ~C 10 Alkylene-(C 3 ~C 8 Heterocyclo)-NH-, -(C 3 ~C 8 Heterocyclo)-C 1 ~C 10 Alkylene-NH-, -C 1 ~C 10 Alkylene-S-, -C 1 ~C 10 Heteroalkylene-S-, -C 3 ~C 8 Carbocyclo-S-, -O-(C 1 ~C 8 Alkyl)-)-S-, -Arylene-S-, -C 1 ~C 10 Alkylene-arylene-S-, -arylene-C 1 ~C 10 Alkylene-S-, -C 1 ~C 10 Alkylene-(C 3 ~C 8 Carbocyclo)-S-, -(C 3 ~C 8 Carbocyclo)-C 1 ~C 10Alkylene-S-, -C 3 ~C 8 Heterocyclo-S-, -C 1 ~C 10 Alkylene-(C 3 ~C 8 Heterocyclo)-S-, -(C 3 ~C 8 Heterocyclo)-C 1 ~C 10 Alkylene-S-, -C 1 ~C 10 Alkylene-OC(=O)-, -C 3 ~C 8 Carbocyclo-OC(=O)-, -O-(C 1 ~C 8 Alkyl)-OC(=O)-, -Arylene-OC(=O)-, -C 1 ~C 10 Alkylene-arylene-OC(=O)-, -arylene-C 1 ~C 10 Alkylene-OC(=O)-, -C 1 ~C 10 Alkylene-(C 3 ~C 8 Carbocyclo)-OC(=O)-, -(C 3 ~C 8 Carbocyclo)-C 1 ~C 10 Alkylene-OC(=O)-, -C 3 ~C 8 Heterocyclo-OC(=O)-, -C 1 ~C 10 Alkylene-(C 3 ~C 8 Heterocyclo)-OC(=O)-, -(C 3 ~C 8 Heterocyclo)-C 1 ~C 10 It can be defined as being or including alkylene -OC(=O)-, in each case -X, -R', -O, -OR', =O, -SR', -S - , -NR' 2 , -NR' 3 + , =NR', -CX 3, -CN, -OCN, -SCN, -N=C=O, -NCS, -NO, -NO 2 , =N 2 , -N 3 , -NR'C(=O)R', -C(=O)R', -C(=O)NR' 2 , -SO 3 - , -SO 3 H, -S(=O) 2 R', -OS(=O) 2 OR', -S(=O) 2 NR', -S(=O)R', -OP(=O)(OR') 2 , -P(=O)(OR') 2 , -PO 3 , -PO 3 H 2 , -C(=O)X, -C(=S)R', -CO 2 R', -CO 2 , -C(=S)OR', C(=O)SR', C(=S)SR', C(=O)NR' 2 , C(=S)NR' 2 , and C(=NR')NR' 2 and each X is independently a halogen, i.e., -F, -Cl, -Br, or -I; and each R' is independently -H, -C 1 ~C 20 Alkyl, -C 6 ~C 20 Aryl, or -C 3 ~C 14 It is a heterocycle.

[0280] In one embodiment, the spacer (Y) can be defined as comprising a reactive group (R) at, for example, one end of a chain, which is reactive with a free amino, hydroxyl, sulfhydryl or carboxyl group on an antibody, or with a carbohydrate, as appropriate. In some aspects, the spacer Y comprises an R group -(succinimid-3-yl-N)-(CH 2 ) n 3 -C(=O) [where n 3 is an integer of 2 to 8, and -(succinimid-3-yl-N) is a group represented by the following formula F:

[0281] [ka] Position 3 of the above structure can be the site of attachment to the antibody. Attachment to the antibody at position 3 is characterized by a bond involving thioether formation.

[0282] In one embodiment, the spacer (Y) can be defined as comprising, as appropriate, a reactive group (R), e.g., at one end of the chain, that is reactive with a complementary reactive group (R') that is attached to an amino acid of the antibody (e.g., via a free amino, hydroxyl, sulfhydryl or carboxyl group, or carbohydrate), or, after conjugation to the anti-Nectin-4 antibody, a residue for reaction of the reactive group (R) with a free amino, hydroxyl, sulfhydryl or carboxyl group on the antibody or a complementary reactive group (R') that is attached to an amino acid of the antibody. Examples of reactive group pairs with R and R' include a variety of groups capable of biorthogonal reactions, preferably cycloadditions, such as between azides and cyclooctynes ​​(copper-free click chemistry), Diels-Alder reactions or 1,3-dipolar cycloadditions, such as between nitrones and cyclooctynes, oxime / hydrazone formation from aldehydes and ketones, and tetrazine ligation (see also WO 2013 / 092983 or US 2017 / 0072068 A1, the disclosures of which are incorporated herein by reference). For example, R may be an alkyne and R' may be an azide, or R may be an azide and R' may be an alkyne. Thus, the resulting linker and functionalized antibody, or Y element thereof, may in any embodiment include a group (RR') resulting from the reaction of R with R', for example RR' may be or may include a triazole resulting from the reaction of an alkyne with an azide.

[0283] In one embodiment, the reactive groups R and R' are complementary reagents (i.e., click chemistry reagents or reactive groups) that can undergo a "click" reaction together. For example, 1,3-dipole functional compounds can react with alkynes in a cyclization reaction to form heterocyclic compounds, preferably in the substantial absence of an addition catalyst (e.g., Cu(I)). A variety of compounds with at least one 1,3-dipole group attached (having a three-atom pi-electron system containing four electrons delocalized to three atoms) can be used to react with the alkynes disclosed herein. Exemplary 1,3-dipole groups include, but are not limited to, azides, nitrile oxides, nitrones, azoxy groups, and acyldiazo groups.

[0284] Examples include o-phosphenearomatic esters, azides, fulminates, alkynes (including any strained cycloalkynes), cyanides, anthracene, 1,2,4,5-tetrazine, or norbornene (or other strained cycloalkenes).

[0285] In one embodiment, R is a moiety bearing a terminal alkyne or azide, such moieties being described, for example, in U.S. Patent No. 7,763,736, the disclosure of which is incorporated herein by reference. Suitable reaction conditions for the use of copper (and other metal salts) as a catalyst for the click reaction between terminal alkynes and azides are provided in U.S. Patent No. 7,763,736.

[0286] In one embodiment, R is a substituted or unsubstituted cycloalkyne.Cycloalkyne containing compounds are described, for example, in U.S. Patent No. 7,807,619, the disclosure of which is incorporated herein by reference.

[0287] In some embodiments, the cycloalkyne has formula A:

[0288] [ka] [In the formula, R 1 is selected from carbonyl, alkyl ester, aryl ester, substituted aryl ester, aldehyde, amide, aryl amide, alkyl halide, thioester, sulfonyl ester, alkyl ketone, aryl ketone, substituted aryl ketone, and halosulfonyl; R 1 may be present at any position in the cyclooctyne group except the two carbons joined by the triple bond. The compound may be:

[0289] In some embodiments, the modified cycloalkyne is a cycloalkyne of formula A, where one or more of the carbon atoms in the cyclooctyne ring other than the two carbon atoms joined by the triple bond are substituted with one or more electron-withdrawing groups, such as halo (bromo, chloro, fluoro, iodo), nitro, cyano, sulfone, or sulfonic acid groups. Thus, for example, in some embodiments, the subject modified cycloalkyne has formula B:

[0290] [ka] [In the formula, R 2 and R 3 each of which is independently: (a) H; (b) a halogen atom (e.g., bromo, chloro, fluoro, iodo); (c) -W-(CH 2 ) n -Z, where n is an integer from 1 to 4 (e.g., n=1, 2, 3, or 4), W, if present, is O, N, or S, and Z is nitro, cyano, sulfonic acid, or halogen; (d) -(CH 2 ) n -W-(CH 2 ) m -R 4wherein n and m are each independently 1 or 2; W is O, N, S, or sulfonyl; and when W is O, N, or S, R 4 is nitro, cyano, or halogen; when W is sulfonyl, R 4 is H], or (e) -CH 2 ) n -R 4 [wherein n is an integer from 1 to 4 (e.g., n=1, 2, 3, or 4), and R 4 is nitro, cyano, sulfonic acid, or halogen; R 1 is selected from carbonyl, alkyl ester, aryl ester, substituted aryl ester, aldehyde, amide, aryl amide, alkyl halide, thioester, sulfonyl ester, alkyl ketone, aryl ketone, substituted aryl ketone, and halosulfonyl. 1 may be present at any position in the cyclooctyne group except the two carbons connected by the triple bond. is a cycloalkyne.

[0291] In one embodiment, R is a substituted or unsubstituted heterocyclic strained alkyne. Cycloalkyne containing compounds are described, for example, in U.S. Pat. No. 8,133,515, the disclosure of which is incorporated herein by reference. In one embodiment, the alkyne is of formula C:

[0292] [ka] [In the formula, Each R 1 is hydrogen, halogen, hydroxy, alkoxy, nitrate, nitrite, sulfate, and C 1 ~C 10 independently selected from the group consisting of alkyl and heteroalkyl; Each R 2 is hydrogen, halogen, hydroxy, alkoxy, nitrate, nitrite, sulfate, and C 1 ~C 10X is independently selected from the group consisting of organic groups, 3 R 4 , N.H.-R. 4 , CH-N-OR 4 , CN-NR 3 R 4 , CHOR 4 , or CHNHR 4 Each R 3 represents hydrogen or an organic group, R 4 represents the linking portion C of the linker. In one embodiment, R or R' is the following DBCO (dibenzycyclooctyl) group.

[0293] [ka]

[0294] Alkynes, such as those described herein above, can be reacted with at least one 1,3-dipole functional compound in a cyclization reaction to form a heterocyclic compound, preferably in the substantial absence of an addition catalyst (e.g., Cu(I)). A wide variety of compounds having at least one 1,3-dipole group attached (having a three-atom pi-electron system containing four electrons delocalized to three atoms) can be used to react with the alkynes disclosed herein. Exemplary 1,3-dipole groups include, but are not limited to, azides, nitrile oxides, nitrones, azoxy groups, and acyldiazo groups.

[0295] In the formulae herein, Y' is optionally absent or may be a spacer, optionally a self-eliminating or non-self-eliminating spacer including, for example, a p-aminobenzyl unit. Y' may be or include a substituted or unsubstituted alkyl or heteroalkyl chain, Y' may have a chain length of 2 to 40 atoms, optionally 2 to 30, 2 to 20, 4 to 40, 4 to 30 or 4 to 20 atoms, optionally one or more atoms may be other than carbon, such as oxygen, sulfur, nitrogen, or other atoms, and optionally any carbon in the chain is substituted with alkoxy, hydroxyl, alkylcarbonyloxy, alkyl-S-, thiol, alkyl-C(O)S-, amine, alkylamine, amide, or alkylamide.

[0296] Exemplary linker-cytotoxic agent molecules (e.g., the XZ moieties of Formulas I-XI) that can be conjugated to anti-Nectin-4 antibodies are suitably represented by Formula V: (R)-(Y)-(Pep)-(Y')-(Z) Formula (V) [In the formula, R is a group reactive with a free amino, hydroxyl, sulfhydryl or carboxyl group on the antibody or with a complementary reactive group (R') attached to an amino acid of the antibody, or after conjugation to the anti-Nectin-4 binding protein, R is a residue of a reactive group (R) with a free amino, hydroxyl, sulfhydryl or carboxyl group on the antibody or with a complementary reactive group (R') attached to an amino acid of the antibody; Y is absent or is a spacer; Pep is or includes a peptidyl linker that is cleaved by an intracellular peptidase or protease enzyme, such as a valine-citrulline, valine-alanine, or phenylalanine-lysine dipeptide; Y' is absent or is a spacer, optionally a self-elimination spacer or a non-self-elimination spacer; Z is a cytotoxic agent, optionally a camptothecin analogue, optionally an exatecan, Dxd or SN-38 molecule. It can be expressed as:

[0297] The resulting Nectin-4 binding immunoconjugate of the present invention can be, for example, represented by formula (VI): Ab-(Y)-(Pep)-(Y')-(Z) Formula (VI) [In the formula, Ab is anti-nectin-4 antibody; Y may be absent or may be a spacer. Formula VI may include a residue of a reactive group (e.g., maleimide, primary amine) between (Ab) and (Y) and a side chain of an amino acid of an anti-Nectin-4 antigen binding protein (Ab) or a carbohydrate. Alternatively, the residue of a reactive group (e.g., maleimide, primary amine) between a side chain of an amino acid of an anti-Nectin-4 antigen binding protein (Ab) and a carbohydrate may be defined as being included in Y, Pep is or includes an amino acid unit (e.g., a peptidyl linker) that is cleaved by an intracellular peptidase or protease enzyme (e.g., (Pep) is a protease-cleavable di-, tri-, tetra-, or pentapeptide, such as a valine-citrulline, valine-alanine, or phenylalanine-lysine unit); Y' is absent or is a spacer, optionally a self-elimination spacer or a non-self-elimination spacer; Z is a cytotoxic agent, optionally a camptothecin derivative, optionally an exatecan, Dxd or SN-38 molecule. It can be expressed as:

[0298] Where appropriate, the formula can be defined as including or including a residue (RR') of reaction between a reactive group (R) [e.g., between (Ab) and the terminus of Y (or (Pep or X) if Y is absent)] and a free amino, hydroxyl, sulfhydryl or carboxyl group on the antibody, or a complementary reactive group (R') attached to an amino acid of the antibody.

[0299] In one example, where (RR') is a residue of a reactive group (R) and a complementary reactive group (R') attached to an antibody (e.g., R' is attached to an amino acid side chain or a glycan of the antibody), the Nectin-4-binding immunoconjugate of the present invention can be, for example, represented by the formula (VI bis ): Ab-(RR')-(Y)-(Pep)-(Y')-(Z) Formula (VI bis ) where Ab, Y, Pep, Y' and Z are as defined in formula VI and RR' is the result of a biorthogonal reaction, preferably a cycloaddition, such as a Diels-Alder reaction or a 1,3-dipolar cycloaddition. In one embodiment, RR' is:

[0300] [ka] [where, X 8 is O or NH, and X 9 is selected from H, methyl and pyridyl, and has the structure (RR ’c ) and (RR ’d )

[0301] [ka] The bonds represent either single or double bonds. The compound has a structure selected from the group consisting of:

[0302] In any embodiment, the exatecan molecule (or other hexacyclic camptothecin) can be defined as being linked to Y' [or (Pep)] if Y' is absent] via the amine at position 1 of exatecan.

[0303] In any embodiment, the SN-38 molecule (or other pentacyclic camptothecin) can be defined as being linked to Y' [or (Pep)] if Y' is absent] via the amine at position 9 of SN-38.

[0304] Cytotoxic agents, also referred to as (Z) moieties, include cytotoxic agents such as, for example, anti-neoplastic agents. Examples of cytotoxic agents are known in the art. For example, Z can be an alkylating agent, preferably a DNA alkylating agent. An alkylation agent is a compound that can replace a hydrogen atom with an alkyl group under physiological conditions (e.g., pH 7.4, 37C, aqueous solution). Alkylation reactions are typically described in terms of substitution reactions between N, O and S heteroatom nucleophiles and electrophilic alkylating agents, although Michael addition reactions are also important. Examples of alkylating agents include nitrogen and sulfur mustards, ethylenimines, methanosulfonates, CC-1065 and duocarmycins, nitrosoureas, platinum-containing agents, agents that result in topoisomerase II-mediated site-dependent alkylation of DNA (e.g., psorospermin and related bisfuranoxanthones), ecteinascidins and other or related DNA minor groove alkylating agents.

[0305] In one embodiment, Z is a chelate of a chelating metal, such as a positive divalent or positive trivalent metal having a coordination number of 2 to 8 (endpoints included). Specific examples of such metals include technetium (Tc), rhenium (Re), cobalt (Co), copper (Cu), gold (Au), silver (Ag), lead (Pb), bismuth (Bi), indium (In), gallium (Ga), yttrium (Y), terbium (Tb), gadolinium (Gd), and scandium (Sc). In general, the metal is preferably a radionuclide. Specific radionuclides include 99mTc, 186Re, 188Re, 58Co, 60Co, 67Cu, 195Au, 199Au, 110Ag, 203Pb, 206Bi, 207Bi, 111In, 67Ga, 68Ga, 88Y, 90Y, 160Tb, 153Gd and 47Sc. The chelated metal can be, for example, one of the above types of metals chelated with any suitable multidentate chelating agent, such as acyclic or cyclic polyamines, polyethers (e.g. crown ethers and their derivatives); polyamides; porphyrins; and carbocyclic derivatives.

[0306] Anti-nectin-4 antibodies or antibody fragments can also be used in diagnostic methods, for example, to detect nectin-4 tumor cells. In such embodiments, antibodies or antibody fragments can be conjugated to effector molecules, such as detectable substances, useful, for example, in diagnosis. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent substances, luminescent substances, bioluminescent substances, radionuclides, positron-emitting metals (for use in positron emission tomography), and non-radioactive paramagnetic metal ions. For a summary of metal ions that can be conjugated to antibodies for use as diagnostic methods, see U.S. Patent No. 4,741,900. Suitable enzymes include horseradish peroxidase, alkaline phosphatase, beta-galactosidase, or acetylcholinesterase; suitable prosthetic groups include streptavidin, avidin, and biotin; suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride, and phycoerythrin; suitable luminescent materials include luminol; suitable bioluminescent materials include luciferase, luciferin, and aequorin; and suitable radionuclides include 125I, 131I, 111In, and 99Tc.

[0307] In one embodiment, the cytotoxic agent (Z) is a DNA minor groove binding and / or alkylating agent, such as a pyrrolobenzodiazepine, a duocarmycin, or a derivative thereof.

[0308] In further embodiments, the cytotoxic agent is selected from the group consisting of taxanes, anthracyclines, camptothecins, epothilones, mitomycins, combretastatins, vinca alkaloids, nitrogen mustards, maytansinoids, calicheamicins, duocarmycins, tubulysins, dolastatins and auristatins, enediynes, amatoxins, pyrrolobenzodiazepines, ethylenimines, radioisotopes, therapeutic proteins and peptides, and toxins or fragments thereof.

[0309] In further embodiments, the cytotoxic agent is cyclophosphamide, ifosfamide, chlorambucil, 4-(bis(2-chloroethyl)amino)phenol, 4-(bis(2-fluoroethyl)ammo)phenol, N,N-bis(2-chloroethyl)-p-phenylenediamine, N,N-bis(2-fluoro-ethyl)-p-phenylenediamine, carmustine, lomustine, treosulfan, dacarbazine, cisplatin, carboplatin, vincristine, vinblastine, vindesine, vinorelbine, paclitaxel, docetaxel, etoposide, teniposide, topotecan, irinotecan, 9-aminocamptothecin, 9-nitrocamptothecin, 10-hydroxycamptothecin, lurtotecan, camptothecin, crisnatol, mitomycin C C), mitomycin A, methotrexate, trimetrexate, mycophenolic acid, triazofurin, ribavirin, hydroxyurea, deferoxamine, 5-fluorouracil, floxuridine, doxifluridine, raltitrexed, cytarabine, cytosine arabinoside, fludarabine, 6-mercaptopurine, thioguanine, raloxifene, megestrol, goserelin, leuprolide acetate, flutamide, bicalutamide, vertoporfin, Phthalocyanine, photosensitizer Pc4, demethoxyhypocrelin A, interferon-alpha, interferon-gamma, tumor necrosis factor, lovastatin, staurosporine, actinomycin D, bleomycin A2, bleomycin B2, peplomycin, daunorubicin, doxorubicin, N-(5,5-diacetoxypentyl)doxorubicin, morpholinodoxorubicin, idarubicin, epirubicin, pirarubicin, zorubicin, mitoxantrone, thapsigargin, N 8-Acetylspermidine, tallysomycin, esperamicin, butyric acid, retinoic acid, 1,8-dihydroxybicyclo[7.3.1]tridec-4-ene-2,6-diyn-13-one, anguidine, podophyllotoxin, combretastatin A-4, pancratistatin, tubulysin A, tubulysin D, carminomycin, streptonigrin, eryptomium acetate, maytansine, maytansinol, calicheamicin, mertansine (DM1), N-acetylglucosamine, ... 1 I -Calicare sewing machine, Calicare sewing machine-γ 1 I , calicheamicin-α 2 I , calicheamicin-α 3 I , duocarmycin SA, duocarmycin A, CC-1065, CBI-TMI, duocarmycin C2, duocarmycin B2, centanamycin, dolastatin, auristatin E, monomethylauristatin E (MMAE), monomethylauristatin F (MMAF), α-amanitin, β-amanitin, γ-amanitin, ε-amanitin, amanine, amaninamide, amanulin, and amanuric acid, and derivatives thereof.

[0310] Exemplary auristatin embodiments have the following formulae (a1) and (a2):

[0311] [ka]

[0312] [ka] wherein the wavy lines in (a1) and (a2) indicate sites of covalent attachment to a linker (e.g., linker X, or moiety Y, Pep, or Y′), independently at each position: R 2 H and C 1 ~C 8 alkyl, R 3, H, C 1 ~C 8 Alkyl, C 1 ~C 8 Carbocyclic, Aryl, C 1 ~C 8 Alkyl-aryl, C 1 ~C 8 Alkyl-(C 3 ~C 8 carbon ring), C 3 ~C 8 Heterocycles and C 1 ~C 8 Alkyl-(C 3 ~C 8 heterocycle); R 4 , H, C 1 ~C 8 Alkyl, C 3 ~C 8 Carbocyclic, Aryl, C 1 ~C 8 Alkyl-aryl, C 1 ~C 8 Alkyl-(C 3 ~C 8 carbon ring), C 3 ~C 8 Heterocycles and C 1 ~C 8 Alkyl-(C 3 ~C 8 heterocycle); R 5 is selected from H and methyl; or R 4 and R 5 together form a carbocyclic ring of the formula -(CR a R b ) n R a and R b , H, C 1 ~C 8 Alkyl and C 3 ~C 8 carbocycle, and n is selected from 2, 3, 4, 5, and 6; R 6 is H and C 1 ~C 8 alkyl, R 7, H, C 1 ~C 8 Alkyl, C 3 ~C 8 Carbocyclic, Aryl, C 1 ~C 8 Alkyl-aryl, C 1 ~C 8 Alkyl-(C 3 ~C 8 carbon ring), C 3 ~C 8 Heterocycles and C 1 ~C 8 Alkyl-(C 3 ~C 8 heterocycle); Each R 8 is H, OH, C 1 ~C 8 Alkyl, C 3 ~C 8 Carbocyclic and O-(C 1 ~C 8 alkyl), R 9 is H and C 1 ~C 8 alkyl, R 10 is aryl or C 3 ~C 8 heterocycles; Z is O, S, NH, or NR 12 and R 12 is C 1 ~C 8 is alkyl, R 11 , H, C 1 ~C 20 Alkyl, aryl, C 3 ~C 8 Heterocycle, -(R 13 O) m -R 14 , or -(R 13 O) m -CH(R 15 ) 2 wherein m is an integer ranging from 1 to 1000; R 13 is C 2 ~C 8 is alkyl, R 14 is H or C 1 ~C 8 is alkyl, R 15 Each occurrence of is independently H, COOH, -(CH 2 ) n -N(R 16 ) 2 , -(CH 2 ) n -SO 3 -C 1 ~C 8 is alkyl, R 16 Each occurrence of is independently H, C 1 ~C 8 Alkyl, or -(CH 2 ) n -COOH, R 18 is -C(R 8 ) 2 -C(R 8 ) 2 -aryl, -C(R 8 ) 2 -C(R 8 ) 2 -(C 3 ~C 8 heterocycle), and -C(R 8 ) 2 -C(R 8 ) 2 -(C 3 ~C 8 carbocyclic rings; n is an integer ranging from 0 to 6. The compound includes an N-terminally linked monomethyl auristatin drug moiety comprising any of the structures:

[0313] In one embodiment, R 3 , R 4 and R 7 is independently isopropyl or sec-butyl; R 5 is -H or methyl. In an exemplary embodiment, R 3 and R 4 are isopropyl, and R 5 is -H, R 7is sec-butyl.

[0314] In yet another embodiment, R 2 and R 6 are methyl, and R 9 is -H.

[0315] In yet another embodiment, R 8 Each occurrence of -OCH 3 It is.

[0316] In an exemplary embodiment, R 3 and R 4 are isopropyl, and R 2 and R 6 are methyl, and R 5 is -H, R 7 is sec-butyl, R 8 Each occurrence of -OCH 3 and R 9 is -H.

[0317] In one embodiment, Z is -O- or -NH-.

[0318] In one embodiment, R 10 is aryl.

[0319] In an exemplary embodiment, R 10 is -phenyl.

[0320] In an exemplary embodiment, when Z is -0-, R 11 is -H, methyl or t-butyl.

[0321] In one embodiment, when Z is -NH, R 11 -CH(R 15 ) 2 where R 15 Ha-(CH 2 ) n -N(R 16 ) 2 and R 16 -C1 ~C 8 Alkyl or -(CH 2 ) n -COOH.

[0322] In another embodiment, when Z is -NH, R 11 -CH(R 15 ) 2 where R 15 Ha-(CH 2 ) n -SO 3 It's H.

[0323] One exemplary auristatin embodiment of formula (a1) is MMAE:

[0324] [ka] where the wavy line indicates a covalent bond to the linker.

[0325] Certain exemplary auristatin embodiments of formula (a2) are MMAF:

[0326] [ka] where the wavy line indicates the covalent attachment of the antibody-drug conjugate to the linker (L) (see U.S. Patent Application Publication No. 2005 / 0238649 and Doronina et al. (2006) Bioconjugate Cfiem. 17: 1 14-124).

[0327] Other exemplary Z embodiments include monomethylvaline compounds having a phenylalanine carboxy modification at the C-terminus of the pentapeptide auristatin drug moiety (WO 2007 / 008848), and monomethylvaline compounds having a phenylalanine side chain modification at the C-terminus of the pentapeptide auristatin drug moiety (WO 2007 / 008603).

[0328] Other drug moieties include the following MMAF derivatives:

[0329] [ka] [ka] [wherein the wavy line indicates a covalent bond to the linker].

[0330] An example of a linker containing a primary amine-containing spacer (Y), valine-citrulline as the (Pep) moiety, and PAB as the (Y') moiety, together with MMAF as the (Z) moiety, is shown below.

[0331] [ka]

[0332] In one embodiment, the Z moiety is a DNA minor groove binder, and Z may comprise a pyrrolobenzodiazepine (PBD). In one embodiment, Z is a pyrrolobenzodiazepine monomer. In one embodiment, Z is a pyrrolobenzodiazepine dimer comprising two pyrrolobenzodiazepine units. In one embodiment, Z is a pyrrolobenzodiazepine trimer comprising three pyrrolobenzodiazepine units. In one embodiment, Z is a pyrrolobenzodiazepine multimer comprising four or more pyrrolobenzodiazepine units. The structure of PBDs, as well as formulas and methods for producing them, are described, for example, in PCT Application Nos. WO2013 / 177481, WO2011 / 130616, WO2004 / 043880, WO2005 / 085251, WO2012 / 112687, and WO2011 / 023883, the disclosures of each of which are incorporated herein by reference.

[0333] Pyrrolo[2,1-c][1,4]benzodiazepines are a family of sequence-selective minor groove binding DNA interactors that covalently bind to guanine residues. It has been reported that (S)-chirality at the C11a position of PBDs gives them the proper three-dimensional shape that fits perfectly into the DNA minor groove. PBDs can have different effects and mechanisms of action. PBDs can be DNA binders or DNA alkylators that do not cause DNA cross-linking, or PBDs can be DNA cross-linking agents.

[0334] A pyrrolobenzodiazepine unit or monomer has the following general structure:

[0335] [ka] [wherein PBD may vary in the number, type and position of substituents in both the aromatic A ring and the pyrrolo C ring, and the degree of saturation of the C ring may vary. In the B ring, N, the electrophilic center responsible for DNA alkylation, 10 ~C 11 At the N=C position, there is either an imine (N=C), a carbinolamine (NH-CH(OH)), or a carbinolamine methyl ether (NH-CH(OMe)). may have:

[0336] The biological activity of a PBD can be increased by linking two PBD monomers or units together via a flexible alkylene linker, typically via the C8 / C8'-hydroxyl functionality.

[0337] In one aspect of any embodiment herein, the pyrrolobenzodiazepine monomer or unit is a pyrrolo[2,1-c][1,4]benzodiazepine. In one aspect of any embodiment herein, the pyrrolobenzodiazepine dimer is a C8 / C8′ linked pyrrolo[2,1-c][1,4]benzodiazepine dimer.

[0338] The PBD can be attached to the linker through any suitable position, for example, the PBD can be connected to the linker through any position in the PBD unit shown below.

[0339] [ka]

[0340] In one embodiment, a PBD dimer has the following general formula, where exemplary points of attachment to other substituents or functional groups in the compound are indicated by arrows:

[0341] [ka] [In the formula, R 12 and R 12’ and / or R 2 and R 2’ Each double bond =CH 2 or =CH-CH 3 or R 2’ and R 12’ does not exist, and R 2 and R 12 teeth, (iia)C 1~5 Saturated aliphatic alkyl, (iib)C 3~6 saturated cycloalkyl, (iic)R 12 When the total number of carbon atoms in the group is 5 or less,

[0342] [ka] [In the formula, R 21 , R 22 and R 23 Each of these is H, C 1~3 Saturated alkyl, C 2~3 Alkenyl, C 2~3 alkynyl and cyclopropyl; (iid)

[0343] [ka] [In the formula, R 25a and R 25b One of them is H and the other is phenyl, optionally substituted with a group selected from halo, methyl, methoxy; pyridyl; and thiophenyl; and (No)

[0344] [ka] [In the formula, R 24 is H;C 1~3 Saturated alkyl;C 2~3 Alkenyl; C 2~3 alkynyl; cyclopropyl; phenyl optionally substituted with a group selected from halo, methyl, methoxy; pyridyl; and thiophenyl. are independently selected from R 6 and R 9 are H, R, OH, OR, SH, SR, NH 2 , NHR, NRR', Nitro, Me 3 Sn and halo, where R and R' are optionally substituted C 1~12 Alkyl, C 3~20 Heterocyclyl and C 5~20 aryl groups, R 7 are H, R, OH, OR, SH, SR, NH 2 , NHR, NHRR', Nitro, Me 3 Sn and halo; (a)R 10 is H and R 11 OH, OR A where R A is alkyl or (b)R 10 and R 11form a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are attached, or (c)R 10 is H and R 11 SO z M, where z is 2 or 3, and M is a pharma- ceutically acceptable monovalent cation. Either R” is C 3~12 It is an alkylene group, the chain of which may contain one or more heteroatoms, e.g., O, S, NR N2 (where R N2 is H or C 1~4 alkyl), and / or may be interrupted by aromatic rings, e.g., benzene or pyridine, Y and Y' are selected from O, S, or NH; R 6’ , R 7’ , R 9’ are R 6 , R 7 and R 9 is selected from the same group as R 10’ and R 11’ is R 10 and R 11 where R 11 and R 11 SO z When M, M may represent a pharma- ceutically acceptable divalent cation. Includes the structure of.

[0345] In another example, the PBD dimer has the general formula:

[0346] [ka] [In the formula, R 6 , R 7 , R 9 , R 6’ , R 7’ , R 9’ , R 10 , R 11 , R 10’ and R 11’is as defined above, and the "K" ring is a substituted or unsubstituted aromatic or non-aromatic ring, optionally a 6-membered ring, optionally phenyl. Includes the structure of.

[0347] In one embodiment, the cytotoxic agent (Z) is a camptothecin, e.g., the cytotoxic agent (Z) has or includes the structure of camptothecin or a camptothecin analog. Camptothecin is well known and there are a variety of camptothecin analogs sharing a core ring system with various substitutions, but preferably have modifications or substitutions in rings A and / or B of the basic camptothecin structure below.

[0348] [ka]

[0349] Many camptothecin analogs have been reported, including topotecan, irinotecan, exatecan, DXd, 9-aminocamptothecin, 9-nitrocamptothecin, 10-hydroxycamptothecin, lurtotecan, camptothecin, gimatecan, belotecan, and rubitecan. Additional camptothecin analogs are disclosed in Li et al., ACS Med. Chem. Lett. 2019, 10, 10, 1386-1392, Jpn. J. Cancer Res. 86: 776-782, and Takiguchi et al. 1997 Jpn. J. Cancer Res. 88: 760-769, the disclosures of which are incorporated herein by reference. Four analogs, topotecan, irinotecan, belotecan, and DXd (as part of trastuzumab deruxtecan), have been approved by the FDA. In one embodiment, the camptothecin analog is a pentacyclic compound (eg, camptothecin lacks an F ring). In one embodiment, the camptothecin analog is a hexacyclic compound, eg, including an F ring.

[0350] Some examples, such as the basic camptothecin structure, the SN-38 molecule (7-ethyl-10-hydroxycamptothecin; the active metabolite of irinotecan), and camptothecin analogs disclosed in Li et al., ACS Med. Chem. Lett. 2019, 10, 10, 1386-139, have five rings (A, B, C, D and E rings) and can be attached to a linker (e.g., spacer Y or Y', or linker X) via, for example, a substituent on the B ring. SN-38:

[0351] [ka] Compounds from Li et al., ACS Med. Chem. Lett. 2019, 10, 10, 1386-139:

[0352] [ka]

[0353] Camptothecin analogs may be hexacyclic compounds (with an additional F ring), where the compound is attached to the linker via a substituent on the F ring. Examples of such hexacyclic compounds include, but are not limited to, DXd (CAS number: 1599440-33-1) and exatecan.

[0354] Thus, camptothecin analogs include exatecan, SN-38, and any of a variety of molecules containing such moieties, e.g., exatecan can be unsubstituted or substituted at the amine at position 1, e.g., the substituents are -C(=O)-, -OC(=O)-, -O-CH 2 -C(=O)-, HO-O-CH 2 -C(=O)-, -CH 2 CH 2 -C(=O)-, -CH 2 CH 2 CH 2 -C(=O)-, -CH 2 -O-CH2 -C(=O)-, -CH 2 CH 2 -O-CH 2 It may be or contain a -C(=O)- group or other groups set forth in US Pat. No. 6,835,807, the disclosure of which is incorporated herein by reference.

[0355] In one embodiment, the antibody of the present disclosure releases an exatecan molecule having the structure of Compound 1 (e.g., by enzymatic cleavage of the cleavable moiety followed by self-elimination of spacer Y') in vivo in the presence of Nectin-4-expressing tumor cells or in vitro.

[0356] The camptothecin derivative or analog exatecan is described in Mitsui et al. 1995 Jpn. J. Cancer Res. 86: 776-782 and Takiguchi et al. 1997 Jpn. J. Cancer Res. 88: 760-769, the disclosures of which are incorporated herein by reference. The structure of exatecan is shown below as compound 1a.

[0357] [ka]

[0358] Exatecan can be coupled to the linker via the nitrogen atom of the amino group at position 1, and therefore, when the exatecan moiety is attached to the linker or is present in a linker-exatecan molecule ((XZ) molecule), exatecan can have the structure of compound 1b when conjugated, for example, to an antibody.

[0359] [ka]

[0360] Thus, when the exatecan of compound 1a is attached to a linker via the amine at position 1 (and, for example, the linker is attached to an antibody), the exatecan is the modified group at position 1 (i.e., the NH 2 It will be understood that the linker may be understood as a linker having a cleavable oligopeptide, in which the aryl group is replaced with NH, or alternatively with an OH or O group. For example, exatecan can be coupled to an antibody via a linker comprising a cleavable oligopeptide. Examples include di-, tri-, tetra- and pentapeptides such as glycine and phenylalanine-containing peptides as shown in U.S. Pat. No. 6,835,807, the disclosure of which is incorporated herein by reference, or the dipeptides valine-citrulline or valine-alanine, linked to a PAB molecule. A variety of suitable linker-Z structures are known that can release active exatecan or exatecan derivatives at the amino at position 1. Exatecan can be linked to a cleavable oligopeptide via a p-aminobenzyloxycarbonyl (PAB) group attached to the amine at position 1, as shown in formulas VII, VIII and IX, or the (PEG(8U)-Val-Ala-PAB-exatecan) linker in Example 7, which upon cleavage results in the release of exatecan having the structure of compound 1a. In one example, exatecan is attached to the amine at the 1 position (CH 2 The NH or NH at position 1 of exatecan in compound 1 can be linked to a cleavable oligopeptide via the -C(=O) group, which upon cleavage results in the release of exatecan-containing compound 13 (Dxd). 2 Examples of the substituents in are -C(=O)-, -OC(=O)-, or -O-CH 2 -C(=O)-, HO-O-CH 2 -C(=O)-, -CH 2 CH 2 -C(=O)-, -CH 2 CH 2 CH 2 -C(=O)-, -CH 2 -O-CH2 -C(=O)- and -CH 2 CH 2 -O-CH 2 -C(=O)- and other groups (CH 2 -C(=O)).

[0361] In one embodiment, a substituted exatecan derivative (eg, derivatized at the 1-position) has the structure of compound 13.

[0362] The structure of Dxd is shown below.

[0363] [ka]

[0364] Dxd can be coupled to the linker via an oxygen atom at the end of the carbon chain, and therefore when the Dxd moiety is attached to the linker or present in a linker-Dxd molecule ((XZ) molecule), the carbon chain terminal OH can be replaced with O when conjugated, for example, to an antibody.

[0365] In one embodiment, the linker moiety (XZ) is or comprises the structure shown in Formula VII below, where (Y) is a spacer comprising (e.g., at its terminus) a residue of reaction between a reactive group (R) and an amino acid residue, such as a free amino, hydroxyl, sulfhydryl or carboxyl group on an antibody (e.g., the epsilon amino group of one or more lysine residues, the free carboxylic acid group of one or more glutamic or aspartic acid residues, or the S atom of one or more cysteinyl residues).Anti-Nectin-4 binding proteins functionalized with a linker comprising the structure of Formula VII or Compound 3 or 4 can release or provide a compound having the structure of Compound 1a (e.g., intracellularly in the presence of Nectin-4-expressing tumor cells).

[0366] [ka]

[0367] An exemplary linker having a maleimide as the R group may have the structure of Compound 3 below. Such a linker may be conjugated to an antibody via a cysteine ​​residue in the antibody after the interchain disulfide bond has been reduced with a reducing agent, such as tris(2-carboxyethyl)phosphine hydrochloride.

[0368] [ka]

[0369] The resulting antibody-drug conjugate may comprise an antibody containing one or more cysteine ​​residues functionalized with a compound having the structure of Compound 3 (wherein Compound 3 is attached via the S atom of the cysteine ​​residue).

[0370] In another embodiment, the linker can have a primary amine as an R group, which when reacted with an antibody in the presence of a transglutaminase enzyme can result in an antibody containing one or more acceptor glutamine residues functionalized with the linker. For example, the linker (XZ) or an antibody functionalized therewith has or includes the structure shown below as compound 4.

[0371] [ka]

[0372] In one embodiment, the linker moiety (XZ) is or comprises the structure shown in formula VIII below, where (Y) is a spacer comprising (e.g., at its terminus) a reactive group (R) and a residue of reaction with an amino acid residue, such as a free amino, hydroxyl, sulfhydryl or carboxyl group on an antibody (e.g., the epsilon amino group of one or more lysine residues, the free carboxylic acid group of one or more glutamic or aspartic acid residues, or the S atom of one or more cysteinyl residues), or a glycan structure, such as a glycosylated amino acid residue (e.g., a native, cleaved or otherwise modified N-glycan attached to Kabat residue N297 of an antibody).Anti-nectin-4 binding proteins functionalized with a linker comprising the structure of formula VIII or compound 5, 6 or 7 can release or provide a compound having the structure of compound Ia (e.g., intracellularly in the presence of nectin-4-expressing tumor cells).

[0373] [ka]

[0374] Exemplary linkers having a maleimide as the R group may have the structure of compounds 5 or 6 below. Such linkers may be conjugated to antibodies via cysteine ​​residues in the antibody after the interchain disulfide bonds are reduced with a reducing agent.

[0375] [ka] [ka]

[0376] In another embodiment, the linker can have a primary amine as an R group, which when reacted with an antibody in the presence of a transglutaminase enzyme can result in an antibody containing one or more acceptor glutamine residues functionalized with the linker. For example, the linker (XZ) or an antibody functionalized therewith has or includes the structure shown below as compound 7.

[0377] [ka]

[0378] In one embodiment, the linker moiety (XZ) is or comprises the structure shown in formula IX below, where (Y) is a spacer comprising (e.g., at its terminus) a reactive group (R) and a residue of reaction with an amino acid residue, such as a free amino, hydroxyl, sulfhydryl or carboxyl group on an antibody (e.g., the epsilon amino group of one or more lysine residues, the free carboxylic acid group of one or more glutamic or aspartic acid residues, or the S atom of one or more cysteinyl residues), or a glycan structure, such as a glycosylated amino acid residue (e.g., a native, cleaved or otherwise modified N-glycan attached to Kabat residue N297 of an antibody). An anti-nectin-4 binding protein functionalized with a linker comprising the structure of formula IX can release a compound having the structure of compound Ia (e.g., intracellularly in the presence of nectin-4-expressing tumor cells).

[0379] [ka]

[0380] An exemplary linker having a maleimide as the R group may have the structure of compound 8 below. Such a linker may be conjugated to an antibody via a cysteine ​​residue in the antibody after the interchain disulfide bond is reduced with a reducing agent.

[0381] [ka]

[0382] In another embodiment, the linker can have a primary amine as an R group, which when reacted with an antibody in the presence of a transglutaminase enzyme can result in an antibody containing one or more acceptor glutamine residues functionalized with the linker. For example, the linker (XZ) or an antibody functionalized therewith has or includes the structure shown below as compound 9.

[0383] [ka]

[0384] In one embodiment, the linker moiety (XZ) is or comprises the structure shown in formula X below, where (Y) is a spacer that comprises (e.g., at its terminus) a residue of reaction between a reactive group (R) and an amino acid residue, e.g., a free amino, hydroxyl, sulfhydryl or carboxyl group on an antibody (e.g., the epsilon amino group of one or more lysine residues, the free carboxylic acid group of one or more glutamic or aspartic acid residues, or the S atom of one or more cysteinyl residues), or a glycan structure, e.g., of a glycosylated amino acid residue (e.g., a native, cleaved or otherwise modified N-glycan attached to Kabat residue N297 of an antibody).

[0385] [ka]

[0386] An exemplary linker having a maleimide as the R group may have the structure of compound 10 below. Such a linker may be conjugated to an antibody via a cysteine ​​residue in the antibody after the interchain disulfide bond has been reduced with a reducing agent, such as tris(2-carboxyethyl)phosphine hydrochloride.

[0387] [ka]

[0388] In one embodiment, the linker moiety (XZ) is or comprises the structure shown in formula XI below, where (Y) is a spacer that comprises (e.g., at its terminus) a residue of reaction between a reactive group (R) and an amino acid residue, e.g., a free amino, hydroxyl, sulfhydryl or carboxyl group on an antibody (e.g., the epsilon amino group of one or more lysine residues, the free carboxylic acid group of one or more glutamic or aspartic acid residues, or the S atom of one or more cysteinyl residues), or a glycan structure, e.g., of a glycosylated amino acid residue (e.g., a native, cleaved or otherwise modified N-glycan attached to Kabat residue N297 of an antibody).

[0389] [ka]

[0390] An exemplary linker having a maleimide as the R group may have the structure of compound 11 below. Such a linker may be conjugated to an antibody via a cysteine ​​residue in the antibody after the interchain disulfide bond is reduced with a reducing agent.

[0391] [ka]

[0392] In another embodiment, the linker can have a primary amine as an R group, which when reacted with an antibody in the presence of a transglutaminase enzyme can result in an antibody containing one or more acceptor glutamine residues functionalized with the linker. For example, the linker (XZ) or an antibody functionalized therewith has or includes the structure shown below as compound 12.

[0393] [ka]

[0394] Anti-Nectin-4 binding proteins functionalized with an oligopeptide-containing linker of formula XI or compounds 11 and 12 result in the release (e.g., intracellularly in the presence of Nectin-4-expressing tumor cells) of substituted exatecans in which an OH-CH2-C(=O) substituent is present at the amine position 1, as shown in the structure below.

[0395] [ka]

[0396] When the exemplary linker of formula III, IV, V, VI, VII, VIII, IX, X or XI is prepared as a structure having a primary amine, it can react with an antibody in the presence of a transglutaminase enzyme (e.g., bacterial transglutaminase, BTG), such that the transglutaminase enzyme catalyzes the conjugation of the linker to the acceptor glutamine residue within the primary structure of the antibody, for example, within the immunoglobulin constant domain or within the TGase recognition tag inserted or added (e.g., fused) to the constant region. Methods for BTG-mediated conjugation to antibodies and linkers for use in the conjugation are described in PCT Publication No. WO2014 / 202773, the disclosure of which is incorporated by reference. BTG-catalyzed conjugation allows precise control of the average drug:antibody ratio in the composition. The term "transglutaminase" is used interchangeably with "TGase" or "TG" and refers to an enzyme that can crosslink proteins by an acyl transfer reaction between the γ-carboxamide group of peptide-bound glutamine and a structurally related primary amine, such as the ε-amino group or aminopentyl group of lysine, resulting in an ε-(γ-glutamyl)lysine isopeptide bond. TGases include, among others, bacterial transglutaminases (BTG), such as the enzyme with EC reference number EC2.3.2.13 (protein-glutamine-γ-glutamyltransferase). The term "acceptor glutamine" residue, when referring to a glutamine residue of an antibody, refers to a glutamine residue that is recognized by TGase and can be crosslinked by TGase via a reaction between glutamine and a structurally related primary amine, such as a lysine or aminopentyl group. Preferably, the acceptor glutamine residue is a surface-exposed glutamine residue. The term "TGase recognition tag" refers to a sequence of amino acids that includes an acceptor glutamine residue and that, when incorporated (e.g., added) to a polypeptide sequence under suitable conditions, is recognized by a TGase and results in cross-linking by the TGase via a reaction between an amino acid side chain in the sequence of amino acids and a reactive partner.The recognition tag may be a peptide sequence that does not naturally occur in a polypeptide that includes the enzyme recognition tag. Examples of TGase recognition tags include the amino acid sequences: LLQ, LLQG, LSQG, GLLQ, SLLQG, GGGQGGL, LLQGG, LLQGA, LLQGG and LLQGA, or EQKLISEEDL, or variants having one or more (e.g., 2, 3, 4, 5, 6, 7, 8 or 9) sequence modifications.

[0397] As exemplified in WO 2013 / 092983 and WO 2020 / 188061, the disclosures of which are incorporated herein by reference, the linker-drug moiety (XZ) can be conjugated to a glutamine residue (acceptor glutamine) in an antibody in a two-step process comprising a first step of conjugating a moiety comprising a primary amine and a first reactive group (R) to the antibody in the presence of BTG, followed by reacting the antibody-linker conjugate with a molecule comprising (i) a second reactive group (R') that is reactive with the first reactive group, and (ii) a cytotoxic agent (Z). Examples of reactive group pairs of R and R' include a variety of groups capable of biorthogonal reactions, such as between azides and cyclooctynes ​​(copper-free click chemistry), 1,3-dipolar cycloaddition between nitrones and cyclooctynes, oxime / hydrazone formation from aldehydes and ketones, and tetrazine ligation (see also WO 2013 / 092983). Thus, the resulting linker and functionalized antibody, or Y element thereof, may contain an RR' group, such as a triazole, resulting from the reaction of R with R'.

[0398] The anti-nectin-4 immunoconjugate can be incorporated into the pharmaceutical formulation at a concentration of 1 mg / ml to 500 mg / ml, wherein the formulation has a pH of 2.0 to 10.0. The formulation may further comprise a buffer system, a preservative, an isotonicity agent, a chelating agent, a stabilizer and a surfactant. In one embodiment, the pharmaceutical formulation is an aqueous formulation, i.e. a formulation comprising water. Such formulations are typically solutions or suspensions. In a further embodiment, the pharmaceutical formulation is an aqueous solution. The term "aqueous formulation" is defined as a formulation comprising at least 50% w / w water. Similarly, the term "aqueous solution" is defined as a solution comprising at least 50% w / w water, and the term "aqueous suspension" is defined as a suspension comprising at least 50% w / w water.

[0399] In another embodiment, the pharmaceutical formulation is a lyophilized formulation, whereto the physician or the patient adds solvents and / or diluents prior to use.

[0400] In another embodiment, the pharmaceutical formulation is a dried formulation (eg a freeze-dried or spray-dried formulation) ready for use without prior dissolution.

[0401] In a further embodiment, a pharmaceutical formulation comprises an aqueous solution of such an antibody and a buffer, wherein the antibody is present in a concentration of 1 mg / ml or greater, and wherein the formulation has a pH of about 2.0 to about 10.0.

[0402] In another embodiment, the pH of the formulation is in the range selected from the list consisting of about 2.0 to about 10.0, about 3.0 to about 9.0, about 4.0 to about 8.5, about 5.0 to about 8.0, and about 5.5 to about 7.5.

[0403] In further embodiments, the buffering agent is selected from the group consisting of sodium acetate, sodium carbonate, citrate, glycylglycine, histidine, glycine, lysine, arginine, sodium dihydrogen phosphate, disodium hydrogen phosphate, sodium phosphate, and tris(hydroxymethyl)-aminomethane, bicine, tricine, malic acid, succinate, maleic acid, fumaric acid, tartaric acid, aspartic acid, or mixtures thereof, each of which constitutes an alternative embodiment of the invention.

[0404] In a further embodiment, the formulation further comprises a pharma- ceutically acceptable preservative. In a further embodiment, the formulation further comprises an isotonicity agent. In a further embodiment, the formulation also comprises a chelating agent. In a further embodiment of the invention, the formulation further comprises a stabilizer. In a further embodiment, the formulation further comprises a surfactant. For ease of explanation, see Remington: The Science and Practice of Pharmacy, 1999. th edition, 1995 is referred to.

[0405] Other components may be present in the pharmaceutical formulation of the present invention.Such additional components can include wetting agents, emulsifiers, antioxidants, bulking agents, osmotic pressure regulators, chelating agents, metal ions, oil media, proteins (e.g., human serum albumin, gelatin or protein) and zwitterions (e.g., amino acids such as betaine, taurine, arginine, glycine, lysine and histidine).Such additional components should of course not adversely affect the overall stability of the pharmaceutical formulation of the present invention.

[0406] Administration of the pharmaceutical compositions of the invention can be by several routes of administration, for example, intravenously. Suitable antibody formulations can also be determined by examining the experience with other already developed therapeutic ADCs.

[0407] In any embodiment, a composition can be characterized as comprising a plurality of Nectin-4-binding immunoconjugates of the present disclosure, where at least 70%, 80%, 90%, 95%, 98% or 99% of the immunoconjugates in a sample have at least 4, 6 or 8 amino acid residues per antibody functionalized with a linker disclosed herein. In any embodiment, a composition can be characterized as comprising a plurality of Nectin-4-binding immunoconjugates of the present disclosure, where at least 70%, 80%, 90%, 95%, 98% or 99% of the immunoconjugates in a sample have at least 2, 4, 6 or 8 amino acid residues per antibody functionalized with a linker-camptothecin moiety, e.g., an (XZ) unit or a (-(Y)-(Pep)-(Y')-(Z)) unit of the formulas herein. In any embodiment, a composition can be characterized as comprising a plurality of Nectin-4-binding immunoconjugates of the present disclosure, where at least 70%, 80%, 90%, 95%, 98% or 99% of the immunoconjugates in a sample have the same number of functionalized amino acids per antibody, which may be 4, 6, or 8.

[0408] Diagnostic methods, prognostic symptoms, and treatment of malignant tumors In some aspects, methods and antibodies, antibody fragments and immunoconjugates useful for the diagnosis, prognosis, monitoring and treatment of cancers characterized by tumor cells expressing Nectin-4 on their surface are described. In therapeutic methods, the treatment comprises administering an antibody of the present disclosure to a human subject or individual. In some embodiments, improved methods are provided for improving the delivery of cytotoxic agents, particular camptothecin analogs, to Nectin-4 positive tumors. The improved delivery of cytotoxic agents may be the result of antibody-mediated inhibition of clustering and / or anchorage-independent growth of Nectin-4 expressing tumor cells, resulting in improved tumor infiltration of the cytotoxic agent and / or ADCs containing such agents. Treatment with the ADCs of the present disclosure is particularly advantageous for treating diseases with lower or heterogeneous Nectin-4 expression, particularly for patients with resistant disease or for whom other ADCs are not suitable, and / or for use in combination with additional therapeutic agents (e.g., chemotherapeutic agents) that mediate toxicity as single agents.

[0409] In one embodiment, anti-Nectin-4 antibody or antibody fragment may be useful for sensitizing tumors to cytotoxic or chemotherapeutic agents. Anti-Nectin-4 antibody may be useful in enhancing or enhancing the toxicity of anti-cancer agents to cancers compared to the anti-cancer agents themselves by reducing the chemoresistance of cancerous cells. Cancer-sensitizing compositions comprising anti-Nectin-4 antibody or antibody fragment may be useful for sensitizing tumors (e.g., Pgp-expressing tumors) to anti-cancer agents, reducing chemoresistance, and improving the therapeutic effect of anti-cancer agents.

[0410] In one embodiment, the anti-Nectin-4 antibody or antibody fragment of the present disclosure can be specified for use in treating tumors in human individuals in combination with a chemotherapeutic agent, where the anti-Nectin-4 antibody, antibody fragment and chemotherapeutic agent are formulated for separate administration and administered simultaneously or sequentially. For example, the treatment can include administering to an individual an effective amount of each of (a) the anti-Nectin-4 antibody or antibody fragment of the present disclosure and (b) an anti-cancer agent, optionally a chemotherapeutic agent, optionally a chemotherapeutic agent known to be capable of being transported by P-glycoprotein (Pgp), optionally an anthracycline, a vinca alkaloid, an etoposide, a taxane, a platinum compound or optionally a camptothecin.

[0411] In one embodiment, the antibody or antibody fragment is conjugated to a cytotoxic agent, such as a camptothecin, exatecan or SN-38 molecule. The antibody or antibody fragment can typically be conjugated to multiple molecules of a cytotoxic agent, such as a camptothecin analog, exatecan. The cytotoxic agent, such as camptothecin or exatecan, can be conjugated to the antibody via a linker, including a protease-cleavable oligopeptide linker. An exemplary pharmaceutical composition can include, on average, 1-8 cytotoxic agent (e.g., camptothecin derivative, exatecan) molecules per antibody molecule, optionally 2-8, 4-8, 6-8 cytotoxic agent molecules per antibody molecule, or, for example, about 2, 4, 5, 6, 7 or 8 cytotoxic agent molecules per antibody molecule. When an antibody or antibody fragment is conjugated to exatecan (i.e., via a linker), such an immunoconjugate is particularly advantageous for treating Pgp-expressing tumors, such as tumors characterized by expression of Pgp (MDR1). Tumors characterized by expression of Pgp include tumors following treatment with chemotherapeutic agents and ADCs, for example, treatment with ADCs containing an auristatin (MMAE) payload has been shown to induce Pgp expression in tumors. In addition, a variety of tumors are known that are characterized by native Pgp / MDR1 expression; for example, significant levels of MDR1 are expressed by renal cancer, adrenocortical carcinoma, bile duct carcinoma, liver cancer, rectal cancer, colon cancer, brain cancer, pancreatic cancer, prostate cancer, mesothelioma, stomach cancer, AML, thyroid cancer, DLBC, esophageal cancer, breast cancer, sarcoma, testical cancer, uterine cancer, thymoma, cervical cancer, lung cancer, bladder cancer (e.g., urothelial carcinoma), and head and neck squamous cell carcinoma.

[0412] A Nectin-4 binding agent (e.g., an anti-Nectin-4 antibody or antibody fragment) conjugated to a cytotoxic agent can be advantageously used to treat individuals with Nectin-4-expressing cancers characterized by tumor cells expressing Nectin-4 (e.g., on the tumor cell membrane or cell surface). Examples of such cancers are urothelial cancer, breast cancer (e.g., triple-negative breast cancer, HER2-positive breast cancer), non-small cell lung cancer, pancreatic cancer, ovarian cancer, gastric cancer, colorectal cancer (e.g., colon cancer), head and neck squamous cell carcinoma, and esophageal cancer.

[0413] Nectin-4 binding agents conjugated to cytotoxic agents can be used in Nectin-4 high expressing tumors.

[0414] Nectin-4 binding agents conjugated to cytotoxic agents can also be used in xenogeneic and / or low Nectin-4 expressing tumors, in which the immunoconjugates of the present disclosure can provide beneficial efficacy, optionally through circumvention of MDR1-mediated resistance and / or bystander antitumor effects.

[0415] A nectin-4 binding agent conjugated to a cytotoxic agent can be advantageously used to treat an individual regardless of the nectin-4 expression level, regardless of the heterogeneity of the nectin-4 expression level in the individual's tumor cells, and / or regardless of whether the individual has been previously treated with enfortumab vedotin. When the cytotoxic agent is exatecan, a nectin-4 binding agent conjugated to a cytotoxic agent can also be advantageously used to treat an individual regardless of the tumor Pgp expression and / or regardless of whether the individual has been previously treated with an ADC comprising a cytotoxic agent capable of being transported by Pgp (e.g., an ADC comprising an anti-nectin-4 antibody conjugated to a camptothecin analog other than exatecan, an ADC comprising an anti-nectin-4 antibody conjugated to Dxd (e.g., via a GGFG-containing linker), or an anti-nectin-4 antibody conjugated to an auristatin, an anthracycline, a vinca alkaloid, an etoposide, a taxane, or a platinum compound).

[0416] In one embodiment, the nectin-4 binding agent conjugated to a camptothecin derivative molecule can be advantageously used to treat an individual who has previously been treated with enfortumab vedotin. Such an individual may optionally have a cancer characterized by heterogeneous and / or low nectin-4 expressing tumors after enfortumab vedotin treatment. Such an individual may optionally have a cancer characterized by Pgp expressing tumors after enfortumab vedotin treatment. The individual may have a cancer that is resistant, unresponsive, relapsed and / or progressed despite (e.g., during or after) treatment with an antibody conjugated to an auristatin or MMAE molecule (e.g., enfortumab vedotin). For example, the individual may have locally advanced or metastatic urothelial carcinoma and have previously been treated with an antibody conjugated to an auristatin or MMAE molecule (e.g., enfortumab vedotin).

[0417] In one embodiment, an immunoconjugate comprising a nectin-4 binding agent conjugated to exatecan via a linker is advantageously used to treat an individual who has previously been treated with an immunoconjugate comprising a nectin-4 binding agent conjugated to a cytotoxic agent capable of transport by Pgp via a linker. In one embodiment, an immunoconjugate comprising a nectin-4 binding agent conjugated to exatecan via a linker is advantageously used to treat an individual with a cancer characterized by xenogeneic and / or low nectin-4 expressing tumors after treatment with an immunoconjugate comprising a nectin-4 binding agent conjugated to a cytotoxic agent capable of transport by Pgp via a linker. In one embodiment, an immunoconjugate comprising a nectin-4 binding agent conjugated to exatecan via a linker is advantageously used to treat individuals with cancer that is resistant, unresponsive, relapsed and / or progressed despite (e.g., during or after) treatment with a nectin-4 binding agent conjugated to a cytotoxic agent capable of being transported by Pgp via a linker. A nectin-4 binding agent conjugated to a cytotoxic agent capable of being transported by Pgp via a linker may comprise an anti-nectin-4 antibody conjugated to a camptothecin analogue via a linker to release a camptothecin analogue other than exatecan (e.g., Dxd or deruxtecan) upon cleavage of the linker. A nectin-4 binding agent conjugated to a cytotoxic agent capable of being transported by Pgp via a linker may comprise an anti-nectin-4 antibody conjugated to Dxd (e.g., via a GGFG-containing linker). The nectin-4 binding agent conjugated via a linker to a cytotoxic agent capable of transport by Pgp may comprise an anti-nectin-4 antibody conjugated to an auristatin, an anthracycline, a vinca alkaloid, an etoposide, a taxane, or a platinum compound. The nectin-4 binding agent conjugated via a linker to a cytotoxic agent capable of transport by Pgp may comprise an anti-nectin-4 antibody that binds to the IgV domain of nectin-4.A nectin-4 binding agent conjugated via a linker to a cytotoxic agent capable of transport by Pgp may comprise an anti-nectin-4 antibody that binds to the VC1 cross-linking domain of nectin-4. In one embodiment, an immunoconjugate comprising a nectin-4 binding agent conjugated via a linker to exatecan comprises a linker having an enzymatically cleavable moiety (and optionally a self-immolative spacer) that upon cleavage results in release of exatecan.

[0418] In advanced recurrent or metastatic urothelial carcinoma, a significant proportion of individuals express high levels of nectin-4 in tumor cells, e.g., H-scores of at least 290 (see EV-201 Clinical Trial Cohort 1 Nectin-4 Expression). However, a subset of patients has an H-score below 250, and some have an H-score below 200. A small number of patients have an H-score below 150, and some have an H-score below 100. In triple-negative breast cancer (TNBC), it has been reported that 62% of patients have high nectin-4 expression in tumor cells, and 38% have low nectin-4 expression in tumor cells (Rabat et al., 2017 Annals Onc. 28: 769-776). In other cancer types, the median H-scores of nectin-4 expression were typically lower than those observed in UC, particularly in non-small cell lung cancer, pancreatic cancer, ovarian cancer, head and neck squamous cell carcinoma, and esophageal cancer.

[0419] In one embodiment, the individual treated in accordance with the present disclosure has progressive, recurrent or metastatic cancer, optionally progressive, recurrent or metastatic urothelial carcinoma.

[0420] In one embodiment, an individual treated according to the present disclosure has a cancer (e.g., breast cancer) that tests positive for estrogen receptors and / or progesterone receptors and tests negative for epidermal growth factor receptor 2 (HER2) or excess HER2 protein, or the cancer may test positive for HER2 but express HER2 at low levels.

[0421] In one embodiment, the individual treated according to the present disclosure has triple negative breast cancer (TNBC), eg, breast cancer that tests negative for estrogen receptors, progesterone receptors, and excess HER2 protein.

[0422] In one embodiment, the individual treated according to the present disclosure has a cancer (e.g., breast cancer) that tests positive for HER2 protein, where the cancer may express excess HER2 protein (HER2 overexpression) or the cancer may express low levels of HER2 protein (less than excess HER2 expression). In one embodiment, the individual is treated with an anti-Nectin-4 ADC in combination with an agent (e.g., an antibody) that binds to a HER2 polypeptide (e.g., trastuzumab, pertuzumab), where the agent that binds to HER2 may be an ADC, where the antibody that binds to HER2 may be conjugated to a cytotoxic agent, optionally an auristatin, a maytansinoid (e.g., DM1), or a camptothecin analog (e.g., compounds 1, 2, or 13), and where the antibody that binds to HER2 may be trastuzumab emtansine or trastuzumab deruxtecan (DS-8201a, Enhertu™).

[0423] In one embodiment, the individual treated in accordance with the present disclosure has non-small cell lung cancer, optionally lung adenocarcinoma.

[0424] In one embodiment, the individual treated in accordance with the present disclosure has pancreatic cancer.

[0425] In one embodiment, the individual treated in accordance with the present disclosure has ovarian cancer.

[0426] In one embodiment, the individual treated according to the present disclosure has head and neck squamous cell carcinoma.

[0427] In one embodiment, the individual treated according to the present disclosure has esophageal cancer.

[0428] In one embodiment, the individual treated according to the present disclosure has colorectal cancer. Colorectal cancer (CRC), as used herein, refers to colon cancer, rectal cancer, and colorectal cancer (cancer of both the colon and rectum).

[0429] In one embodiment, the individual treated according to the present disclosure has NSCLC or lung adenocarcinoma, gastric cancer, colorectal carcinoma, pancreatic cancer, urothelial carcinoma or bladder cancer that tests positive for HER2 protein, where the cancer may express too much HER2 protein (HER2 overexpression) or the cancer may express low levels of HER2 protein (less than too much HER2 expression). In one embodiment, an individual is treated with an anti-Nectin-4 ADC of the disclosure in combination with an agent (e.g., an antibody) that binds a HER2 polypeptide (e.g., an antibody comprising the heavy and light chain CDRs or variable regions of trastuzumab or pertuzumab), where the agent that binds HER2 may be an ADC, the antibody that binds HER2 may be conjugated to a cytotoxic agent, optionally an auristatin, a maytansinoid (e.g., DM1) or a camptothecin analog (e.g., compounds 1, 2 or 13), and the antibody that binds Her2 may be trastuzumab emtansine or trastuzumab deruxtecan (DS-8201a).

[0430] As shown herein, ADCs that release exatecan upon cleavage (e.g., upon cleavage of an intracellularly cleavable linker that contains a cytotoxic agent Z) are particularly advantageous for treating tumors that are resistant to ADCs having linkers that release cytotoxic agents (other than exatecan) transported by Pgp, such as auristatins or Dxd, upon cleavage. Thus, in one embodiment, when a HER2-positive cancer is treated with a combination of an anti-Nectin-4 binding agent (e.g., an anti-Nectin-4 ADC) and an anti-HER2 ADC, the anti-HER2 ADC can be designed to release exatecan upon cleavage (e.g., upon cleavage of an intracellularly cleavable linker that contains a cytotoxic agent Z). Anti-Nectin-4 binding agents (e.g., anti-Nectin-4 ADCs) can be designed to release exatecan upon cleavage (e.g., upon cleavage of an intracellularly cleavable linker that contains a cytotoxic agent Z), or can release any other cytotoxic agent (Z), where, for example, Z is a taxane, anthracycline, camptothecin, epothilone, mitomycin, combretastatin, vinca alkaloid, nitrogen mustard, maytansinoid, duocarmycin, tubulysin, dolastatin, auristatin, enediyne, pyrrolobenzodiazepine, amatoxine, or ethylenimine.

[0431] Thus, in one aspect, the disclosure provides an immunoconjugate that binds a human Nectin-4 polypeptide for use in treating cancer (e.g., HER2-positive Nectin-4-positive cancer), comprising the formula: Ab N4 -(X N4 -(Z N4 )) [In the formula, Ab N4 is a polypeptide, peptide or antibody that specifically binds to a human Nectin-4 polypeptide, X N4 Ab N4 and Z N4 It is a molecule that connects X N4comprises a moiety which is cleavable under physiological conditions, which may for example be intracellular conditions, suitably a protease-cleavable di-, tri-, tetra- or pentapeptide, Z N4 contains cytotoxic agents] and is represented by the formula: Ab HER2 -(X HER2 -(Z HER2 )) [In the formula, Ab HER2 is a polypeptide, peptide or antibody that specifically binds to a human HER2 polypeptide, HER2 may comprise the heavy and light chain CDRs or variable regions of trastuzumab or pertuzumab, X HER2 Ab HER2 and Z HER2 It is a molecule that connects X HER2 comprises a moiety which is cleavable under physiological conditions, which may for example be intracellular conditions, suitably a protease-cleavable di-, tri-, tetra- or pentapeptide, Z HER2 is exatecan. The immunoconjugate that binds to the human HER2 polypeptide releases exatecan upon cleavage of the cleavable moiety. N4 may be exatecan, and the immunoconjugate that binds to the human nectin-4 polypeptide may release exatecan upon cleavage of the cleavable moiety.

[0432] Also, in one aspect, the disclosure provides an immunoconjugate that binds a human HER2 polypeptide for use in treating cancer, e.g., a HER2-positive, Nectin-4-positive cancer, comprising the formula: Ab HER2 -(X HER2 -(Z HER2 )) [In the formula, Ab HER2is a polypeptide, peptide or antibody that specifically binds to a human HER2 polypeptide, HER2 may comprise the heavy and light chain CDRs or variable regions of trastuzumab or pertuzumab, X HER2 Ab HER2 and Z HER2 It is a molecule that connects X HER2 comprises a moiety which is cleavable under physiological conditions, which may for example be intracellular conditions, suitably a protease-cleavable di-, tri-, tetra- or pentapeptide, Z HER2 is exatecan] and is represented by the formula: Ab N4 -(X N4 -(Z N4 )) [In the formula, Ab N4 is a polypeptide, peptide or antibody that specifically binds to a human Nectin-4 polypeptide, X N4 Ab N4 and Z N4 It is a molecule that connects X N4 comprises a moiety which is cleavable under physiological conditions, which may for example be intracellular conditions, suitably a protease-cleavable di-, tri-, tetra- or pentapeptide, Z N4 The immunoconjugate that binds to the human HER2 polypeptide is for use in combination with an immunoconjugate that binds to the human Nectin-4 polypeptide, the immunoconjugate being represented by the formula: Z (wherein Z includes a cytotoxic agent). The immunoconjugate that binds to the human HER2 polypeptide releases exatecan upon cleavage of the cleavable moiety. N4 may be exatecan, and the immunoconjugate that binds to the human nectin-4 polypeptide may release exatecan upon cleavage of the cleavable moiety.

[0433] In one embodiment, the treatment method of the present disclosure does not depend on the assessment or detection of Nectin-4 expression in tumor tissue and / or does not depend on the expression level of Nectin-4 in tumor cells and / or the frequency or number of Nectin-4-expressing tumor cells in a tissue sample from said individual. In one embodiment, the treatment method of the present disclosure does not depend on the assessment or detection of Pgp(MDR1) expression in tumors.

[0434] In one aspect, the present invention provides a method of treating cancer and / or inducing an anti-tumor immune response in an individual in need thereof, wherein the individual has progressive, recurrent or metastatic urothelial carcinoma or breast cancer (e.g., TNBC), and wherein the method does not require prior determination of whether the individual has tumor tissue comprising cells (e.g., tumor cells) that express Nectin-4.

[0435] In one aspect, the present invention provides a method of treating cancer and / or killing tumor cells in an individual in need thereof, wherein the individual has progressive, recurrent or metastatic urothelial carcinoma or breast cancer (e.g., TNBC), and the method does not require prior determination of whether the individual has tumor tissue that contains cells (e.g., tumor cells) that express high levels of Nectin-4, e.g., as defined by immunohistochemical assessment (e.g., H-score or other suitable IHC scoring method).

[0436] In one embodiment, the method of treating cancer and / or killing tumor cells in an individual does not require pre-determining the level of Nectin-4 expression in the tumor cells.

[0437] In one embodiment, a method of treating cancer in an individual, optionally progressive recurrent or metastatic urothelial carcinoma or breast cancer (e.g., TNBC, HER2-positive cancer), comprises treating an individual having a cancer characterized by an H-score of less than or equal to 290, 250, 200, 150 or 100 for Nectin-4 expression.

[0438] In any embodiment relating to treating or preventing cancer in an individual, the method can be defined as comprising the steps of (i) identifying an individual whose tumor cells express Nectin-4 (e.g., as determined by immunohistochemistry), and (ii) administering to the individual an effective amount of an anti-Nectin-4 antibody drug conjugate of the present disclosure.

[0439] In any embodiment relating to treating or preventing cancer in an individual, the method includes the steps of (i) identifying an individual whose tumor cells express (a) Nectin-4 (e.g., as determined by immunohistochemistry), and (b) HER2 (wherein the tumor cells may express low levels of HER2) (e.g., as determined by immunohistochemistry; by Herceptest™), and (ii) administering an effective amount of an anti-Nectin-4 antibody drug conjugate of the present disclosure, optionally together with an agent that binds to a Her2 polypeptide (e.g., The method can be defined as comprising administering to an individual in combination with an antibody (e.g., an antibody) (e.g., trastuzumab, pertuzumab), where the antibody that binds Her2 may be an ADC, the antibody that binds Her2 may be conjugated to a cytotoxic agent, optionally an auristatin, a maytansinoid (e.g., DM1) or a camptothecin derivative (e.g., compounds 1, 2 or 13), and the antibody that binds Her2 may be trastuzumab emtansine or trastuzumab deruxtecan (DS-8201a).

[0440] In any embodiment relating to treating or preventing cancer in an individual, the method can be defined as comprising the steps of (i) identifying an individual whose tumor cells have low or moderate levels of Nectin-4 expression (e.g., as determined by immunohistochemistry), and (ii) administering an effective amount of an anti-Nectin-4 antibody drug conjugate of the present disclosure to the individual identified in step (i).

[0441] In any embodiment relating to treating or preventing cancer (e.g., Nectin-4 positive cancer) in an individual, the method can be defined as comprising (i) identifying an individual whose cancer is characterized by a low level of Nectin-4 expression (e.g., as determined by immunohistochemistry), and (ii) administering an effective amount of an anti-Nectin-4 antibody drug conjugate of the present disclosure to the individual identified in step (i). In one embodiment, the individual has a cancer characterized by an H-score of less than or equal to 150 or 100 for Nectin-4 expression.

[0442] In any embodiment relating to treating or preventing cancer (e.g., Nectin-4 positive cancer) in an individual, the method can be defined as comprising (i) identifying an individual whose cancer is characterized by a moderate level of tumor Nectin-4 expression (e.g., as determined by immunohistochemistry), and (ii) administering to the individual an effective amount of an anti-Nectin-4 antibody drug conjugate of the present disclosure. In one embodiment, the individual has a cancer characterized by an H-score for Nectin-4 expression of less than or equal to 290, 250, 200, 150, or less, and further, the cancer may be characterized by an H-score for Nectin-4 expression of at least 100.

[0443] In a further embodiment, a method for treating or preventing cancer (e.g., Nectin-4 positive cancer) in an individual is provided, comprising (i) identifying an individual whose cancer is characterized by an H-score for tumor Nectin-4 expression of less than or equal to 290, 250, 200, 150, 120 or 100, and (ii) administering to the individual an effective amount of an anti-Nectin-4 antibody drug conjugate of the present disclosure. Optionally, step (i) may be defined as comprising evaluating Nectin-4 expression in tumor cells by histochemistry (e.g., IHC).

[0444] In a further embodiment, a method for treating or preventing cancer (e.g., Nectin-4 positive cancer, breast cancer) in an individual is provided, comprising (i) identifying an individual whose cancer is characterized by a QS score of less than or equal to 200, 150, 120 or 100 for tumor Nectin-4 expression, and (ii) administering to the individual an effective amount of an anti-Nectin-4 antibody drug conjugate of the present disclosure. Optionally, step (i) may be defined as comprising evaluating Nectin-4 expression in tumor cells by histochemistry (e.g., IHC).

[0445] Biological samples from individuals, such as from biopsies, can be obtained and evaluated. Samples can be preserved as formaldehyde (e.g., formalin) fixed paraffin embedded (FFPE) samples. After deparaffinization, slides can be subjected to methods for detecting Nectin-4 (and / or HER2) expression.

[0446] The expression of Nectin-4 and / or HER2 in tumor cells can be determined by any method known in the art.In certain embodiments, assays include immunohistochemistry (IHC) assay, fluorescence-activated cell sorting (FACS) assay, such as quantitative FACS, ELISA, immunoblotting (such as Western blotting, dot blotting, or in-cell Western blotting), and other immunoassays.

[0447] IHC staining of tissue sections has been shown to be a reliable method of evaluating or detecting the presence of proteins in samples. Immunohistochemistry techniques generally utilize antibodies to probe and visualize cellular antigens in situ by chromogenic or fluorescent methods. Thus, antibodies or antisera specific to each marker are used to detect expression, in some embodiments polyclonal antisera, and in some embodiments monoclonal antibodies. Antibodies can be detected by direct labeling of the antibody itself, for example, with radioactive labels, fluorescent labels, hapten labels such as biotin, or enzymes such as horseradish peroxidase or alkaline phosphatase. Alternatively, unlabeled primary antibodies are used with labeled secondary antibodies, including antisera, polyclonal antisera, or monoclonal antibodies specific to the primary antibodies. Immunohistochemistry protocols and kits are well known in the art and are commercially available.

[0448] In some embodiments, the IHC assay is a direct assay that directly determines the binding of an antibody to a target antigen. This direct assay uses a labeling reagent that can be visualized without further antibody interaction, such as a fluorescent tag or an enzyme-labeled primary antibody. In some embodiments, the IHC assay is an indirect assay. In a typical indirect assay, an unconjugated primary antibody binds to the antigen, and then a labeled secondary antibody binds to the primary antibody. If the secondary antibody is conjugated to an enzyme label, a chromogenic or fluorogenic substrate is added to provide visualization of the antigen. Signal amplification is performed because some secondary antibodies may react with different epitopes of the primary antibody. The primary and / or secondary antibodies used for immunohistochemistry are typically labeled with a detectable molecule. Numerous labels are available, including radioisotopes, colloidal gold particles, fluorescent labels, and enzyme-substrate labels.

[0449] Strong staining, moderate staining, and weak staining are well-known descriptions to those skilled in the art. In some embodiments, strong staining, moderate staining, and weak staining are calibrated levels of staining, where a range is established and the intensity of the staining is binned within the range. In some embodiments, strong staining is staining above the 75th percentile of the intensity range, moderate staining is staining between the 25th and 75th percentiles of the intensity range, and low staining is staining below the 25th percentile of the intensity range. In some embodiments, those skilled in the art and those familiar with a particular staining technique will adjust the bin size and define the staining category.

[0450] Control cell lines (e.g., centrifuged into pellets, formalin-fixed paraffin-embedded, prepared as tissue microarrays, and stained with anti-nectin-4 antibodies) with various staining intensities (e.g., when stained with anti-nectin-4 antibodies) can be utilized as controls for IHC analysis. Those skilled in the art will appreciate that other control cell pellets with negative, weak, moderate, and high c-met staining intensities can be readily identified using the teachings of the present application and methods well known in the art and disclosed herein.

[0451] In some embodiments, a cancer or tumor is considered to be a Nectin-4-expressing cancer tumor if it is Nectin-4 positive (eg, determined to be Nectin-4 positive using an IHC assay).

[0452] In some embodiments, an individual's cancer or tumor is Nectin-4 positive when 5% or more of the tumor cells in a sample express Nectin-4 protein (e.g., express Nectin-4 protein at any intensity). In some embodiments, an individual's cancer or tumor is Nectin-4 positive when 10% or more of the tumor cells in a sample express Nectin-4 protein (e.g., express Nectin-4 protein at any intensity). In some embodiments, an individual's cancer or tumor is Nectin-4 positive when 20% or more of the tumor cells in a sample express Nectin-4 protein (e.g., express Nectin-4 protein at any intensity). In some embodiments, an individual's cancer or tumor is Nectin-4 positive when 30% or more of the tumor cells in a sample express Nectin-4 protein (e.g., express Nectin-4 protein at any intensity). In some embodiments, an individual's cancer or tumor is Nectin-4 positive when 40% or more of the tumor cells in a sample express Nectin-4 protein (e.g., express Nectin-4 protein at any intensity). In some embodiments, an individual's cancer or tumor is Nectin-4 positive when 50% or more of the tumor cells in a sample express Nectin-4 protein (e.g., express Nectin-4 protein at any intensity). In some embodiments, an individual's cancer or tumor is Nectin-4 positive when 60% or more of the tumor cells in a sample express Nectin-4 protein (e.g., express Nectin-4 protein at any intensity). In some embodiments, an individual's cancer or tumor is Nectin-4 positive when 70% or more of the tumor cells in a sample express Nectin-4 protein (e.g., express Nectin-4 protein at any intensity). In some embodiments, an individual's cancer or tumor is Nectin-4 positive if 80% or more of the tumor cells in a sample express Nectin-4 protein (e.g., express Nectin-4 protein at any intensity).In some embodiments, an individual's cancer or tumor is Nectin-4 positive if 90% or more of the tumor cells in a sample express Nectin-4 protein (e.g., express Nectin-4 protein at any intensity).

[0453] In some embodiments, an individual's cancer or tumor is Nectin-4 positive when 5% or more of the tumor cells in a sample express Nectin-4 protein at moderate and / or strong staining intensity. In some embodiments, an individual's cancer or tumor is Nectin-4 positive when 10% or more of the tumor cells in a sample express Nectin-4 protein at moderate and / or strong staining intensity. In some embodiments, an individual's cancer or tumor is Nectin-4 positive when 20% or more of the tumor cells in a sample express Nectin-4 protein at moderate and / or strong staining intensity. In some embodiments, an individual's cancer or tumor is Nectin-4 positive when 30% or more of the tumor cells in a sample express Nectin-4 protein at moderate and / or strong staining intensity. In some embodiments, an individual's cancer or tumor is Nectin-4 positive when 40% or more of the tumor cells in a sample express Nectin-4 protein at moderate and / or strong staining intensity. In some embodiments, an individual's cancer or tumor is Nectin-4 positive when 50% or more of the tumor cells in a sample express Nectin-4 protein at moderate and / or strong staining intensity. In some embodiments, an individual's cancer or tumor is Nectin-4 positive when 60% or more of the tumor cells in a sample express Nectin-4 protein at moderate and / or strong staining intensity. In some embodiments, an individual's cancer or tumor is Nectin-4 positive when 70% or more of the tumor cells in a sample express Nectin-4 protein at moderate and / or strong staining intensity. In some embodiments, an individual's cancer or tumor is Nectin-4 positive when 80% or more of the tumor cells in a sample express Nectin-4 protein at moderate and / or strong staining intensity. In some embodiments, an individual's cancer or tumor is Nectin-4 positive when 90% or more of the tumor cells in a sample express Nectin-4 protein at moderate and / or strong staining intensity.

[0454] Evaluating an immunohistochemical assay to determine whether an individual's cancer or tumor is characterized by high Nectin-4 expression (e.g., low or moderate Nectin-4 expression) may typically involve the application of known scoring methods.

[0455] Low, medium and high tumor Nectin-4 expression can be determined based on the "H score" as described in US Patent Application Publication No. 2013 / 0005678. The H score is obtained by the formula: (3×percentage of strongly stained cells)+(2×percentage of moderately stained cells)+(percentage of weakly stained cells) and ranges from 0 to 300. The H score has been used especially in UC.

[0456] In some embodiments of any of the methods herein, low or moderate Nectin-4 expression (e.g., a tumor or tumor cell having a low or moderate level of Nectin-4 expression) corresponds to an H-score of about 250 or less, about 220 or less, about 200 or less, about 180 or less, about 160 or less, about 150 or less, about 140 or less, about 130 or less, about 120 or less, about 110 or less, or about 100 or less.

[0457] In some embodiments of any of the methods herein, low Nectin-4 expression (e.g., a tumor or tumor cells having a low level of Nectin-4 expression) corresponds to an H-score of 200 or less, about 180 or less, about 160 or less, about 150 or less, about 140 or less, about 130 or less, about 120 or less, about 110 or less, or about 100 or less.

[0458] In some embodiments of any of the methods herein, high Nectin-4 expression (eg, a tumor or tumor cells having a high level of Nectin-4 expression) corresponds to an H-score of about 290 or greater.

[0459] In another example, Nectin-4 staining can be scored by Quick Score (QS) using the following formula: QS=P (percentage of positive cells)×I (intensity), with a maximum score of 300. QS has been used, for example, in breast cancer. For example, in TNBC, some research groups have defined low Nectin-4 expression groups as QS≦100. In some embodiments of any of the methods herein, low or medium Nectin-4 expression (e.g., tumors or tumor cells with low or medium levels of Nectin-4 expression) corresponds to a QS score of about 200 or less, about 180 or less, about 160 or less, about 150 or less, about 140 or less, about 130 or less, about 120 or less, about 110 or less, or about 100 or less.

[0460] Assays for evaluating tumor cell expression of HER2 are well known in the art. For example, assays such as SPoT-Light HER2 CISH, which is approved by FDA, can be used to detect HER2 overexpression. Chromogenic in situ hybridization (CISH) detects HER2 gene amplification. This technique, also called Subtraction Probe Technology Chromogenic In Situ Hybridization, is a test used to confirm whether breast cancer cells overexpress HER2 receptor protein on the cell surface.

[0461] Another widely used assay for HER2 is HercepTest™ (Dako North America, Inc.), a semi-quantitative immunohistochemistry assay used to determine HER2 protein overexpression in formalin-fixed, paraffin-embedded cancer tissues. For example, tumors expressing low levels of HER2 can be identified by HercepTest™ with a score of +1 to +2.

[0462] In one embodiment, the treatment is used in individuals with pre-existing neuropathy, diabetes or hyperglycemia, heart failure, eye conditions. Such conditions may make the individual unsuitable for treatment with an anti-Nectin-4 ADC, such as enfortumab vedotin, which has higher toxicity or a narrower therapeutic window than the anti-Nectin-4 antibody drug conjugates of the present disclosure.

[0463] In any embodiment, the method of treatment may optionally include (a) assessing the cancer stage and / or disease progression in the individual, and (b) if the individual has recurrent, metastatic and / or progressing cancer, administering to the individual an effective amount of an anti-Nectin-4 antibody drug conjugate of the present disclosure.

[0464] In some embodiments, the present invention includes a method of treating a tumor in an individual having urothelial carcinoma, comprising: (a) assessing the cancer stage and / or disease progression in the individual; and (b) if the individual has recurrent, metastatic and / or advanced cancer, administering to the individual an effective amount of an anti-Nectin-4 antibody drug conjugate of the present disclosure.

[0465] Optionally, an individual treated with an anti-Nectin-4 antibody drug conjugate of the present disclosure may have a cancer (e.g., urothelial cancer, breast cancer (e.g., triple-negative breast cancer, HER2-positive cancer), non-small cell lung cancer, pancreatic cancer, ovarian cancer, gastric cancer, colorectal cancer, head and neck squamous cell carcinoma, or esophageal cancer) that is resistant, has not responded, or has relapsed and / or progressed despite (e.g., during or after) surgical treatment and / or treatment with a therapeutic agent, such as a chemotherapeutic agent, an antibody, an ADC, or radiation therapy.

[0466] In any embodiment herein, treatment response can be defined and / or evaluated according to well-known criteria, such as the Response Evaluation Criteria In Solid Tumors (RECIST), e.g., version 1.1 (see Eisenhauer et al. (2009) Eur. J. Cancer 45:228-247), or the Immune-Related Response Criteria (irRC) (see Wolchock et al. (2009) Clinical Cancer Research 15:7412-7420).

[0467] Individuals treated with the anti-Nectin-4 antibody drug conjugates of the present disclosure may have tumors or cancers that are resistant to, unresponsive to, or have progressed following treatment with chemotherapeutic agents known to be capable of transport by P-glycoprotein (Pgp), such as anthracyclines (doxorubicin, daunorubicin, taxanes (paclitaxel, docetaxel), vinca alkaloids (vincristine, vinblastine, vindesine), and etoposides. Compounds recognized by Pgp are typically characterized as being moderately hydrophobic (octanol-water partition coefficient, logP>1), often contain titratable protons with a net positive charge under physiological conditions, and are "natural products...

Claims

1. An antibody-drug conjugate (ADC) comprising an anti-Nectin-4 antibody conjugated to a cytotoxic agent (Z) via a linker, wherein the anti-Nectin-4 antibody binds to the VC1 cross-linking domain of human Nectin-4 polypeptide.

2. 2. The antibody-drug conjugate of claim 1, wherein the cytotoxic agent (Z) is camptothecin, optionally a pentacyclic camptothecin analogue, optionally a hexacyclic camptothecin analogue, optionally exatecan, SN-38 or Dxd.

3. The antibody-drug conjugate of claim 1 or 2, wherein the antibody binds to the Ig-like V domain and the Ig-like C1 type 2 domain of Nectin-4.

4. The antibody-drug conjugate of any one of claims 1-3, wherein the antibody binds to an epitope comprising amino acid residues K197 and / or S199 (according to SEQ ID NO: 1) of Nectin-4 and / or the antibody has reduced binding to a mutated Nectin-4 polypeptide comprising mutations at residues K197 and / or S199 compared to the binding between the antibody and a wild-type Nectin-4 polypeptide comprising the amino acid sequence of SEQ ID NO:

1.

5. The antibody-drug conjugate of any one of claims 1 to 4, wherein the antibody binds to a membrane-anchored human nectin-4 protein having the amino acid sequence of SEQ ID NO: 1, a membrane-anchored human nectin-4 protein having the amino acid sequence of SEQ ID NO: 32, and the antibody does not bind to a membrane-anchored human nectin-4 protein having the amino acid sequence of SEQ ID NO:

33.

6. The antibody, (a) a VH comprising a Kabat CDR1, CDR2 and / or CDR3 of a heavy chain variable region having the amino acid sequence of SEQ ID NO: 6, and a VL comprising a Kabat CDR1, CDR2 and / or CDR3 of a light chain variable region having the amino acid sequence of SEQ ID NO: 7; (b) a VH comprising a Kabat CDR1, CDR2 and / or CDR3 of a heavy chain variable region having the amino acid sequence of SEQ ID NO: 24, and a VL comprising a Kabat CDR1, CDR2 and / or CDR3 of a light chain variable region having the amino acid sequence of SEQ ID NO: 25; (c) a VH comprising a Kabat CDR1, CDR2 and / or CDR3 of a heavy chain variable region having the amino acid sequence of SEQ ID NO: 42, and a VL comprising a Kabat CDR1, CDR2 and / or CDR3 of a light chain variable region having the amino acid sequence of SEQ ID NO: 43; or (d) a VH comprising a Kabat CDR1, CDR2 and / or CDR3 of a heavy chain variable region having the amino acid sequence of SEQ ID NO: 50, and a VL comprising a Kabat CDR1, CDR2 and / or CDR3 of a light chain variable region having the amino acid sequence of SEQ ID NO: 51; The antibody-drug conjugate of any one of claims 1 to 5, comprising:

7. the antibody comprising an HCDR1 region comprising the amino acid sequence: SYWMH (SEQ ID NO:52); an HCDR2 region comprising the amino acid sequence: EIDPSDSYTNYNQKFKG (SEQ ID NO:53); an HCDR3 region comprising the amino acid sequence: SGNYDAMDY (SEQ ID NO:54); an LCDR1 region comprising the amino acid sequence: RSSKSLLHSNGITYLY (SEQ ID NO:55); an LCDR2 region comprising the amino acid sequence: QMSNLAS (SEQ ID NO:56); and an LCDR3 region comprising the amino acid sequence: AQNLELPWT (SEQ ID NO:57). The antibody-drug conjugate of any one of claims 1 to 6, comprising:

8. The antibody-drug conjugate of any one of claims 1 to 7, wherein the cytotoxic agent (Z) is exatecan.

9. The antibody-drug conjugate of claim 1, represented by formula (I): Ab-(X-(Z)) Formula (I) [In the formula, Ab is a polypeptide, peptide, or antibody that specifically binds to the VC1 cross-linking domain of the human Nectin-4 polypeptide; X is a molecule connecting Ab and Z, X comprises a protease-cleavable di-, tri-, tetra-, or pentapeptide; Z comprises a cytotoxic agent, optionally a camptothecin analogue, optionally a pentacyclic camptothecin analogue, optionally a hexacyclic camptothecin analogue, optionally exatecan, SN-38 or Dxd. , antibody-drug conjugates.

10. The antibody-drug conjugate of claim 9, wherein Z comprises exatecan.

11. The antibody-drug conjugate of claim 9 or 10, wherein the protease-cleavable peptide or peptidyl linker comprises valine-citrulline or valine-alanine.

12. The antibody-drug conjugate of any one of claims 9-11, wherein the antibody binds to a membrane-anchored human nectin-4 protein having the amino acid sequence of SEQ ID NO: 1, a membrane-anchored human nectin-4 protein having the amino acid sequence of SEQ ID NO: 32, but does not bind to any of the nectin family proteins having the amino acid sequences of SEQ ID NOs: 37 to 40.

13. The antibody binds to an epitope comprising amino acid residues K197 and / or S199 (according to SEQ ID NO: 1) of Nectin-4, and / or the antibody has reduced binding to a mutant Nectin-4 polypeptide comprising a mutation at residues K197 and / or S199, as compared to the binding between the antibody and a wild-type Nectin-4 polypeptide comprising the amino acid sequence of SEQ ID NO:1; An antibody-drug conjugate according to any one of claims 9 to 12.

14. The antibody of claim 1, wherein: (a) a heavy chain variable region (VH) comprising heavy chain CDR1, 2 and 3 of the heavy chain variable region of SEQ ID NO: 6, and a light chain variable region (VL) comprising light chain CDR1, 2 and 3 of the light chain variable region of SEQ ID NO: 7; (b) a VH comprising a Kabat CDR1, CDR2 and / or CDR3 of a heavy chain variable region having the amino acid sequence of SEQ ID NO: 24, and a VL comprising a Kabat CDR1, CDR2 and / or CDR3 of a light chain variable region having the amino acid sequence of SEQ ID NO: 25; (c) a VH comprising a Kabat CDR1, CDR2 and / or CDR3 of a heavy chain variable region having the amino acid sequence of SEQ ID NO: 42, and a VL comprising a Kabat CDR1, CDR2 and / or CDR3 of a light chain variable region having the amino acid sequence of SEQ ID NO: 43; or (d) a VH comprising a Kabat CDR1, CDR2 and / or CDR3 of a heavy chain variable region having the amino acid sequence of SEQ ID NO: 50, and a VL comprising a Kabat CDR1, CDR2 and / or CDR3 of a light chain variable region having the amino acid sequence of SEQ ID NO: 51; The antibody-drug conjugate of any one of claims 9 to 13, comprising:

15. The antibody-drug conjugate of any one of claims 9 to 14, wherein the antibody comprises an HCDR1 having the amino acid sequence: SYWMH (SEQ ID NO: 52); an HCDR2 having the amino acid sequence: EIDPSDSYTNYNQKFKG (SEQ ID NO: 53); an HCDR3 having the amino acid sequence: SGNYDAMDY (SEQ ID NO: 54); an LCDR1 having the amino acid sequence: RSSKSLLHSNGITYLY (SEQ ID NO: 55); an LCDR2 region having the amino acid sequence: QMSNLAS (SEQ ID NO: 56); and an LCDR3 region having the amino acid sequence: AQNLELPWT (SEQ ID NO: 57).

16. An antibody-drug conjugate according to any one of claims 1 to 15 for use in the treatment of cancer.

17. The antibody-drug conjugate for use according to claim 16, wherein the cancer is a cancer that has relapsed and / or progressed following treatment with a nectin-4 binding agent conjugated to an auristatin, and the nectin-4 binding agent conjugated to an auristatin may be enfortumab vedotin.